 EXHIBIT 2.1      



  

Exhibit 2.1

  



  

ARRANGEMENT AGREEMENT

  



  

SUNOVION CNS DEVELOPMENT CANADA ULC

  



  

\- and -

  



  

SUNOVION PHARMACEUTICALS INC.

  



  

\- and -

  



  

CYNAPSUS THERAPEUTICS INC.

  



  

August 31, 2016

  



    



 



    



  

TABLE OF CONTENTS

  



  

     Article 1 Interpretation  | 2 
---|--- 
   1.1  | Definitions  | 2 
   1.2  | Construction  | 17 
   1.3  | Currency  | 18 
   1.4  | Accounting Matters  | 18 
   1.5  | Knowledge  | 18 
   1.6  | Accounting Terms  | 18 
   1.7  | Subsidiaries  | 19 
   1.8  | Disclosure Letter  | 19 
   1.9  | Schedules  | 19 
     |   | 
   Article 2 Arrangement  | 19 
   2.1  | Arrangement  | 19 
   2.2  | Interim Order  | 19 
   2.3  | The Meeting  | 20 
   2.4  | The Circular  | 21 
   2.5  | Final Order  | 23 
   2.6  | Court Proceedings  | 23 
   2.7  | Articles of Arrangement and Effective Date  | 24 
   2.8  | Payment of Consideration  | 24 
   2.9  | Announcement and Shareholder Communications  | 24 
   2.10  | Withholding Taxes  | 25 
   2.11  | List of Securityholders  | 25 
     |   | 
   Article 3 Representations and Warranties of the Parent and Acquiror  |
25 
   3.1  | Representations and Warranties  | 25 
   3.2  | Survival of Representations and Warranties  | 25 
     |   | 
   Article 4 Representations and Warranties of the Corporation  | 26 
   4.1  | Representations and Warranties  | 26 
   4.2  | Survival of Representations and Warranties  | 26 
     |   | 
   Article 5 Conduct of Business  | 26 
   5.1  | Conduct of Business by the Corporation  | 26 
     |   | 
   Article 6 Covenants Relating to Acquisition Proposals  | 31 
   6.1  | Non-Solicitation  | 31 
   6.2  | Notification of Acquisition Proposals  | 33 
   6.3  | Responding to Acquisition Proposals and Superior Proposals  | 33 
     |   | 
   Article 7 Covenants Relating to Regulatory Approvals  | 37 
   7.1  | Regulatory Filings and Approvals  | 37 
   7.2  | Cooperation Regarding Regulatory Filings and Approvals  | 38 
    

  



    

 | (i)| 
---|---|--- 

 



    



  

     Article 8 Other Covenants  | 38 
---|--- 
   8.1  | Further Assurances  | 38 
   8.2  | 338 Election  | 41 
   8.3  | Access  | 41 
   8.4  | Pre-Acquisition Reorganization  | 42 
   8.5  | De-listing and Deregistration  | 44 
   8.6  | Shareholder Litigation  | 44 
   8.7  | Directors and Officers Insurance and Indemnification  | 44 
   8.8  | Employment Matters  | 45 
   8.9  | Covenants of the Parent  | 45 
   8.10  | Outstanding Rights  | 46 
     |   | 
   Article 9 Conditions  | 46 
   9.1  | Mutual Conditions  | 46 
   9.2  | Corporation Conditions  | 47 
   9.3  | Acquiror Conditions  | 47 
   9.4  | Notice and Cure  | 49 
   9.5  | Merger of Conditions  | 50 
     |   | 
   Article 10 Termination  | 50 
   10.1  | Term  | 50 
   10.2  | Termination  | 50 
   10.3  | Termination and Payment  | 52 
   10.4  | Effect of Termination  | 53 
   10.5  | Remedies  | 54 
     |   | 
   Article 11 General Provisions  | 54 
   11.1  | Amendment  | 54 
   11.2  | Waiver  | 55 
   11.3  | Expenses and Expense Reimbursement.  | 55 
   11.4  | Notices  | 55 
   11.5  | Process Agent  | 57 
   11.6  | Severability  | 58 
   11.7  | Entire Agreement  | 58 
   11.8  | Assignment  | 58 
   11.9  | Governing Law  | 58 
   11.10  | Contra Proferentem  | 58 
   11.11  | No Third Party Beneficiaries  | 58 
   11.12  | Time of Essence  | 58 
   11.13  | No Liability  | 59 
   11.14  | Counterparts  | 59 
    



    

 | (ii)| 
---|---|--- 

 



    



  

Schedule A Plan of Arrangement under Section 192 of the _Canada Business
Corporations Act_

  



  

Schedule B Representations and Warranties of the Parent and Acquiror

  



  

Schedule C Representations and Warranties of the Corporation

  



  

Schedule D Arrangement Resolution

  



    

 | (iii)| 
---|---|--- 

 



    



  

ARRANGEMENT AGREEMENT

  



  

THIS AGREEMENT made August 31, 2016, between

  



  

SUNOVION CNS DEVELOPMENT CANADA ULC, 
an unlimited liability company existing under the laws of British
Columbia, (hereinafter referred to as the "Acquiror")

  



  

\- and -

  



  

SUNOVION PHARMACEUTICALS INC., 
 a corporation existing under the laws of Delaware, 
(hereinafter referred to as the "Parent")

  



  

\- and -

  



  

CYNAPSUS THERAPEUTICS INC., 
 a corporation existing under the laws of Canada, 
 (hereinafter referred to as the "Corporation")

  



  

WHEREAS the Acquiror desires to acquire all of the common shares of the
Corporation (the "Common Shares") pursuant to an arrangement under section
192 of the Act (as hereinafter defined);

  



  

AND WHEREAS contemporaneously herewith, the Acquiror has entered into voting
and support agreements (the "Voting and Support Agreements") with each of the
directors and officers of the Corporation and Dexcel Pharma Technologies Ltd.
and Dexxon Holdings Ltd., pursuant to which, among other things, such
Securityholders (as hereinafter defined) have agreed to vote all of the
Common Shares and Warrants held by them in favour of the Arrangement
Resolution (as hereinafter defined) on the terms and subject to the
conditions set forth in the Voting and Support Agreements;

  



  

AND WHEREAS the board of directors of the Corporation (the "Board") has
unanimously determined, after receiving financial and legal advice and
following the receipt and review of recommendations from its special committee
of directors, that the Arrangement (as hereinafter defined) is fair, from a
financial point of view, to Securityholders and that the Arrangement is in the
best interests of the Corporation and has unanimously approved the entering
into of this Agreement and its recommendation that Securityholders vote for
the Arrangement Resolution, all on the terms and subject to the conditions
contained herein;

  



  

AND WHEREAS the Acquiror is a wholly-owned subsidiary of the Parent, and the
Parent has agreed to guarantee all of the obligations of the Acquiror under
this Agreement;

  



  

NOW THEREFORE THIS AGREEMENT WITNESSES that, in consideration of the mutual
covenants and agreements hereinafter set forth and for other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged by each party, the parties hereby covenant and agree as follows:

  



    



 



    



  

Article 1 
 Interpretation

  



   | 1.1| Definitions 
---|---|--- 
  



  

In this Agreement, unless something in the subject matter or context is
inconsistent therewith, the following terms shall have the respective
meanings set out below and grammatical variations shall have the
corresponding meanings:

  



  

"Acquiror" has the meaning set out in the preamble to this Agreement;

  



  

"Acquisition Proposal" means, other than any of the transactions contemplated
by this Agreement, any proposal, offer or inquiry (whether or not in writing)
by any person or group of persons other than the Acquiror or any of its
Affiliates relating to:

  



   | (a)| any  merger, amalgamation, plan of arrangement, business
combination, consolidation, share  exchange, recapitalization, redemption,
reorganization or similar transaction, or any  liquidation, dissolution or
winding-up, in any case, in respect of the Corporation or  any of its
subsidiaries; 
---|---|--- 
  



   | (b)| any  take-over-bid, tender offer, exchange offer, treasury
issuance or other transaction that,  if consummated, would result in any
person or group of persons beneficially owning 20%  or more of any class of
voting or equity securities or any other equity interests (including 
securities convertible into or exercisable or exchangeable for voting or
equity securities)  of the Corporation or any of its subsidiaries (in terms
of the number of securities outstanding  of any class of voting or equity
securities or other equity interests, in each case calculated  on a non-
diluted basis); 
---|---|--- 
  



   | (c)| any  direct or indirect sale, transfer, disposition, alliance or
joint venture (or any lease,  long-term supply arrangement, licence or other
arrangement having the same economic effect  as a sale), in a single
transaction or a series of related transactions, of assets of  the
Corporation representing 20% or more of the consolidated assets of the
Corporation;  or 
---|---|--- 
  



   | (d)| any  other similar transaction or series of transactions
involving the Corporation or any  of its subsidiaries. 
---|---|--- 
  



  

"Act" means the _Canada Business Corporations Act_ , as amended, including
the regulations promulgated thereunder;

  



  

"Adagio" means Adagio Pharmaceuticals Ltd., a former subsidiary of the
Corporation;

  



  

"Adagio Purchase Agreement" means the share purchase agreement dated December
22, 2011, among the Corporation, Adagio, and the shareholders of Adagio, as
further amended by an agreement dated January 28, 2015, as further amended by
an agreement dated August 31, 2016, providing for the acquisition of all of
the common shares of Adagio by the Corporation;

  



  

"Affiliate" has the meaning given to it in the Securities Act;

  



    

 | \- 2 -| 
---|---|--- 

 



    



  

"Agreement" means this arrangement agreement entered into by the Corporation,
the Acquiror and the Parent, together with the Schedules attached hereto and
the Disclosure Letter, as the same may be amended, supplemented or otherwise
modified from time to time in accordance with the terms hereof;

  



  

"Approval Requirement" has the meaning ascribed thereto in Section 20(c) of
Schedule C hereto;

  



  

"Arrangement" means the arrangement under the provisions of section 192 of
the Act, on the terms and subject to the conditions set out herein and in the
Plan of Arrangement, subject to any amendments or variations thereto made in
accordance with this Agreement or the Plan of Arrangement or made at the
direction of the Court in the Final Order with the prior written consent of
the parties, each acting reasonably;

  



  

"Arrangement Resolution" means the special resolution of Securityholders
approving the Arrangement to be considered at the Meeting, substantially in
the form attached as Schedule D to this Agreement and any amendments or
variations thereto made in accordance with the provisions of this Agreement
or the Plan of Arrangement;

  



  

"Articles of Arrangement" means the articles of arrangement of the
Corporation in respect of the Arrangement to be filed with the Director after
the Final Order is made, which shall include the Plan of Arrangement and
otherwise be in a form and content satisfactory to the parties, each acting
reasonably;

  



  

"Authorization" means, with respect to any person, any order, permit,
approval, registration, right, grant, consent, waiver, licence or
similar authorization of any Governmental Authority having jurisdiction over
the person;

  



  

"Board" has the meaning set out in the recitals to this Agreement;

  



  

"Board Recommendation" has the meaning set out in Section 2.4(b);

  



  

"BofA Fairness Opinion" means the oral opinion (to be confirmed by delivery
of a written opinion) of Merrill Lynch, Pierce, Fenner and Smith Incorporated
rendered to the Board to the effect that, as of the date of the written
opinion and based upon and subject to the various assumptions and limitations
to be set forth in the written opinion, the Consideration to be
received under the Arrangement by the Shareholders is fair, from a financial
point of view, to the Shareholders;

  



  

"Business Day" means a day, other than a Saturday or a Sunday, on which the
principal commercial banks located in Toronto, Ontario and New York, New York
are open for the conduct of non-automated business;

  



  

"Change of Control Payments" has the meaning set out in Section 25 of
Schedule C to this Agreement;

  



  

"Circular" means the notice of the Meeting and accompanying management
information circular of the Corporation, including all schedules, appendices
and exhibits thereto, and all information incorporated by reference therein,
to be prepared and sent to the Securityholders in connection with the
Meeting, as amended, supplemented or otherwise modified from time to time in
accordance with the terms of this Agreement;

  



    

 | \- 3 -| 
---|---|--- 

 



    



  

"Claim" means any demand, complaint, investigation, action, cause of action,
suit, damage, liability (actual or contingent) or obligation;

  



  

"Commercialization" means any activities, including pre-launch activities,
directed to preparation for sale of, offering for sale of, or sale of
a Product, including activities related to marketing, advertising, promoting,
detailing, manufacturing (including the API included in the Product),
distributing, importing, exporting such Product;

  



  

"Common Share" means a common share of the Corporation;

  



  

"Company Assets" means all of the assets, properties, permits, rights or
other privileges (whether contractual or otherwise) of the Corporation and
its subsidiaries;

  



  

"Company IP" means all Intellectual Property Rights that are owned, licensed
or controlled by the Corporation or any of its subsidiaries (including
without limitation those set forth in the Disclosure Letter);

  



  

"Company Licensed Registered IP" means all Registered Company IP that is
licensed by the Corporation or any of its subsidiaries and set forth in
Section 34(a)(aii) of the Disclosure Letter;

  



  

"Company Owned IP" means all Intellectual Property Rights that are owned by
the Corporation or the any of its subsidiaries (including without limitation
those set forth in the Disclosure Letter);

  



  

"Company Owned Registered IP" means all Registered Company IP that is owned
by the Corporation or any of its subsidiaries and set forth in Section
34(a)(ai) of the Disclosure Letter;

  



  

"Competition Act" means the _Competition Act_ , R.S.C. 1985, c. C-34, and
includes the regulations thereunder;

  



    

 | \- 4 -| 
---|---|--- 

 



    



  

"Confidentiality Agreement" means the mutual confidentiality disclosure
agreement effective October 29, 2015 between the Acquiror and the
Corporation;

  



  

"Consideration" means $40.50 in cash per Common Share or, in the case of a
Right, the excess of $40.50 over the exercise price of such Right;

  



  

"Contemplated Transactions" has the meaning set out in Section 2 of Schedule
B to this Agreement;

  



  

"Contract" means any agreement, commitment, engagement, contract, franchise,
licence, lease, obligation, undertaking or joint venture (written or oral) to
which the Corporation or any of its subsidiaries is a party or by which it or
any of its subsidiaries is bound or affected or to which any of their
respective properties or assets is subject;

  



  

"Corporation" has the meaning set out in the preamble to this Agreement;

  



  

"Corporation Associate" means each current or former officer or other
employee, or individual or entity who is an independent
contractor, consultant or director, of or to the Corporation, excluding for
clarification only ARx LLC;

  



  

"Corporation Sub" means an unlimited liability company to be formed pursuant
to the _Business Corporations Act_ (British Columbia) as a direct, wholly-
owned subsidiary of the Corporation for the purposes of effectuating the
Arrangement;

  



  

"Corporation's Constating Documents" means the articles of amalgamation and
by-laws of the Corporation and all amendments to such articles or by-laws;

  



  

"Court" means the Ontario Superior Court of Justice (Commercial List) or any
appellate court, as the case may be;

  



  

"Depositary" means any trust company, bank or financial institution agreed to
in writing by the Acquiror and the Corporation to act as depository for the
Arrangement;

  



  

"Development" means the conduct of all research, formulating, preclinical and
other testing, nonclinical activities, clinical trials, and other studies,
and all other activities (including test method development, stability
testing, toxicology studies, process development, statistical analysis and
report writing, packaging, labeling and regulatory affairs, product approval,
and registration activities) required by a Governmental Authority in
connection with the Product;

  



    

 | \- 5 -| 
---|---|--- 

 



    



  

"Director" means the director appointed pursuant to Section 260 under the
Act;

  



  

"Disclosing Party" has the meaning ascribed thereto in Section 7.2(c);

  



  

"Disclosure Letter" means the disclosure letter dated the date of this
Agreement delivered by the Corporation to the Acquiror contemporaneously with
the execution and delivery of this Agreement;

  



  

"Dissent Rights" means the rights of dissent granted in favour of
Securityholders in respect of the Arrangement as described in the Plan of
Arrangement and the Interim Order;

  



  

"EDGAR" means the U.S. Securities and Exchange Commission's Electronic Data
Gathering, Analysis and Retrieval system;

  



  

"Effective Date" means the date shown on the Certificate of Arrangement
giving effect to the Arrangement;

  



  

"Effective Time" has the meaning set out in the Plan of Arrangement;

  



  

"Employee Plans" has the meaning ascribed thereto in Section 24(a) of
Schedule C hereto;

  



  

"Encumbrance" means any lien (statutory or otherwise), pledge, hypothecation,
charge, restriction or adverse right or Claim, mortgage,
encroachments, option, right of first refusal or first offer, occupancy
right, covenant, assignment, security interest, adverse interest, defect of
title, statutory or deemed trust, other third party interest or encumbrance of
any kind, in each case, whether contingent or absolute, except in each case
for any Permitted Encumbrance;

  



  

"Environmental Laws" means all Canadian or foreign federal, provincial,
state, municipal or local Laws of any Governmental Authority, including
common law, and all other statutory requirements relating to safety, noise
control, pollution or the protection of the environmental or health matters,
including legislation governing the generation, production, installation, use,
handling, manufacturing, processing, labeling, importing, transportation,
recycling, treatment, storage and release or threatened release of any
pollutant, contaminant, waste of any nature, hazardous substance, deleterious
substance, hazardous material, toxic substance, dangerous substance or
dangerous good as defined, judicially interpreted or identified in any Laws
and under Canada's Workplace Hazardous Materials Information System (WHMIS),
including civil responsibility for acts or omissions with respect to the
environment, and all Authorizations issued pursuant to such Laws, agreements
or other statutory requirements;

  



  

"Environmental Liabilities" means, with respect to any person, all
liabilities, Losses, investigations, assessments and Legal Proceedings to the
extent based upon, related to or arising under or pursuant to any: (a)
Environmental Law; (b) agreement with or administrative order issued by any
Governmental Authority or other person which relates to the environment; (c)
condition in the environment; (d) actual presence or alleged release or
threatened release of any material, contaminant, substance, pollutant or
waste as those terms are defined or identified under any Environmental Laws;
(e) actual or alleged exposure of any person to any substance, material,
contaminant, pollutant or waste as those terms are defined or identified under
Environmental Laws;

  



    

 | \- 6 -| 
---|---|--- 

 



    



  

"Exchanges" means the Toronto Stock Exchange and The Nasdaq Global Market, as
applicable, and "Exchange" means any one of them;

  



  

"Fairness Opinions" means the BofA Fairness Opinion and the Stifel Fairness
Opinion;

  



  

"FDA" means the United States Food and Drug Administration or any successor
thereto;

  



  

"FDCA" means the Federal Food, Drug, and Cosmetic Act of 1938, as amended;

  



  

"Final Order" means the final order of the Court in a form and content
satisfactory to the parties, each acting reasonably, approving the
Arrangement, as such order may be amended by the Court (with the consent of
the parties, each acting reasonably) at any time prior to the Arrangement
becoming effective or, if appealed, then, unless such appeal is withdrawn or
denied, as affirmed or as amended (provided that any such amendment is in a
form and content satisfactory to the parties, each acting reasonably) on
appeal;

  



  

"Governmental Authority" means any:

  



   | (a)| nation,  state, commonwealth, province, territory, county,
municipality, district or other jurisdiction  of any nature; 
---|---|--- 
  



   | (b)|   international, multinational, national, federal, state,
provincial, local, regional,  municipal or other government; 
---|---|--- 
  



   | (c)| governmental  or quasi-governmental authority of any nature
including any governmental division, department,  agency, board, body,
commission, instrumentality, official, ministry, center, organization,  unit,
body or entity and any regulatory authority, court, arbitrator or other
tribunal  or any political subdivision thereof, or any central bank (or
similar monetary or regulatory  authority) thereof, any expropriation or
taxing authority, any ministry or department  or agency of any of the
foregoing, including authorities and agencies having regulatory  powers in
their respective health care systems such as the FDA and Health Canada; 
---|---|--- 
  



   | (d)| stock  exchange, including the Exchanges; 
---|---|--- 
  



   | (e)| entity  exercising executive, legislative, judicial, regulatory
or administrative functions of  or pertaining to government; 
---|---|--- 
  



   | (f)| corporation  or other entity owned or controlled, through stock
or capital ownership or otherwise,  by any of such entities or other bodies
pursuant to the foregoing; or 
---|---|--- 
  



   | (g)| subdivision or authority of any of the above; 
---|---|--- 
  



  

"HSR Act" means the United States Hart-Scott-Rodino Antitrust Improvements
Act of 1976;

  



    

 | \- 7 -| 
---|---|--- 

 



    



  

"HSR Approval" means the expiration or early termination of any waiting
period, and any extension thereof, applicable to the completion of the
transactions contemplated hereby under the HSR Act;

  



  

"IFRS" means the International Financial Reporting Standards and the official
pronouncements issued by the International Accounting Standards Board;

  



  

"Intellectual Property Rights" means all past, present and future rights in
any type of intellectual property which may exist or be created under the
Laws of any jurisdiction in the world, including without limitation: patents,
industrial designs, copyrights, trademarks, trade names, domain names, social
media accounts, inventions, trade secrets, confidential information, know-how,
moral and economic rights of authors and inventors, any and all applications
and registrations, including without limitation the right to claim priority,
obtain extensions of term and listing in the Orange Book, the Canadian Patent
Register, or any equivalent thereof, for any of the foregoing, all goodwill
associated with any of the foregoing, and any and all past, present and future
causes of action and rights to sue or seek other remedies and receive damages
arising from or relating to the foregoing, including without limitation past
damages;

  



  

"Interim Order" means the interim order of the Court, in a form and content
satisfactory to the parties, each acting reasonably, as the same may be
amended by the Court (with the consent of the parties, each acting
reasonably), containing declarations and directions with respect to the
Arrangement and providing for, among other things, the holding of the Meeting;

  



  

"Investment Canada Act" means the _Investment Canada Act_ , R.S.C. 1985, c.
28 (1st Supp), and includes regulations thereunder;

  



  

  

"IP Contracts" means any Contract that is a Contract under which the
Corporation or any of its subsidiaries: (a) was or is assigned, granted,
obtained, or obtains or agrees to be assigned, granted or to obtain any
license, ownership or any other rights or interests with respect to, any
Intellectual Property Rights, including without limitation any and all
Intellectual Property Rights relating in any way to the Product (other than
standard form Contracts granting rights to use readily available shrink wrap
or click wrap software having a replacement cost and annual license fee of
less than $100,000 in the aggregate for all such related Contracts, other non-
exclusive rights with respect to non-material Intellectual Property Rights
entered into in the Ordinary Course and proprietary information
and inventions agreements entered into with employees of the Corporation or a
subsidiary in the Ordinary Course, other than agreements with named inventors
on any patents included in the Company IP); (b) is restricted in its right to
use or register any Intellectual Property Rights; (c) grants rights to or
permits or agrees to grant rights to or to permit any other person to use,
enforce or register, or grants any other rights or interests with respect to,
any Intellectual Property Rights owned by or non-exclusively or exclusively
licensed to the Corporation or any of its subsidiaries, including license
agreements, collaboration agreements, research and/or development agreements,
non-assertion or co-existence agreements, grants of royalty or revenue
interest, research and development or commercialization financing
arrangements, or covenants not to sue, other than Contracts for sales of the
Corporation's product and associated non-exclusive licenses entered into in
the Ordinary Course; or (d) that would, as a result of the Arrangement and
the transactions contemplated thereby, require the Acquiror to license or
assign rights in its or its Affiliates' Intellectual Property Rights to any
other person, or prohibit the Acquiror from using any of its or its
Affiliates' Intellectual Property Rights due to the Acquiror or its
Affiliates constituting an Affiliate of the Corporation;

  



    

 | \- 8 -| 
---|---|--- 

 



    



  

"Laws" means , with respect to any person, any and all applicable laws
(statutory, civil, common or otherwise) including supranational, national,
provincial, state, municipal and local civil laws, treaties, statutes,
judgments, decrees, injunctions, writs, certificates and orders, by-laws,
rules, regulations, ordinances, policies, notices, directions or other
requirements of any Governmental Authority that is binding upon or applicable
to such person or its business, undertaking, property or securities, and to
the extent that they have the force of law, policies, guidelines, notices and
protocols of any Governmental Authority, as amended unless
expressly specified otherwise, including, but not limited to, the Securities
Laws;

  



  

"Legal Proceeding" means any action, suit, charge, complaint, litigation,
arbitration, proceeding (including any civil, criminal, administrative,
investigative or appellate proceeding), hearing, inquiry, audit, examination,
oppositions, interferences, re-examinations, post-grant proceeding, or
investigation commenced, brought, conducted or heard by or before, or
otherwise involving, any court or other Governmental Authority or any
arbitrator or arbitration panel;

  



  

"Licensed Field" means apomorphine, alone or in combination with any
antiemetic, for the treatment of humans in the indications of: (a) the acute,
intermittent treatment of hypomobility, "off" episodes associated with
Parkinson's disease in patients that have motor fluctuations; (b) restless
leg syndrome; and (c) erectile dysfunction;

  



  

"Loss" means any loss (including loss of profits and punitive damages), cost,
liability, Tax liability, damage, fine, penalty, settlement, judgment, award
or expense, including where applicable costs and expenses (including
attorneys' fees and expenses of investigation and defence);

  



  

  

"Market Value" market value of a class of securities for a period is
calculated by multiplying the number of securities of the class outstanding,
as of the close of business on the last Business Day of the period, by:

  



   | (a)| the arithmetic average of the closing prices of the securities of
that class on the Published Market on which that class was principally traded
for each of the trading days during the period, if the Published Market
provides a closing price for the securities; or 
---|---|--- 
  



   | (b)| the arithmetic average of the simple averages of the highest and
lowest prices of the securities of that class on the Published Market on
which that class was principally traded for each of the trading days for which
the securities traded during the period, if the Published Market does not
provide a closing price, but provides only the highest and lowest prices of
securities traded on a particular day; 
---|---|--- 
  



    

 | \- 9 -| 
---|---|--- 

 



    



  

"Match Period" has the meaning set out in Section 6.3(b)(iv);

  



  

"Material Adverse Effect" means any change, event, occurrence, effect, state
of facts or circumstances that:

  



   | (a)| is, or would reasonably be expected to be, individually or in
the aggregate material and adverse to the business, financial condition,
operations or results of operations, assets, properties, condition (financial
or otherwise) or liabilities (contingent or otherwise) of the Corporation and
its subsidiaries, taken as a whole, other than any such change, event,
occurrence, effect, state of facts or circumstances:  
---|---|--- 
  



   | (i)| relating  to the Canadian or U.S. economy, political conditions
or securities markets in general; 
---|---|--- 
  



   | (ii)| affecting  the industry in which the Corporation operates; 
---|---|--- 
  



   | (iii)| arising  directly or indirectly from any act of terrorism,
war, national or international calamity  or any other similar event; 
---|---|--- 
  



   | (iv)| relating  to a change in the market trading price or volume of
the Common Shares (it being understood  that the causes underlying such
change in market price or trading volume may be taken  into account in
determining whether a Material Adverse Effect has occurred); 
---|---|--- 
  



   | (v)| relating  to or arising from or out of the execution,
announcement or performance of this Agreement  and the Arrangement; 
---|---|--- 
  



   | (vi)| relating  to any action taken (or omitted to be taken) by the
Corporation at the request, or with  the approval, of the Acquiror; 
---|---|--- 
  



   | (vii)| any  Legal Proceeding against the Corporation by
Securityholders challenging or seeking to  restrain or prohibit the
consummation of the Arrangement; 
---|---|--- 
  



   | (viii)| arising  from or out of the results of any of the
Corporation's clinical trials relating  to the Product; 
---|---|--- 
  



   | (ix)| relating  to any determination by, or delay of a determination
by, the FDA, the European Medicines  Agency or any other Governmental
Authority, or any panel or advisory body empowered or  appointed thereby, or
any indication that any such entity, panel or body will make any 
determination or delay in making any determination, with respect to the
approvability,  labeling, contents of package insert, prescribing
information, risk management profile,  pre-approval inspection matters or
requirements relating to the results of any pre-clinical  or clinical testing
sponsored by the Corporation and relating to the Product; 
---|---|--- 
  



   | (x)| arising  from or out of the launch of any drug products that
compete with the Product; 
---|---|--- 
  



    

 | \- 10 -| 
---|---|--- 

 



    



   | (xi)| any  recommendations or statements published or proposed by any
professional medical organization,  Governmental Authority or panel or
advisory body empowered or appointed thereby, relating  to the Products or to
any product or product candidates of any competitor to the extent  that such
recommendation or statement compares such product or product candidate to
the  Product; or 
---|---|--- 
  



   | (xii)| relating  to any generally applicable change or proposed
change in applicable IFRS or Laws, including  the rules, regulations and
administrative policies of the FDA or the European Medicines  Agency or
interpretations of any of the foregoing; 
---|---|--- 
  



  

provided, however, that the effect referred to in clauses (i), (ii), (iii)
and (xii) above does not have a materially disproportionate effect on the
Corporation and its subsidiaries, taken as a whole, compared to other
companies operating in the industry or jurisdictions in which the Corporation
and its subsidiaries operate; or

  



   | (b)| would,  or would reasonably be expected to, prevent or
materially delay the ability of the Corporation  to consummate the
transactions contemplated by this Agreement by the Outside Date; 
---|---|--- 
  



  

"Material Contract" means any Contract: (a) that if terminated or modified or
if it ceased to be in effect, would reasonably be expected to have a Material
Adverse Effect; (b) relating to the formation, creation or operation of any
corporation, partnership, limited liability company, joint venture or similar
agreement in which the Corporation and/or its subsidiaries have an interest;
(c) relating directly or indirectly to the guarantee of any liabilities
or obligations or to indebtedness (currently outstanding or which may become
outstanding) for borrowed money; (d) restricting the incurrence of
indebtedness by the Corporation or any of its subsidiaries or (including by
requiring the granting of an equal and rateable Encumbrance) the incurrence
of any Encumbrances on any properties or assets of the Corporation or any of
its subsidiaries, or restricting the payment of dividends by the Corporation
or by any of its subsidiaries; (e) under which the Corporation or any of its
subsidiaries is obligated to make or expects to receive payments (including
royalties) on an annual basis in excess of $250,000 or in excess of $250,000
over the remaining term; (f) under which the Corporation or any of its
subsidiaries is obligated to make or expects to receive payments (including
royalties or milestone payments) in excess of $250,000, (g) that creates an
exclusive dealing arrangement, right of first offer or refusal or "most
favoured nation" obligation; (h) that is a collective agreement or other
agreement with a union; (i) providing for employment, severance or change in
control payments; (j) between the Corporation or any of its subsidiaries and
any director or executive officer of the Corporation or any of
its subsidiaries; (k) containing a put, call or similar right pursuant to
which the Corporation or any subsidiary would be required to purchase or
sell, as applicable, any equity interests of any person; (l) providing for the
purchase, sale or exchange of, or option to purchase, sell or exchange, any
property where the purchase or sale price of such property exceeds $250,000;
(m) providing for the lease of any real property; (n) involving the settlement
of any Legal Proceeding or threatened Legal Proceeding that exceeds $250,000;
(o) that limits or restricts in any material respect (1) the ability of the
Corporation or any subsidiary to engage in any line of business or carry on
business in any geographic area, or (2) the scope of persons to whom the
Corporation or any of its subsidiaries may sell products or deliver services;
(p) that requires the consent of any other party to the Contract to a change
in control of or assignment by the Corporation or any of its subsidiaries of
such Contract; (q) that is an IP Contract; (r) that relates to research, pre-
clinical, clinical or other development, manufacturing or supply (including of
any components, and any quality and other ancillary agreements), testing,
distribution, marketing, promotion or other commercialization of any
pharmaceutical product or medical device (including pharmaceutical products or
medical devices under development) of or licensed to the Corporation or any
of its subsidiaries; or (s) that is otherwise material to the Corporation and
its subsidiaries, taken as a whole;

  



    

 | \- 11 -| 
---|---|--- 

 



    



  

"Meeting" means the special meeting of Securityholders to be called and held
for the purpose of considering the Arrangement Resolution and any
adjournments or postponements thereof in accordance with the terms of this
Agreement;

  



  

"MI 61-101" means Multilateral Instrument 61-101 - _Protection of Minority
Shareholders in Special Transactions_ ;

  



  

"Misrepresentation" means an untrue statement of a material fact or an
omission to state a material fact that is required to be stated or that
is necessary to make the statements contained therein not misleading in light
of the circumstances in which they are made;

  



  

"NASDAQ Rules" means the NASDAQ Marketplace Rules as promulgated by The
Nasdaq Global Market, as amended;

  



  

"NI 54-101" means National Instrument 54-101 - _Communications with
Beneficial Owners of Securities of a Reporting Issuer_ ;

  



  

"officer" has the meaning ascribed thereto in the Securities Act;

  



  

"Option Plan" means the stock option plan of the Corporation as amended and
restated on May 10, 2016;

  



  

"Optionholder" means a holder of Options;

  



  

"Options" means the outstanding options to purchase Common Shares issued
pursuant to the Option Plan or any predecessor plan, as set forth in the
Disclosure Letter;

  



  

"Ordinary Course" means, with respect to an action taken by any person, any
action that is taken in the ordinary course of the normal day to day
operations of the business of such person consistent with past practice;

  



  

"Outside Date" means December 31, 2016 or such later date as may be agreed to
in writing by the parties, provided that if the Effective Date has not
occurred by December 31, 2016 as a result of the failure to obtain any of the
approvals set out in Section 9.1(e), and provided that the parties have a
reasonable expectation to receive such approval, either party may elect, by
notice in writing delivered to the other party prior to December 31, 2016 to
extend the Outside Date by a specified period of not more than two (2)
months, provided that, notwithstanding the foregoing, neither party shall
be permitted to extend the Outside Date if the failure to obtain the
approvals set out in Section 9.1(e) is primarily the result of such party's
failure to comply with its covenants herein or if such person is not using
commercially reasonable efforts to obtain such approvals;

  



    

 | \- 12 -| 
---|---|--- 

 



    



  

"Parent" has the meaning set out in the preamble to this Agreement;

  



  

"party" means a party to this Agreement;

  



  

"Permitted Encumbrance" means, in respect of the Corporation or any of its
subsidiaries, any one or more of the following (a) easements, servitudes,
restrictions, restrictive covenants, party wall agreements, rights of way,
licenses, permits and other similar rights in land or real property,
including rights of way and servitudes for highways and other roads, railways,
sewers, drains, gas and oil pipelines, gas and water mains, electric light,
power, telephone, telegraph or cable television conduits, poles, wires
and cables that do not materially adversely affect the use of the Company
Assets or otherwise materially impair business operations at the affected
properties; (b) Encumbrances imposed by Law and incurred in the Ordinary
Course for obligations not yet due or delinquent; (c) zoning and building by-
laws and ordinances and regulations made by public authorities that do not
materially adversely affect the use of the Company Assets or otherwise
materially impair business operations at the affected properties; (d)
Encumbrances incurred, created and granted in the Ordinary Course to a public
utility or private supplier of services, municipality or Governmental
Authority in connection with operations conducted with respect to any Company
Assets that do not materially adversely affect the use of the Company Assets
or otherwise materially impair business operations at the affected
properties; (e) the reservations, limitations, provisos and conditions in any
original grant from the applicable Governmental Authority of any of the lands
forming part of any Company Assets, or interests in them and statutory
exceptions to title that do not materially adversely affect the use of the
Company Assets or otherwise materially impair business operations at the
affected properties; (f) Encumbrances for Taxes for which appropriate
provisions have been made in accordance with IFRS and either which (i)
are not due or delinquent, or (ii) are being contested in good faith by
appropriate proceedings; (g) inchoate or statutory Encumbrances of
contractors, subcontractors, mechanics, workers, suppliers, materialmen,
carriers and others in respect of the construction, maintenance, repair or
operation of any Company Assets, provided that such Encumbrances are related
to obligations not due or delinquent, are not registered against title to any
Company Assets and in respect of which adequate holdbacks are
being maintained as required by Law; (h) the right reserved to or vested in
any Governmental Authority by any statutory provision or by the terms of any
lease, licence, franchise, grant or permit forming part of any Company Assets,
to terminate any such lease, licence, franchise, grant or permit, or to
require annual or other payments as a condition of their continuance; or (i)
such other non-financial rights, imperfections or irregularities of title,
encroachments and encumbrances or Encumbrances as do not materially affect
the use of the real properties subject thereto or affected thereby or
otherwise materially impair business operations at such real properties;

  



  

"person" means an individual, general partnership, limited partnership,
corporation, company, limited liability company, unincorporated association,
unincorporated syndicate, unincorporated organization, trust, estate, trustee,
executor, administrator or other legal representative, government (including
Governmental Authority) or other entity, whether or not having legal status;

  



    

 | \- 13 -| 
---|---|--- 

 



    



  

"Plan of Arrangement" means the plan of arrangement substantially in the form
attached as Schedule A and any amendment or variation thereto from time to
time made in accordance with this Agreement or upon the direction of the Court
in the Final Order with the prior written consent of the parties, each acting
reasonably;

  



  

"Pre-Acquisition Reorganization" has the meaning ascribed thereto in Section
8.4(a);

  



  

"Product" means sublingual apomorphine strip or film, APL-130277 and its
associated packaging (and shall include any new or previously used name under
which it is branded or tested);

  



  

"Proxy Cut-off" has the meaning given to it in Section 2.4(c);

  



  

"Public Disclosure Record" means all documents filed or furnished by or on
behalf of the Corporation on SEDAR or EDGAR since January 1, 2014 and June
12, 2015, respectively;

  



  

"Published Market" means a recognized national Canadian or United States
stock exchange;

  



  

"Receiving Party" has the meaning ascribed thereto in Section 7.2(c);

  



  

"Registered Company IP" means all Registered IP that is Company IP;

  



  

"Registered IP" means all pending applications, issuances and registrations
with any Governmental Authority for any Intellectual Property Rights,
including without limitation all patents and patent applications (including
industrial designs), inventor certificates, registered copyrights, registered
mask works, and registered trademarks, service marks and trade dress,
registered domain names, social media accounts and registered business names;

  



  

"related party" has the meaning given to such term in MI 61-101;

  



  

"Representative" means, in respect of a person, its subsidiaries and its
Affiliates and its and their directors, officers, employees,
shareholders, agents and representatives (including any financial, legal,
accounting or other advisors);

  



  

"Rights" means the Options and the Warrants;

  



  

"Securities Act" means the _Securities Act_ (Ontario), as amended from time
to time;

  



  

"Securities Authority" means the Ontario Securities Commission and the
applicable securities commissions or securities regulatory authority of a
province or territory of Canada and, in case of the Corporation, also includes
the United States Securities and Exchange Commission;

  



  

"Securities Laws" means the Securities Act and any other applicable Canadian
provincial and territorial securities laws, rules and regulations and
published policies thereunder, and the U.S. Securities Laws;

  



  

"Securityholders" means, collectively, Shareholders and Warrantholders;

  



    

 | \- 14 -| 
---|---|--- 

 



    



  

" SEDAR" means the System for Electronic Document Analysis and Retrieval;

  



  

"Shareholders" means holders of the Common Shares;

  



  

"Special Committee" means the committee of independent directors of the Board
comprised of Rochelle Stenzler, Ronald Hosking and Tamar Howson;

  



  

"Stifel Fairness Opinion" means the oral opinion (to be confirmed by delivery
of a written opinion) of Stifel, Nicolaus and Company, Incorporated rendered to
the Special Committee to the effect that, as of the date of the written
opinion and based upon and subject to the various assumptions and limitations
to be set forth in the written opinion, the Consideration to be received under
the Arrangement by the Shareholders is fair, from a financial point of view,
to the Shareholders;

  



  

"subsidiary" means, with respect to a person, any entity, whether
incorporated or unincorporated, (a) of which such person or any other
subsidiary of such person is a general partner; or (b) at least a majority of
the securities or other interests of which having by their terms ordinary
voting power to elect a majority of the board of directors or other persons
performing similar functions with respect to such corporation or other
organization is directly or indirectly owned or controlled by such person
and/or by any one or more of its subsidiaries; and shall include any body
corporate, partnership, joint venture or other entity over which it exercises
direction or control. For purposes of this definition, "control" when used
with respect to any person means the power to direct the management and
policies of such person, directly or indirectly, whether through the
ownership of voting securities, by contract or otherwise. For greater
certainty, Cynapsus Therapeutics (USA) Inc. and, once formed, the Corporation
Sub shall each be considered a subsidiary of the Corporation for the purposes
of this Agreement;

  



  

"Superior Proposal" means any unsolicited _bona fide_ written Acquisition
Proposal made subsequent to the date hereof from a person who is an arm's
length third party:

  



   | (a)| to purchase  or otherwise acquire, directly or indirectly, not
less than all of the Common Shares  not owned by the person making such
Acquisition Proposal or its Affiliates or all or  substantially all of the
assets of the Corporation on a consolidated basis; 
---|---|--- 
  



   | (b)| that  did not result from a breach of Article 6 of this
Agreement or result from a material  breach of any agreement between the
person making such Acquisition Proposal and the Corporation; 
---|---|--- 
  



   | (c)| that  the upfront consideration payable on closing of such
transaction shall consist of only  (i) cash, (ii) securities of a class of
such person listed on a Published Market, or  (iii) a combination of (i) and
(ii), and that has an aggregate value, calculated as of  the date of receipt
of the Acquisition Proposal, of at least $625,000,000, and for purposes  of
determining value, the value of any such securities shall be determined based
on the  Market Value during the 20 consecutive trading days immediately
preceding the date of  receipt of the Acquisition Proposal; 
---|---|--- 
  



    

 | \- 15 -| 
---|---|--- 

 



    



   | (d)| that  is not subject, either by the terms of such Acquisition
Proposal or by virtue of any  Law, to any requirement that the approval of
the shareholders of the person making the  Acquisition Proposal be obtained; 
---|---|--- 
  



   | (e)| that  is not subject to any financing condition and in respect
of which it has been demonstrated  to the satisfaction of the Board, acting
in good faith (after receipt of advice from  its financial advisors and its
outside legal counsel) that any required financing or  other consideration to
complete such Acquisition Proposal will be available at closing  of such
transaction; 
---|---|--- 
  



   | (f)| that  is not subject to any due diligence condition; and 
---|---|--- 
  



   | (g)| that  the Board and any relevant committee thereof has
determined, acting in good faith (after  receipt of advice from its financial
advisors and its outside legal counsel): 
---|---|--- 
  



   | (i)| is reasonably  capable of consummation without undue delay
taking into account all legal, financial,  regulatory and other aspects of
such Acquisition Proposal and the person making such  Acquisition Proposal;
and 
---|---|--- 
  



   | (ii)| would,  if consummated in accordance with its provisions (but
not assuming away any risk of non-  consummation), result in a transaction
more favourable to the Shareholders from a financial  point of view than the
Arrangement (including any adjustment to the terms and conditions  of the
Arrangement proposed by the Acquiror pursuant to this Agreement); 
---|---|--- 
  



  

"Superior Proposal Notice" has the meaning set out in Section 6.3(b)(iv);

  



  

"Tax" or "Taxes" means (a) any and all taxes, duties, fees, excises,
premiums, assessments, imposts, levies and other charges or assessments of
any kind whatsoever imposed by any Governmental Authority, whether computed on
a separate, consolidated, unitary, combined or other basis, including those
levied on, or measured by, or described with respect to, income, gross
receipts, profits, gains, windfalls, capital, capital stock, production,
recapture, transfer, land transfer, license, gift, occupation, wealth,
environment, net worth, indebtedness, surplus, sales, goods and services,
harmonized sales, use, value-added, excise, special assessment, stamp,
withholding, business, franchising, real or personal property, health,
employee health, payroll, workers' compensation, employment or unemployment,
severance, social services, social security, education, utility,
surtaxes, customs, import or export, and including all license and
registration fees and all employment insurance, health insurance
and government pension plan premiums or contributions; (b) all interest,
penalties, fines, additions to tax or other additional amounts imposed by any
Governmental Authority on or in respect of amounts of the type described in
clause (a) above or this clause (b); (c) any liability for the payment of any
amounts of the type described in clauses (a) or (b) as a result of being a
member of an affiliated, consolidated, combined or unitary group for any
period; and (d) any liability for the payment of any amounts of the type
described in clauses (a) or (b) as a result of any express or implied
obligation to indemnify any other person or as a result of being a transferee
or successor in interest to any party;

  



    

 | \- 16 -| 
---|---|--- 

 



    



  

"Tax Act" means the _Income Tax Act_ (Canada) and the regulations promulgated
thereunder, as amended;

  



  

"Tax Returns" means any and all returns, reports, declarations, elections,
notices, forms, designations, filings, statements and other similar documents
(including estimated tax returns and reports, withholding tax returns and
reports, and information returns and reports) filed or required under Laws to
be filed with any Governmental Authority in respect of Taxes, including
any amendments or supplements thereto;

  



  

"Termination Payment" has the meaning set out in Section 10.3;

  



  

"Termination Payment Event" has the meaning set out in Section 10.3;

  



  

"United States" or "U.S." means the United States of America, its territories
and possessions, any State of the United States and the District of Columbia;

  



  

"U.S. Exchange Act" means the United States Securities Exchange Act of 1934,
as amended, and the rules and regulations promulgated thereunder;

  



  

"U.S. Securities Act" means the United States Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder;

  



  

"U.S. Securities Laws" means the NASDAQ Rules and the U.S. Securities Act,
the U.S. Exchange Act and all other applicable U.S. federal and state
securities laws, rules and regulations and published policies thereunder;

  



  

"Voting and Support Agreements" has the meaning set out in the recitals to
this Agreement;

  



  

"Warrantholder" means a holder of Warrants; and

  



  

"Warrants" means the common share purchase warrants of the Corporation set
out in the Disclosure Letter.

  



   | 1.2| Construction 
---|---|--- 
  



  

In this Agreement, unless otherwise expressly stated or the context otherwise
requires:

  



   | (a)| references  to "herein", "hereby", "hereunder", "hereof"  and
similar expressions are references to this Agreement and not to any particular
Section  of or Schedule to this Agreement; 
---|---|--- 
  



   | (b)| references  to a "Section" or a "Schedule" are references to a
Section of  or Schedule to this Agreement; 
---|---|--- 
  



   | (c)| words  importing the singular shall include the plural and vice
versa, and words importing gender  shall include the masculine, feminine and
neuter genders; 
---|---|--- 
  



    

 | \- 17 -| 
---|---|--- 

 



    



   | (d)| the  use of headings is for convenience of reference only and
shall not affect the construction  or interpretation hereof; 
---|---|--- 
  



   | (e)| if the  date on which any action is required to be taken
hereunder by any of the parties is not  a Business Day, such action shall be
required to be taken on the next succeeding day  that is a Business Day; 
---|---|--- 
  



   | (f)| a period  of Business Days is to be computed as beginning on the
day following the event that began  the period and ending at 4:30 p.m.
(Eastern Daylight Time) on the last day of the  period if the period is a
Business Day or at 4:30 p.m. on the next Business Day  if the last day of the
period does not fall on a Business Day; 
---|---|--- 
  



   | (g)| references  to any legislation or to any provision of any
legislation shall include any modification  or re-enactment thereof, any
legislation provision substituted therefor and all regulations,  rules and
interpretations issued thereunder or pursuant thereto; 
---|---|--- 
  



   | (h)| references  to any agreement or document shall be to such
agreement or document (together with the  schedules and exhibits attached
thereto), as it may have been or may hereafter be amended,  modified,
supplemented, waived or restated from time to time; and 
---|---|--- 
  



   | (i)| wherever  the term "includes" or "including" is used, it shall
be deemed  to mean "includes, without limitation" or "including, without
limitation",  respectively. 
---|---|--- 
  



   | 1.3| Currency 
---|---|--- 
  



  

Unless otherwise indicated, all dollar amounts referred to in this Agreement
are expressed in United States dollars. All references to "C$" are to
Canadian dollars.

  



   | 1.4| Accounting  Matters 
---|---|--- 
  



  

Unless otherwise stated, all accounting terms used in this Agreement shall
have the meanings attributable thereto under IFRS and all determinations of
an accounting nature required to be made shall be made in accordance with IFRS
consistently applied.

  



   | 1.5| Knowledge 
---|---|--- 
  



  

References to the "knowledge of the Corporation" mean the actual knowledge of
any of Anthony Giovinazzo, Andrew Williams, Dr. Albert Agro and Dr. Thierry
Bilbault, after reasonable inquiry, in their capacities as officers or
employees of the Corporation and not in their personal capacities.

  



   | 1.6| Accounting  Terms 
---|---|--- 
  



  

All accounting terms are to be interpreted in accordance with IFRS and all
determinations of an accounting nature in respect of the Corporation required
to be made shall be made in a manner consistent with IFRS.

  



    

 | \- 18 -| 
---|---|--- 

 



    



   | 1.7| Subsidiaries 
---|---|--- 
  



  

To the extent any covenants or agreements relate, directly or indirectly, to
a subsidiary of the Corporation, each such provision shall be construed as a
covenant by the Corporation to cause (to the fullest extent to which it is
legally capable) such subsidiary to perform the required action.

  



   | 1.8| Disclosure  Letter 
---|---|--- 
  



  

Any reference to a matter being disclosed or set out in the Disclosure Letter
shall mean disclosure in such section of the Disclosure Letter that
corresponds to the relevant Section of this Agreement and disclosure in any
section of the Disclosure Letter shall not be disclosure for the purposes of
any other section of the Disclosure Letter except that disclosure in a Section
of the Disclosure Letter that is referred to in another section of the
Disclosure Letter shall be disclosure for the purposes of the section of the
Disclosure Letter in which such reference is made.

  



   | 1.9| Schedules 
---|---|--- 
  



  

The Schedules to this Agreement, as listed below, are an integral part of
this Agreement:

  



     Schedule  |   | Description 
---|---|--- 
     |   | 
   Schedule A  |   | Plan of Arrangement 
  under Section 192 of the 
  _Canada Business Corporations Act_ 
     |   | 
   Schedule B  |   | Representations and Warranties of the Parent and
Acquiror 
     |   | 
   Schedule C  |   | Representations and Warranties of the Corporation 
     |   | 
   Schedule D  |   | Arrangement Resolution 
  



  

Article 2 
 Arrangement

  



   | 2.1| Arrangement 
---|---|--- 
  



  

The Corporation and the Acquiror agree that the Arrangement will be
implemented in accordance with and subject to the terms and conditions
of this Agreement and the Plan of Arrangement.

  



   | 2.2| Interim  Order 
---|---|--- 
  



  

As soon as reasonably practicable following the date hereof, but in any event
not later than September 13, 2016, the Corporation shall apply to the Court
in a manner acceptable to the Acquiror, acting reasonably, pursuant to section
192 of the Act and, in cooperation with the Acquiror, prepare, file and
diligently pursue an application for the Interim Order providing, among other
things:

  



    

 | \- 19 -| 
---|---|--- 

 



    



   | (a)| for  the calling and holding of the Meeting; 
---|---|--- 
  



   | (b)| for  the class of persons to whom notice is to be provided in
respect of the Arrangement and  the Meeting and for the manner in which such
notice is to be provided; 
---|---|--- 
  



   | (c)| that  the requisite approval for the Arrangement Resolution
shall be: 
---|---|--- 
  



   | (i)| at least  662/3% of the votes cast on the Arrangement Resolution
by the Securityholders  present in person or represented by proxy at the
Meeting voting as a single class and,  in the case of Warrantholders, on an
"as exercised" basis; and 
---|---|--- 
  



   | (ii)| to  the extent required, a majority of the votes attached to
Common Shares, voting as a separate  class, held by Shareholders present in
person or represented by proxy at the Meeting,  excluding for this purpose
votes attached to such Common Shares and Warrants held by  persons described
in items (a) through (d) of section 8.1(2) of MI 61-101; 
---|---|--- 
  



   | (d)| that,  subject to the foregoing and in all other respects, the
terms and conditions of the Corporation's  Constating Documents, including
quorum requirements, shall apply in respect of the Meeting; 
---|---|--- 
  



   | (e)| for  the grant of Dissent Rights; 
---|---|--- 
  



   | (f)| for  the notice requirements with respect to the presentation of
the application to the Court  for the Final Order; 
---|---|--- 
  



   | (g)| that  the Meeting may be adjourned or postponed from time to
time by the Corporation with the  consent of the Acquiror subject to the
terms of this Agreement without the need for additional  approval of the
Court; 
---|---|--- 
  



   | (h)| for  confirmation of the record date of the Meeting; and 
---|---|--- 
  



   | (i)| that  the record date for the Securityholders entitled to notice
of and to vote at the Meeting  will not change in respect of any
adjournment(s) or postponement(s) of the Meeting, unless  required by
applicable securities Laws. 
---|---|--- 
  



   | 2.3| The Meeting 
---|---|--- 
  



   | (a)| The  Corporation shall convene and conduct the Meeting in
accordance with the Interim Order,  the Corporation's Constating Documents
and Law as soon as reasonably practicable,  but in any event not later than
October 17, 2016, for the purpose of considering the  Arrangement Resolution
and for any other proper purpose as may be set out in the Circular  and
agreed to by the Acquiror, acting reasonably, and not adjourn, postpone or
cancel  (or propose the adjournment, postponement or cancellation of) the
Meeting without the  prior written consent of the Acquiror, except (i) for an
adjournment or postponement  for a maximum of four (4) Business Days for any
_bona fide_ reason entirely beyond  the control of the Corporation, provided
that such reason is not related to any other  Acquisition Proposal, (ii) as
otherwise required or permitted under this Agreement, (iii)  as required by
applicable Laws or (iv) for quorum purposes; 
---|---|--- 
  



    

 | \- 20 -| 
---|---|--- 

 



    



   | (b)| The  Corporation shall use commercially reasonable efforts to
abridge the timing contemplated  by NI 54-101 to the extent practicable and
permissible; 
---|---|--- 
  



   | (c)| Subject  to Article 6, the Corporation shall use its
commercially reasonable efforts to solicit  proxies for the approval of the
Arrangement Resolution and against any resolution submitted  by any person
that is inconsistent with the Arrangement Resolution and the completion  of
any of the transactions contemplated by this Agreement, including, if so
required  by, and at the cost of, the Acquiror, using the services of a proxy
solicitation agent; 
---|---|--- 
  



   | (d)| The  Corporation shall consult with the Acquiror in fixing the
date of the Meeting and the  record date of the Meeting, give notice to the
Acquiror of the Meeting and allow the  Acquiror and its Representatives to
attend the Meeting; 
---|---|--- 
  



   | (e)| The  Corporation shall promptly advise the Acquiror of any
communication (written or oral)  from or claims brought by (or threatened to
be brought by) any person in opposition to  the Arrangement and/or purported
exercise or withdrawal of Dissent Rights by Shareholders;  and not settle or
compromise, or agree to settle or compromise, any such claims without  the
prior written consent of the Acquiror which consent shall not be unreasonably
withheld  or delayed; 
---|---|--- 
  



   | (f)| The  Corporation shall not change the record date for the
Securityholders entitled to vote  at the Meeting in connection with any
adjournment or postponement of the Meeting unless  required by Law or
approved by the Acquiror; and 
---|---|--- 
  



   | (g)| The  Corporation shall instruct the Corporation's transfer agent
and any proxy solicitation  agent to report to the Acquiror and its
designated representatives concurrently with  their reports to the
Corporation and its representatives, and to promptly advise the  Acquiror, at
such times as the Acquiror may reasonably request and at least on a daily 
basis on each of the last 10 Business Days prior to the date of the Meeting,
as to the  aggregate tally of the proxies received by the Corporation in
respect of the Arrangement  Resolution and any other matters to be considered
at the Meeting. 
---|---|--- 
  



   | 2.4| The Circular 
---|---|--- 
  



   | (a)| As soon  as reasonably practicable after the date hereof, the
Corporation shall prepare and complete,  in consultation with the Acquiror,
the Circular, together with any other documents required  by the Interim
Order or applicable Laws in connection with the Meeting, in accordance  with
applicable Laws, which Circular shall, subject to Article 6, reflect the
unanimous  approval by the Board of this Agreement and the recommendation
that Securityholders vote  for the Arrangement Resolution and include a
written copy of each of the Fairness Opinions,  and the Corporation shall,
promptly after obtaining the Interim Order, cause the Circular  and such
other documents to be filed and sent to each Securityholder and other person 
as required by the Interim Order and Law, in each case so as to permit the
Meeting to  be held by the date specified in Section 2.3(a). 
---|---|--- 
  



    

 | \- 21 -| 
---|---|--- 

 



    



   | (b)| The  Corporation shall ensure that the Circular complies in all
material respects with the  Interim Order and Law, does not contain any
Misrepresentation (except that the Corporation  shall not be responsible for
any information relating to the Acquiror or its Affiliates).  Without
limiting the generality of the foregoing, the Circular must include a
statement  that the Board and the Special Committee, as applicable, has
received the Fairness Opinions,  and has unanimously, after receiving legal
and financial advice and the recommendation  of the Special Committee,
determined that the Arrangement Resolution is in the best interests  of the
Corporation and is fair to the Securityholders and recommends that the
Shareholders  and Warrantholders (voting together as a single class on an "as
exercised"  basis) vote in favour of the Arrangement Resolution (the "Board
Recommendation"). 
---|---|--- 
  



   | (c)| The  Corporation shall specify in the Circular the time that is
48 hours, excluding Saturdays  and holidays, before the Meeting (or any
permitted adjournment(s) or postponement(s)  thereof) (the "Proxy Cut-off")
before which time proxies to be used  at the Meeting must be deposited with
the Corporation or its transfer agent, and shall  not waive the Proxy Cut-
off, in whole or in part, without the prior written consent of  the Acquiror,
such consent not to be unreasonably withheld or delayed. 
---|---|--- 
  



   | (d)| Prior  to the printing of the Circular and during the course of
its preparation, the Corporation  shall provide the Acquiror and its counsel
with a reasonable opportunity to review and  comment on it and other related
documents, and reasonable consideration shall be given  to any comments made
by them, provided that all information relating solely to Acquiror  or its
Affiliates included in the Circular shall be in form and content
satisfactory  to Acquiror, acting reasonably. The Acquiror shall provide to
the Corporation for inclusion  in the Circular or other related documents
such information regarding the Acquiror and  its Affiliates as is required by
applicable Laws or reasonably requested by the Corporation  to be included in
the Circular. The Acquiror represents, warrants and covenants that  any
information it provides to the Corporation for inclusion in the Circular will
be  accurate and complete in all material respects as of the relevant date of
such information  and will not contain any Misrepresentation. 
---|---|--- 
  



   | (e)| The  Corporation and the Acquiror shall each promptly notify the
other party if at any time  before the Meeting it becomes aware (in the case
of the Corporation only with respect  to the Corporation and in the case of
the Acquiror only with respect to the Acquiror  and its Affiliates) that the
Circular contains a Misrepresentation, or that otherwise  requires an
amendment or supplement to the Circular, and the parties shall co-operate  in
the preparation of any amendment or supplement to the Circular, as required or
appropriate,  and the Corporation shall promptly mail, file or otherwise
publicly disseminate any amendment  or supplement to the Circular to the
Securityholders as required by the Court or applicable  Laws. 
---|---|--- 
  



    

 | \- 22 -| 
---|---|--- 

 



    



   | 2.5| Final Order 
---|---|--- 
  



  

If the Arrangement Resolution has been approved by the Securityholders at the
Meeting in accordance with the Interim Order, subject to the terms of this
Agreement, the Corporation shall as soon as reasonably practicable thereafter,
take all steps necessary or desirable to submit the Arrangement to the Court
and diligently pursue an application for the Final Order pursuant to section
192 of the Act, but in any event not later than two (2) Business Days after
the Arrangement Resolution is passed at the Meeting or within such other time
period as may be agreed upon by the parties, each acting reasonably.

  



   | 2.6| Court Proceedings 
---|---|--- 
  



  

Subject to the terms of this Agreement, the Acquiror shall cooperate with and
assist the Corporation in seeking the Interim Order and the Final Order,
including by providing to the Corporation, on a timely basis, any information
required to be supplied by the Acquiror in connection therewith. The
Corporation shall provide the Acquiror and its counsel with reasonable
opportunity to review and comment upon drafts of all material to be filed
with the Court in connection with the Arrangement, and will give reasonable
consideration to all such comments. The Corporation shall provide to the
Acquiror and its counsel, on a timely basis, copies of any notice
of appearance, evidence or other documents served on the Corporation or its
counsel in respect of the application for the Interim Order or the Final
Order or any appeal therefrom and of any notice (written or oral) received by
the Corporation indicating any intention to oppose the granting of the
Interim Order or the Final Order or to appeal the Interim Order or the Final
Order. The Corporation shall ensure that all material filed with the Court in
connection with the Arrangement is consistent in all material respects with
the terms of this Agreement and the Plan of Arrangement. The Corporation shall
not file any material with the Court in connection with the Arrangement or
serve any such material, or agree to modify or amend any material so filed or
served, except as contemplated by this Agreement or with the Acquiror's prior
written consent, acting reasonably, provided the Acquiror is not required to
agree or consent to any increase in, or variation of the form of, the
Consideration or other modification or amendment to such filed or served
materials that expands or increases the Acquiror's obligations, or diminishes
or limits the Acquiror's rights, set forth in any such filed or served
materials or under this Agreement. The Corporation shall oppose any proposal
from any person that the Final Order contain any provision materially
inconsistent with this Agreement, and if required by the terms of the Final
Order or by Law to return to Court with respect to the Final Order do so only
after notice to, and in consultation and cooperation with, the Acquiror. The
Corporation shall not object to legal counsel to the Acquiror making
submissions on the application for the Interim Order and the application for
the Final Order as such counsel considers appropriate, provided that the
Corporation is advised of the nature of any submissions not less than two
Business Days prior to the hearing and such submissions are consistent in all
material respects with this Agreement and the Plan of Arrangement.

  



    

 | \- 23 -| 
---|---|--- 

 



    



   | 2.7| Articles  of Arrangement and Effective Date 
---|---|--- 
  



  

The parties agree that the Arrangement shall be implemented in accordance
with the terms and conditions of this Agreement and the Plan of Arrangement.
The Articles of Arrangement shall implement the Plan of Arrangement. As soon
as reasonably practicable and in any event no later than the third (3rd)
Business Day after the satisfaction or waiver (subject to applicable Laws) of
the conditions set forth in Article 9 (excluding conditions that, by their
terms, cannot be satisfied until the Effective Date, but subject to the
satisfaction or waiver (subject to applicable Law) of those conditions as of
the Effective Date), and unless another date is agreed to in writing by the
parties, the Corporation shall file the Articles of Arrangement with the
Director pursuant to section 192 of the Act to give effect to the Arrangement
and implement the Plan of Arrangement provided that the Articles of
Arrangement shall not be sent to the Director, for endorsement and filing by
the Director, except as contemplated hereby or with the Acquiror's prior
written consent such consent not to be unreasonably withheld or delayed. The
Arrangement shall become effective at the Effective Time and will have all of
the effects provided by applicable Law, and the steps to be carried out
pursuant to the Arrangement shall become effective at the Effective Time in
the order and at the times set forth in the Plan of Arrangement. The closing
of the Arrangement will take place at the offices of Borden Ladner Gervais
LLP, Toronto, Ontario, or such other place as agreed upon by the parties.

  



   | 2.8| Payment  of Consideration 
---|---|--- 
  



  

The Acquiror shall, subject to the satisfaction or waiver of the conditions
set out in Sections 9.1 and 9.3, following receipt of the Final Order and
prior to the filing by the Corporation of the Articles of Arrangement with the
Director, deliver or cause to be delivered sufficient cash to the Depositary
to pay in full the aggregate Consideration payable to Securityholders (other
than Securityholders exercising Dissent Rights and who have not withdrawn
their notice of objection) pursuant to the Plan of Arrangement.

  



   | 2.9| Announcement  and Shareholder Communications 
---|---|--- 
  



  

The Acquiror and the Corporation shall jointly publicly announce the
transactions contemplated hereby promptly following the execution of
this Agreement, the text and timing of such announcement to be approved in
writing by the parties in advance, acting reasonably. The parties shall
cooperate in the preparation of presentations, if any, to the Securityholders
regarding the Arrangement. Neither party shall (a) issue any press release or
otherwise make public announcements with respect to this Agreement or the
Plan of Arrangement without the prior written consent of the other party
(which consent shall not be unreasonably withheld or delayed), except as
permitted by Article 6, or (b) subject to Article 7, make any filing with any
Governmental Authority with respect thereto without the prior written consent
of the other party; provided, however, that the foregoing shall be subject to
each party's overriding obligation to make any disclosure or filing required
under applicable Laws or stock exchange rules, and the party making such
disclosure shall use commercially reasonable efforts to give prior oral or
written notice to the other party and reasonable opportunity to review or
comment on the disclosure or filing, and if such prior notice is not
possible, to give such notice immediately following the making of such
disclosure or filing.

  



    

 | \- 24 -| 
---|---|--- 

 



    



   | 2.10| Withholding  Taxes 
---|---|--- 
  



  

The Acquiror, the Corporation and the Depositary shall be entitled to deduct
and withhold from any consideration or other payments payable or otherwise
deliverable to any person hereunder or under the Plan of Arrangement such
amounts as the Acquiror, the Corporation or the Depositary are entitled,
required or reasonably believe to be required to deduct and withhold therefrom
under any provision of any applicable Laws or the interpretation or
administration thereof in respect of Taxes and remit such deducted and
withheld amounts to the appropriate Governmental Authority. To the extent
that such amounts are so properly deducted, withheld and remitted on a timely
basis to the relevant Governmental Authority, such amounts shall be treated
for all purposes under this Agreement or the Plan of Arrangement as having
been paid to the person to whom such amounts would otherwise have been paid.

  



   | 2.11| List of  Securityholders 
---|---|--- 
  



  

At the reasonable request of the Acquiror from time to time, at the cost of
the Corporation, the Corporation shall promptly provide the Acquiror with a
list (in both written and electronic form) of (i) the registered Shareholders,
together with their addresses and respective holdings of Common Shares, (ii)
the names, addresses and holdings of all persons having rights issued by the
Corporation to acquire Common Shares (including Warrantholders and
Optionholders), and (iii) participants and book-based nominee
registrants such as CDS and Co., CEDE and Co. and DTC, and non-objecting
beneficial owners of Common Shares, together with their addresses and
respective holdings of Common Shares. The Corporation shall from time to time
require that its registrar and transfer agent furnish the Acquiror with such
additional information, including updated or additional lists of Shareholders,
and lists of securities positions and other assistance as the Acquiror may
reasonably request in order to be able to communicate with respect to the
Arrangement with the Shareholders and with such other persons as are entitled
to vote on the Arrangement Resolution.

  



  

Article 3 
 Representations and Warranties of the Parent and Acquiror

  



   | 3.1| Representations  and Warranties 
---|---|--- 
  



  

The Acquiror and the Parent each jointly makes to the Corporation the
representations and warranties set out in Schedule B to this Agreement and
acknowledges that the Corporation is relying upon these representations and
warranties in connection with the entering into of this Agreement.

  



   | 3.2| Survival  of Representations and Warranties 
---|---|--- 
  



  

The representations and warranties of the Acquiror and the Parent contained
in this Agreement shall survive the execution and delivery of this
Agreement and shall expire and be terminated and extinguished upon the
Effective Time.

  



    

 | \- 25 -| 
---|---|--- 

 



    



  

Article 4 
 Representations and Warranties of the Corporation

  



   | 4.1| Representations  and Warranties 
---|---|--- 
  



  

Subject to anything disclosed in (i) the applicable section or subsection of
the Disclosure Letter (it being agreed that the disclosure of any fact or
item in any section or subsection of the Disclosure Letter shall only be
deemed to be an exception to (or, as applicable, disclosure for the purposes
of) the representations and warranties of the Corporation that are contained
in the corresponding section of this Agreement), the Corporation hereby makes
to the Acquiror the representations and warranties set out in Schedule C to
this Agreement, and acknowledges that the Acquiror is relying upon these
representations and warranties in connection with the entering into of this
Agreement.

  



   | 4.2| Survival  of Representations and Warranties 
---|---|--- 
  



  

The representations and warranties of the Corporation contained in this
Agreement shall survive the execution and delivery of this Agreement and
shall expire and be terminated and extinguished at the Effective Time.

  



  

Article 5 
 Conduct of Business

  



   | 5.1| Conduct  of Business by the Corporation 
---|---|--- 
  



  

The Corporation agrees that during the period from the date of this Agreement
until the earlier of the Effective Time and the time that this Agreement is
terminated in accordance with its terms, unless the Acquiror shall otherwise
consent in writing or as otherwise expressly contemplated or permitted by
this Agreement, the Plan of Arrangement or the Disclosure Letter, or as
required by Law or any Governmental Authority, the Corporation shall, and
shall cause each of its subsidiaries to:

  



   | (a)| conduct  its business in the Ordinary Course and use
commercially reasonable efforts to preserve  intact its present business
organization and assets; 
---|---|--- 
  



   | (b)| use  commercially reasonable efforts to maintain and preserve
intact the current business  organization, assets, properties and business of
the Corporation and its subsidiaries; 
---|---|--- 
  



   | (c)| use  commercially reasonable efforts to keep available the
services of the present employees  and agents of the Corporation; 
---|---|--- 
  



   | (d)| use  commercially reasonable efforts to maintain and preserve
good relations with, and the  goodwill of relationships with key suppliers,
distributors, employees, inventors, vendors,  contract research
organizations, customers and others having material business relationships 
with it and its subsidiaries; 
---|---|--- 
  



    

 | \- 26 -| 
---|---|--- 

 



    



   | (e)| not  split, combine, consolidate or reclassify any outstanding
shares of the Corporation or  its subsidiaries nor undertake any other
capital reorganization, nor declare, set aside  or pay any dividends on or
make any other distributions (whether in cash, stock or property  or any
combination thereof), nor reduce capital in respect of outstanding shares of
the  Corporation or its subsidiaries; 
---|---|--- 
  



   | (f)| not  amend its articles or by-laws, constating documents,
including the Corporation's  Constating Documents, or the terms of its
outstanding securities, or, in the case of  any subsidiary which is not a
corporation, its similar organizational documents; 
---|---|--- 
  



   | (g)| not  issue, grant, deliver, sell, pledge, award or otherwise
encumber, or authorize the issuance,  grant, delivery, sale, pledge or other
encumbrance of any shares of capital stock, securities,  options, warrants or
similar rights exercisable or exchangeable for or convertible into  such
capital stock, of the Corporation or any of its subsidiaries, other than the
issuance  of Common Shares upon the exercise of currently outstanding Rights
in accordance with  their terms; 
---|---|--- 
  



   | (h)| not  redeem or purchase or otherwise acquire or offer to redeem,
purchase or otherwise acquire  any outstanding securities of the Corporation
or its subsidiaries; 
---|---|--- 
  



   | (i)| not  reorganize, amalgamate, combine or merge with any other
person or adopt or enter into  a plan of liquidation or dissolution or
resolutions providing for the liquidation or  dissolution of the Corporation
or any of its subsidiaries; 
---|---|--- 
  



   | (j)| not,  without consent or permission of the Acquiror, which
consent or permission not to be  unreasonably withheld, delayed, or
conditioned, enter into or modify any employment,  consultant, severance,
collective bargaining or similar plans, agreements, policies or  arrangements
(including any Employee Plans) with, or establish, grant or increase in  any
material respect any bonuses, salary increases, remuneration, stock options,
pension  or supplemental pension or other benefits (including any Employee
Plans), profit sharing,  retirement allowances, deferred compensation,
incentive compensation, severance or termination  pay or any other form of
compensation to, or make any loan to, any of its employees,  consultants,
directors or officers, other than (i) as required by Law, or (ii) as
required  pursuant to the terms of any employment, pension, supplemental
pension, termination or  compensation plans, agreements, arrangements or
policies (including any Employee Plans)  existing as of the date hereof, or
take or propose any action to effect any of the foregoing; 
---|---|--- 
  



   | (k)| not  acquire or commit to acquire (by amalgamation, arrangement,
merger, consolidation, acquisition  of stock or assets or otherwise),
directly or indirectly, in one transaction or in a  series of related
transactions, assets, securities, properties, interests or businesses  having
a value in excess of $100,000 in the aggregate; 
---|---|--- 
  



    

 | \- 27 -| 
---|---|--- 

 



    



  



   | (l)| not,  without consent or permission of the Acquiror, which
consent or permission not to be  unreasonably withheld, delayed, or
conditioned, sell, pledge, lease, dispose of, surrender,  mortgage, license,
option, encumber or otherwise dispose of, or commit to sell, pledge,  lease,
dispose of, surrender, mortgage, license, option, encumber or otherwise
dispose  of, or transfer any assets or group of related assets (through one
or more related or  unrelated transactions), or any interest in any assets or
group of related assets, including  any interest in any of the Company Owned
IP or instruct the owner of any of the Company  Licensed Registered IP to
sell, pledge, lease, dispose of, surrender, mortgage, license,  option,
encumber or otherwise dispose of, or commit to sell, pledge, lease, dispose
of,  surrender, mortgage, license, option, encumber or otherwise dispose of,
or transfer any  of the Company Licensed Registered IP, other than in the
Ordinary Course or immaterial  assets; 
---|---|--- 
  



   | (m)| not  incur or commit to any capital expenditures having a value
in excess of $250,000 in the  aggregate; 
---|---|--- 
  



   | (n)| not  make any loan or advance to, or any capital contribution or
investment in, or assume,  guarantee or otherwise become liable with respect
to the liabilities or obligations of,  any person; 
---|---|--- 
  



   | (o)| not  prepay any indebtedness (whether on account of borrowed
money, deferred purchase price  of property or otherwise) before its
scheduled maturity; 
---|---|--- 
  



   | (p)| not  increase, create, incur, assume or otherwise become liable,
in one transaction or in  a series of related transactions, with respect to
any indebtedness for borrowed money  or guarantees thereof; 
---|---|--- 
  



   | (q)| not  make any bonus or profit sharing distribution or similar
payment of kind except as required  pursuant to the terms of any Contract or
profit sharing plan existing on the date hereof; 
---|---|--- 
  



   | (r)| not  enter into any interest rate, currency, equity or commodity
swaps, hedges, derivatives,  forward sales contracts or similar financial
instruments; 
---|---|--- 
  



   | (s)| not  pay, discharge or satisfy any material Claims, liabilities
or obligations other than  the payment, discharge or satisfaction, in the
Ordinary Course of liabilities reflected  or reserved against in the
Corporation's annual audited financial statements for  the year ended
December 31, 2015, incurred in the Ordinary Course subsequent to  December
31, 2015 and reflected in the Corporation's reviewed financial statements 
for the six month period ended June 30, 2016 or costs related to the
Arrangement or incurred  in the Ordinary Course, in each case after June 30,
2016; 
---|---|--- 
  



   | (t)| not  waive, release, compromise, terminate or relinquish any
material contractual right, material  right under any licence or permit or
other material legal rights or Claims, other than  in the Ordinary Course; 
---|---|--- 
  



   | (u)| not  amend or modify or terminate or waive any right under any
Material Contract or enter  into any contract or agreement that would be a
Material Contract if in effect on the  date hereof; 
---|---|--- 
  



    

 | \- 28 -| 
---|---|--- 

 



    

  



   | (v)| duly  and on a timely basis file all Tax Returns required to be
filed by it, which shall be  correct and complete in all material respects,
on or after the date hereof pursuant to  applicable Laws in a manner
consistent with past practice; 
---|---|--- 
  



   | (w)| timely  pay, withhold, collect and remit to the appropriate
Governmental Entity in a timely fashion  all amounts required to be so paid,
withheld, collected or remitted; 
---|---|--- 
  



   | (x)| not  (i) make, rescind or change any election relating to Taxes,
annual Tax accounting  period or method of Tax accounting in any material
respect, (ii) enter into (or  offer to enter into) any agreement (including
any waiver) with any Governmental Authority  relating to Taxes, (iii) without
the prior written consent of the Acquiror, settle  (or offer to settle) any
material Tax claim, audit, proceeding or re-assessment, or (iv) amend  any
Tax Return or change from most recent practice any manner of reporting income
or  claiming deductions for Tax purposes; 
---|---|--- 
  



   | (y)| except  as required by Law and in a manner consistent with past
practice, not make any material  Tax election, information schedule, return
or designation, settle or compromise any material  Tax claim, assessment,
reassessment or liability, file any amended Tax Return, enter  into any
material agreement with a Governmental Authority with respect to Taxes,
surrender  any right to claim a material Tax abatement, reduction, deduction,
exemption, credit  or refund, consent to the extension or waiver of the
limitation period applicable to  any material Tax matter or materially amend
or change any of its methods or reporting  income, deductions or accounting
for income Tax purposes except as may be required by  Law; 
---|---|--- 
  



   | (z)| keep  the Acquiror informed, on a current basis, of any events,
discussions, notices or changes  with respect to any Tax (other than
communications in the Ordinary Course which could  not reasonably be expected
to be material to the Corporation), criminal or regulatory  investigation or
action involving the Corporation and any of its subsidiaries; 
---|---|--- 
  



   | (aa)| not  make any changes to the Corporation's existing accounting
policies other than as  required by applicable Laws, a Governmental Authority
or IFRS; 
---|---|--- 
  



   | (bb)| not  amend, modify, terminate, cancel or let lapse any material
insurance (or re-insurance)  policy of the Corporation or any subsidiary in
effect on the date of this Agreement,  unless simultaneously with such
termination, cancellation or lapse, replacement policies  underwritten by
insurance and re-insurance companies of nationally recognized standing 
providing coverage equal to or greater than the coverage under the terminated,
cancelled  or lapsed policies for substantially similar premiums are in full
force and effect; 
---|---|--- 
  



   | (cc)| not  engage in any transaction with any related parties; 
---|---|--- 
  



    

 | \- 29 -| 
---|---|--- 

 



    



   | (dd)| subject  to Section 5.1(ee), not, without consent or permission
of the Acquiror, which consent  or permission not to be unreasonably
withheld, delayed, or conditioned, commence or cancel,  waive, release,
assign, settle or compromise any Claims or any rights relating to or  any
interest in any litigation, proceeding, Claim, action, assessment or
investigation  involving the Corporation or any of its material assets; 
---|---|--- 
  



   | (ee)| not  settle, compromise, concede or acquiesce to any threat,
assertion, demand or claim against  the Corporation regarding Company IP or
the Product; 
---|---|--- 
  



   | (ff)| not,  without consent or permission of the Acquiror, which
consent or permission not to be  unreasonably withheld, delayed, or
conditioned, abandon or materially reduce the scope  of any pending or
Registered IP; 
---|---|--- 
  



   | (gg)| not,  without consent or permission of the Acquiror, which
consent or permission not to be  unreasonably withheld, delayed, or
conditioned, (i) in respect of any Company Assets  other than Company IP,
waive, release, surrender, let lapse, grant or transfer any material  right
or value or amend, modify or change, or agree to amend, modify or change, in
any  material respect any existing material Authorization, right to use,
contract or other  material document or, (ii) in respect of Company IP,
waive, release, surrender,  let lapse, grant or transfer any material right
or value in the Company IP or instruct  the owner of Company Licensed
Registered IP to waive, release, surrender, let lapse,  grant or transfer any
material right or value in any Company Licensed Registered IP; 
---|---|--- 
  



   | (hh)| not  abandon or fail to diligently pursue any application for
any material Authorizations,  licenses, leases, or registrations or take any
action, or fail to take any action, that  could lead to the termination of
any material Authorizations, licenses, leases or registrations; 
---|---|--- 
  



   | (ii)| not,  without consent or permission of the Acquiror, which
consent or permission not to be  unreasonably withheld, delayed, or
conditioned, except in the Ordinary Course, (i) grant  or acquire, agree to
grant to or acquire from any person, abandon or permit to lapse  any rights
to any material Intellectual Property Rights or disclose or agree to
disclose  to any person, other than Representatives of the Acquiror, any
material trade secrets,  or (ii) fail to take any action necessary or
material action advisable to protect  or maintain the Intellectual Property
Rights; 
---|---|--- 
  



   | (jj)| not  enter into or amend any Contract with any broker, finder
or investment banker, including  any amendment of any of the Contracts listed
in Section 17 of the Disclosure Letter; 
---|---|--- 
  



   | (kk)| not,  without consent or permission of the Acquiror, which
consent or permission not to be  unreasonably withheld, delayed, or
conditioned, grant or commit to grant an exclusive  licence or otherwise
transfer any Intellectual Property Rights or exclusive rights in or in 
respect thereto, other than in the Ordinary Course or to a wholly-owned
subsidiary of  the Corporation; 
---|---|--- 
  



    

 | \- 30 -| 
---|---|--- 

 



    



   | (ll)| not  take any action or fail to take any action that is
intended to, or would reasonably be  expected to, individually or in the
aggregate, prevent, materially delay or materially  impede the ability of the
Corporation to consummate the Arrangement or the other transactions 
contemplated by this Agreement; 
---|---|--- 
  



   | (mm)| not  take any action that would cause any representation or
warranty of the Corporation set  out in Schedule C to be untrue or incorrect
in any respect such that the condition  at Section 9.3(a) would not be
satisfied; 
---|---|--- 
  



   | (nn)| not  announce an intention, enter into any agreement, or
otherwise authorize, agree, resolve  or make a commitment, whether or not in
writing, to do any of the things prohibited by  any of the foregoing
subparagraphs; and/or 
---|---|--- 
  



   | (oo)| except  to the extent required by Law to protect patient
safety, not amend the protocol for clinical  trials CTH-300 or CTH-301,
modify or take any action that deviates from the current clinical  trial
study designs, time lines and protocols for clinical trials CTH-300 and
CTH-301  (excluding the amendment for at home titration recommended by the
Data and Safety Monitoring  Board), including without limitation, taking any
action that would impact the study cycle  time line, patient and study site
recruitment and enrollment status, patient standards  of care, study
objectives or strategy, protocol complexity, or the statistical analysis. 
---|---|--- 
  



  

Article 6 
 Covenants Relating to Acquisition Proposals

  



   | 6.1| Non-Solicitation 
---|---|--- 
  



   | (a)| Except  as provided in Section 6.3 of this Agreement, the
Corporation and its subsidiaries  shall not, directly or indirectly through
any Representative of the Corporation, or otherwise,  and shall not permit
any such person to: 
---|---|--- 
  



   | (i)| solicit,  initiate, encourage or otherwise facilitate (including
by way of furnishing or providing  copies of, access to, or disclosure of,
any confidential information, properties, facilities,  books or records of
the Corporation or any subsidiary or entering into any form of agreement, 
arrangement or understanding) any inquiry, proposals or offer from any person
(other  than the Acquiror and its Affiliates) that relates to, constitutes or
would reasonably  be expected to constitute or lead to, an Acquisition
Proposal or otherwise cooperate  in any way with, or assist or participate
in, facilitate or encourage, any effort or  attempt by any other person to do
or seek to do any of the foregoing; 
---|---|--- 
  



   | (ii)| enter  into or otherwise engage or participate in any
discussions or negotiations with any person  (other than the Acquiror, its
Affiliates and their Representatives) regarding, or provide  information to
any person with respect to, any inquiry, proposal or offer that relates  to,
constitutes or would reasonably be expected to constitute or lead to, an
Acquisition  Proposal; 
---|---|--- 
  



    

 | \- 31 -| 
---|---|--- 

 



    



   | (iii)| withdraw,  modify or qualify, or propose publicly or state an
intention to withdraw, modify or qualify  the Board Recommendation; 
---|---|--- 
  



   | (iv)| accept,  approve, endorse, recommend or take no position or
remain neutral with respect to, or  propose to accept, approve, endorse,
recommend or take no position or remain neutral  with respect to any
Acquisition Proposal (it being understood that publicly taking no  position
or a neutral position with respect to a publicly announced, or otherwise
publicly  disclosed, Acquisition Proposal for a period of no more than five
(5) Business Days following  such public announcement or public disclosure
will not be considered to be in violation  of this Section 6.1, provided the
Board has rejected such Acquisition Proposal and  affirmed the Board
Recommendation before the end of such five (5) Business Day period (or  in
the event the Meeting is scheduled to occur within such five (5) Business Day
period,  prior to the third (3rd) Business Day prior to the date of the
Meeting)); or 
---|---|--- 
  



   | (v)| accept,  approve, endorse, recommend or enter into (other than a
confidentiality agreement as  contemplated under Section 6.3) or publicly
propose to accept, approve, endorse,  recommend or enter into any agreement,
understanding or arrangement in respect of an  Acquisition Proposal. 
---|---|--- 
  



   | (b)| The  Corporation shall, and shall cause its subsidiaries and its
and their respective Representatives  to, immediately cease and terminate,
and cause to be terminated, any existing solicitation,  encouragement,
discussion, negotiation, or other activities commenced on or prior to  the
date of this Agreement with any person (other than the Acquiror, its
Affiliates or  any of their Representatives) with respect to any inquiry,
proposal or offer that relates  to, constitutes or would reasonably be
expected to constitute or lead to, an Acquisition  Proposal, and in
connection therewith, the Corporation will: 
---|---|--- 
  



   | (i)| immediately  discontinue access to and disclosure of all
information, including any data room and  any confidential information,
properties, facilities, books and records of the Corporation  or any of its
subsidiaries; and 
---|---|--- 
  



   | (ii)| promptly  request and exercise the rights it has to require (A)
the return or destruction of all  copies of any confidential information
regarding the Corporation or any subsidiary provided  to any person, and (B)
the destruction of all material including or incorporating or  otherwise
reflecting such confidential information regarding the Corporation or any
subsidiary. 
---|---|--- 
  



    

 | \- 32 -| 
---|---|--- 

 



    



   | (c)| The  Corporation represents and warrants that neither it nor any
of its subsidiaries has waived  any confidentiality, standstill or similar
agreement and further represents, warrants  and covenants (as applicable)
that (a) the Corporation and its subsidiaries shall  use commercially
reasonable efforts to enforce each confidentiality, standstill, non-
disclosure,  non-solicitation, use, business purpose or similar agreement,
restriction or covenant  to which the Corporation or any subsidiary is a
party, and (b) neither the Corporation,  nor any subsidiary or any of their
respective Representatives have or will, without the  prior written consent
of the Acquiror (which may be withheld or delayed in the Acquiror's  sole and
absolute discretion), release any person from, or waive, amend, suspend or
otherwise  modify such person's obligations respecting the Corporation or any
of its subsidiaries,  under any confidentiality, standstill, non-disclosure,
non-solicitation, use, business  purpose or similar agreement, restriction or
covenant to which the Corporation or any  subsidiary is a party (it being
acknowledged by the Acquiror that any automatic termination  or release of
any standstill or other restriction of any such agreements as the result  of
entering into this Agreement or as otherwise provided in the applicable
agreement,  will not constitute a breach of this Section 6.1(c), provided
that all agreements  containing such a standstill restriction have been
disclosed in Section 6.1(c) of  the Disclosure Letter and includes a
description of all such standstill provisions. 
---|---|--- 
  



   | (d)| The  Corporation shall ensure that its Representatives are aware
of the prohibitions in this  Section 6.1. 
---|---|--- 
  



   | 6.2| Notification  of Acquisition Proposals 
---|---|--- 
  



  

If the Corporation or any of its subsidiaries or any of their respective
Representatives, receives or otherwise becomes aware of any inquiry,
proposal or offer that constitutes or would reasonably be expected to
constitute or lead to an Acquisition Proposal, or any request for copies of,
access to, or disclosure of, confidential information relating to the
Corporation or any subsidiary in connection with an Acquisition Proposal,
including but not limited to information, access, or disclosure relating to
the properties, facilities, books or records of the Corporation or any
subsidiary, the Corporation shall promptly (and in any event within 24 hours)
notify the Acquiror, at first orally and then as soon as practicable (and in
any event within 24 hours) in writing, of such Acquisition Proposal, inquiry,
proposal, offer or request, including a description of its material terms and
conditions, and, unless and only to the extent prohibited by any
confidentiality agreement or applicable provisions entered into by the
Corporation prior to the date hereof, shall provide the Acquiror the identity
of such person making such Acquisition Proposal, inquiry, proposal, offer or
request and with copies of all material written documents, material or
substantive correspondence or other material received (and, if not in writing
or electronic form, a description of the material terms thereof) in respect
of, from or on behalf of any such person. The Corporation shall keep the
Acquiror reasonably informed of the status of developments and (to the extent
permitted by Section 6.3) negotiations with respect to any Acquisition
Proposal, inquiry, proposal, offer or request following a change of status as
soon as practicable but not less than on a daily basis.

  



   | 6.3| Responding  to Acquisition Proposals and Superior Proposals 
---|---|--- 
  



   | (a)| Notwithstanding  Section 6.1(a), if at any time prior to
obtaining the approval by the Securityholders  of the Arrangement Resolution,
the Corporation receives a written Acquisition Proposal  made after the date
hereof (that was not solicited in contravention of 6.1(a)), the Corporation 
and its Representatives may: 
---|---|--- 
  



    

 | \- 33 -| 
---|---|--- 

 



    



   | (i)| contact  the person making such Acquisition Proposal and its
Representatives solely to clarify  the terms and conditions of such
Acquisition Proposal; and 
---|---|--- 
  



   | (ii)| engage  in discussions and negotiations with the person making
such Acquisition Proposal and  its Representatives, and may provide copies
of, access to or disclosure of information,  properties, facilities, books or
records of the Corporation or its subsidiaries for a  maximum of 10 calendar
days after the day on which access or disclosure is first afforded  to the
person making the Acquisition Proposal or its Representatives, provided that: 
---|---|--- 
  



   | (A)| the  Board, after consultation with its financial advisors and
its outside legal counsel,  determines in good faith that such Acquisition
Proposal constitutes or could reasonably  be expected to constitute or lead
to a Superior Proposal; 
---|---|--- 
  



   | (B)| such  person was not prohibited from making such Acquisition
Proposal pursuant to an existing  confidentiality, standstill, non-
disclosure, use, business purpose or similar restriction  with the
Corporation or any of its subsidiaries; 
---|---|--- 
  



   | (C)| the  Corporation has been, and continues to be, in compliance
with its obligations under this  Article 6; and 
---|---|--- 
  



   | (D)| the  Corporation first enters into a confidentiality and
standstill agreement with such person  that contains a standstill provision
that restricts such person from acquiring, or publicly  announcing an
intention to acquire, any securities or assets of the Corporation (other 
than pursuant to a Superior Proposal) for a period of not less than 12 months
from the  date of such Agreement (unless such person is already a party to a
confidentiality or  standstill agreement with the Corporation) provided that
such confidentiality and standstill  agreement may not include any provision
calling for an exclusive right to negotiate with  the Corporation or any of
its subsidiaries and may not restrict the Corporation from  complying with
this Agreement (including this Article 6) and provided the Corporation  sends
a copy of any such confidentiality and standstill agreement to the Acquiror
promptly  upon its execution and thereafter the Acquiror is provided with
access to any information  that was provided to such person and not
previously provided to the Acquiror prior to  or concurrently with such
information being provided to such person. 
---|---|--- 
  



  

Notwithstanding the foregoing, the Corporation shall not provide any
commercially sensitive non-public information to any person that might
be considering an Acquisition Proposal that was not, or concurrently
therewith is not, provided to the Acquiror.

  



    

 | \- 34 -| 
---|---|--- 

 



    



   | (b)| If the  Corporation receives an Acquisition Proposal prior to
the approval of the Arrangement  Resolution by the Securityholders that the
Board determines in good faith, after consultation  with its financial
advisors and outside counsel, constitutes a Superior Proposal, the  Board may
enter into a definitive agreement with respect to such Superior Proposal, if 
and only if: 
---|---|--- 
  



   | (i)| the  person making the Superior Proposal was not prohibited from
making such Superior Proposal  pursuant to an existing confidentiality,
standstill, non-disclosure, use, business purpose  or similar restriction
with the Corporation or any of its subsidiaries; 
---|---|--- 
  



   | (ii)| the  Corporation has been, and continues to be, in compliance
with its obligations under this  Article 6; 
---|---|--- 
  



   | (iii)| the  Corporation has delivered written notice to the Acquiror
of the determination of the  Board that the Acquisition Proposal is a
Superior Proposal and of the intention of the  Board to approve or recommend
such Superior Proposal and/or of the Corporation to enter  into an agreement
with respect to such Superior Proposal, together with a copy of such 
agreement (including any financing documents supplied to the Corporation in
connection  therewith unless precluded to do so by confidentiality provisions
contained therein)  (the "Superior Proposal Notice"); 
---|---|--- 
  



   | (iv)| at  least five (5) Business Days have elapsed since the date
the Superior Proposal Notice was  received by the Acquiror and the date on
which the Acquiror received all of the materials  set forth in Section
6.3(b)(iii), which five (5) Business Day period is referred to  as the "Match
Period"; 
---|---|--- 
  



   | (v)| during  any Match Period, the Acquiror has had the opportunity
(but not the obligation), in accordance  with Section 6.3(c), to offer to
amend this Agreement and the Arrangement in order  for such Acquisition
Proposal to cease to be a Superior Proposal; 
---|---|--- 
  



   | (vi)| after  the Match Period, the Board has determined in good
faith, after consultation with its  outside legal counsel and financial
advisors, that such Acquisition Proposal continues  to constitute a Superior
Proposal (if applicable, compared to the terms of the Arrangement  as
proposed to be amended by the Acquiror under Section 6.3(c)); and 
---|---|--- 
  



   | (vii)| the  Corporation terminates this Agreement pursuant to Section
10.2(e) and the Corporation  has previously paid or, concurrently with
termination, pays the Termination Payment to  the Acquiror. 
---|---|--- 
  



    

 | \- 35 -| 
---|---|--- 

 



    



   | (c)| During  the Match Period, (i) the Acquiror shall have the
opportunity, but not the obligation,  to offer to amend the terms of the
Arrangement and this Agreement, (ii) the Board  shall review any such offer
by the Acquiror to amend the terms of the Arrangement and  this Agreement in
order to determine, in good faith, after consultation with its financial 
advisors and outside counsel, whether the Acquiror's offer to amend the
Arrangement  and this Agreement, upon its acceptance, would result in the
Acquisition Proposal ceasing  to be a Superior Proposal compared to the
amendment to the terms of the Arrangement and  this Agreement offered by the
Acquiror, and (iii) the Corporation shall negotiate  in good faith with the
Acquiror to make such amendments to the terms of this Agreement  and the
Arrangement as would enable the Acquiror to proceed with the transactions
contemplated  by this Agreement on such amended terms. If the Board
determines that the Acquisition  Proposal would cease to be a Superior
Proposal, the Corporation shall promptly so advise  the Acquiror and the
Corporation and the Acquiror shall enter into an amendment to this  Agreement
reflecting the offer by the Acquiror to amend the terms of the Arrangement 
and this Agreement, and shall take and cause to be taken all such actions as
are necessary  to give effect to the foregoing. 
---|---|--- 
  



   | (d)| At the  written request of the Acquiror, the Board shall
promptly reaffirm the Board Recommendation  by press release after: (i) any
Acquisition Proposal (which is determined not to  be a Superior Proposal) is
publicly announced, made or disclosed; or (ii) the Board  determines that a
proposed amendment to the terms of the Arrangement and this Agreement  would
result in a previously announced Acquisition Proposal not being a Superior
Proposal.  The Acquiror and its counsel shall be given a reasonable
opportunity to review and comment  on the form and content of any such press
release, and the Corporation shall reasonably  consider any such comments,
recognizing that whether or not such comments are appropriate  will be
determined by the Corporation. 
---|---|--- 
  



   | (e)| Nothing  in this Agreement shall prevent the Board from
complying with Section 2.17 of National  Instrument 62-104 - _Take-Over Bids
and Issuer Bids_ and similar provisions  under Securities Laws relating to
the provision of a directors' circular in respect  of an Acquisition Proposal
for the Corporation; provided, however, that, notwithstanding  that the Board
shall be permitted to make such disclosure, the Board shall not be permitted 
to make a change to the Board Recommendation, other than as permitted by
Section 6.3(a).  The Acquiror and its counsel shall be given a reasonable
opportunity to review and comment  on the form and content of any such
disclosure relating to this Agreement and the transactions  contemplated
hereby. 
---|---|--- 
  



   | (f)| If the  Corporation provides the Acquiror with a Superior
Proposal Notice on a date that is less  than five (5) Business Days prior to
the Meeting, at the request of the Acquiror, the Corporation  will either
proceed with or adjourn the Meeting to a date that is not less than three 
(3) Business Days and not more than 10 Business Days after the date the
Superior Proposal  Notice is provided to the Acquiror, as such date is
requested by the Acquiror. 
---|---|--- 
  



    

 | \- 36 -| 
---|---|--- 

 



    



   | (g)| Each  successive material modification of any Acquisition
Proposal shall constitute a new Acquisition  Proposal for purposes of Section
6.3(b) and all of the provisions of this Section 6.3  shall apply again to
such new Acquisition Proposal, provided that the Acquiror shall  be afforded
a new five (5) Business Day Match Period from the later of the date on which 
the Acquiror received the Superior Proposal Notice and the date on which the
Acquiror  received all of the materials set forth in Section 6.3(b)(iii) with
respect to the  new Superior Proposal from the Corporation. 
---|---|--- 
  



   | (h)| The  Corporation shall advise its subsidiaries and their
respective Representatives of the  prohibitions set out in this Article 6 and
any violation of the restrictions set  forth in this Article 6 by the
Corporation, its subsidiaries or their respective  Representatives is deemed
to be a breach of this Article 6 by the Corporation. 
---|---|--- 
  



  

Article 7 
 Covenants Relating to Regulatory Approvals

  



   | 7.1| Regulatory  Filings and Approvals 
---|---|--- 
  



   | (a)| As soon  as reasonably practicable after the date hereof until
the Effective Time, each party  shall (i) promptly make all necessary
filings, applications and submissions with,  give all notices to,
Governmental Authorities under all applicable Laws that are required  for the
lawful completion of the transactions contemplated by this Agreement and the 
Plan of Arrangement, and (ii) take, or to cause to be taken, all actions, and
to  do, or to cause to be done, all things reasonably necessary, proper or
advisable, to  obtain as promptly as practicable all such Authorizations from
Governmental Authorities. 
---|---|--- 
  



   | (b)| Without limiting the generality of Section 7.1(a), the Acquiror
and the Corporation shall use their commercially reasonable efforts to obtain
the HSR Approval.  
---|---|--- 
  



   | (c)| The Corporation will pay one-half of one requisite filing fee and
the Acquiror shall pay the balance of all requisite filing fees in relation
to any filing or application made in respect of the HSR Approval. 
---|---|--- 
  



  

    

 | \- 37 -| 
---|---|--- 

 



    



   | 7.2| Cooperation  Regarding Regulatory Filings and Approvals 
---|---|--- 
  



   | (a)| Subject to applicable Laws, each party shall provide the other
party with reasonable opportunity to review and comment on all
filings, applications and submissions with Governmental Authorities to be
made by it and the other party shall use its commercially reasonable efforts
to cooperate with and assist such party in the preparation and making of all
such filings, applications and submissions and the obtaining of all consents,
approvals, authorizations or waivers required to be obtained by such party
(including participating and appearing in any proceedings before Governmental
Authorities). Acquiror, acting in its reasonable discretion and with
appropriate input from the Corporation, shall be entitled to coordinate any
actual or proposed supplemental submissions to (and substantive meetings or
discussions, as contemplated by Section 7.2(b), with) Governmental Authorities
in respect of the HSR Approval. 
---|---|--- 
  



   | (b)| In furtherance  of the undertakings in Section 7.2(a), each
party shall promptly notify the other party  of any material communication to
such party from any Governmental Authority in respect  of the transactions
contemplated herein (and provide a copy thereof if such communication  is in
writing) and, subject to applicable Laws, provide the other party with
reasonable  opportunity to review and comment on any proposed written
material communication to any  such Governmental Authority. Each party shall
consult with the other party prior to participating  in any substantive
meeting or discussion with any Governmental Authority in respect of  the
transactions contemplated herein and use commercially reasonable efforts to
give  the other party (except in respect of competitively sensitive,
privileged or confidential  matters, which may be withheld entirely except
where it can be shared with the other  party's external counsel without risk
of loss of secrecy, privilege or confidentiality)  the opportunity to attend
and participate thereat. 
---|---|--- 
  



   | (c)| Notwithstanding  any other requirement in this Section 7.2 where
a Party (a "Disclosing  Party") is required under this Section 7.2 to provide
information to another  party (a "Receiving Party") that the Disclosing Party
deems to be  competitively sensitive information or otherwise reasonably
determines in respect thereof  that disclosure should be restricted, the
Disclosing Party may restrict the provision  of such competitively sensitive
and other information only to external legal counsel  of the Receiving Party,
provided that the Disclosing Party also provides the Receiving  Party a
redacted version of such information which does not contain any such
competitively  sensitive or other restricted information. 
---|---|--- 
  



  

Article 8 
 Other Covenants

  



   | 8.1| Further  Assurances 
---|---|--- 
  



   | (a)| The  Corporation shall use commercially reasonable efforts to
perform, and to cause its subsidiaries  to perform, all obligations required
or desirable to be performed by the Corporation  or any of its subsidiaries
under this Agreement, cooperate with the Acquiror in connection  therewith,
and do all such other commercially reasonable acts and things as may be
necessary  or desirable in order to consummate and make effective, as soon as
reasonably practicable,  the transactions contemplated by this Agreement and,
without limiting the generality  of the foregoing, the Corporation shall and,
where appropriate, shall cause each of its  subsidiaries to: 
---|---|--- 
  



    

 | \- 38 -| 
---|---|--- 

 



    



   | (i)| use  commercially reasonable efforts to satisfy all conditions
precedent in this Agreement  and take all steps set forth in the Interim
Order and Final Order applicable to it; 
---|---|--- 
  



   | (ii)| use  commercially reasonable efforts to obtain and maintain all
third party or other consents,  waivers, permits, exemptions, orders,
approvals, agreements, amendments or confirmations  that are (A) necessary or
advisable to be obtained under the Material Contracts  in connection with the
Arrangement or (B) required in order to maintain the Material  Contracts and
the HSR Approval in full force and effect following completion of the
Arrangement, in each case, on terms that are reasonably satisfactory to the
Acquiror,  acting reasonably; 
---|---|--- 
  



   | (iii)| use  commercially reasonable efforts to effect all necessary
registrations, filings and submissions  of information required by
Governmental Authority from the Corporation and its subsidiaries  relating to
the Arrangement; 
---|---|--- 
  



   | (iv)| use  commercially reasonable efforts to, on prior written
approval of the Acquiror, oppose,  lift or rescind any injunction,
restraining or other order, decree, judgment or ruling  seeking to restrain,
enjoin or otherwise prohibit or adversely affect the consummation  of the
Arrangement and defend, or cause to be defended, any proceedings to which it
is  a party or brought against it or its directors or officers challenging
the Arrangement  or this Agreement; and 
---|---|--- 
  



   | (v)| not  take any action, or refrain from taking any commercially
reasonable action, or permitting  any action to be taken or not taken, which
is inconsistent with this Agreement or which  would reasonably be expected to
materially prevent, delay or impede the consummation  of the Arrangement or
the transactions contemplated by this Agreement. 
---|---|--- 
  



   | (b)| The  Corporation shall promptly notify the Acquiror in writing
of: 
---|---|--- 
  



   | (i)| any  Material Adverse Effect; 
---|---|--- 
  



   | (ii)| any  notice or other communication from any person alleging
that the consent (or waiver, permit,  exemption, order, approval, agreement,
amendment or confirmation) of such person (or  another person) is or will be
required in connection with this Agreement or the Arrangement; 
---|---|--- 
  



   | (iii)| any  notice or other communication from any supplier,
marketing partner or licensor of Intellectual  Property Rights to the effect
that such person is terminating, may terminate or is otherwise  materially
adversely modifying or may materially adversely modify its relationship with 
the Corporation or any of its subsidiaries as a result of this Agreement or
the Arrangement; 
---|---|--- 
  



    

 | \- 39 -| 
---|---|--- 

 



    



   | (iv)| any  notice or other communication from any Governmental
Authority in connection with the  Agreement (and contemporaneously provide a
copy of any such written notice or communication  to the Acquiror); 
---|---|--- 
  



   | (v)| any  material Claim or Legal Proceeding commenced or, to its
knowledge, threatened against,  relating to or involving or otherwise
affecting the Corporation, its subsidiaries or  the Corporation Assets; or 
---|---|--- 
  



   | (vi)| any  communication, including written or oral, from any
Governmental Authority in connection  with the Company Owned Registered IP,
including, but not limited to office actions, notices,  maintenance fees, and
generally relating to the examination of the Company Owned Registered  IP,
the status of developments and negotiations, including with Examiners, with
respect  to any patent and trademark prosecution relating to Company Owned
Registered IP. 
---|---|--- 
  



   | (c)| The  Acquiror shall use commercially reasonable efforts to
perform all obligations required  or desirable to be performed by it under
this Agreement, cooperate with the Corporation  in connection therewith, and
do all such other commercially reasonable acts and things  as may be
necessary or desirable in order to consummate and make effective, as soon as 
reasonably practicable, the transactions contemplated by this Agreement and,
without  limiting the generality of the foregoing, the Acquiror shall: 
---|---|--- 
  



   | (i)| use  commercially reasonable efforts to satisfy all conditions
precedent in this Agreement  and take all steps set forth in the Interim
Order and Final Order applicable to it; 
---|---|--- 
  



   | (ii)| use  commercially reasonable efforts to effect all necessary
registrations, filings and submissions  of information required by
Governmental Authorities from it relating to the Arrangement; 
---|---|--- 
  



   | (iii)| use  commercially reasonable efforts to oppose, lift or
rescind any injunction, restraining  or other order, decree, judgment or
ruling seeking to restrain, enjoin or otherwise prohibit  or adversely affect
the consummation of the Arrangement and defend, or cause to be defended,  any
proceedings to which it is a party or brought against it or its directors or
officers  challenging the Arrangement or this Agreement; 
---|---|--- 
  



   | (iv)| not  take any action, or refrain from taking any commercially
reasonable action, or permit  any action to be taken or not taken, which is
inconsistent with this Agreement or the  Arrangement or which would
reasonably be expected to materially prevent, delay or otherwise  impede the
consummation of the Arrangement or the transactions contemplated by this
Agreement;  and 
---|---|--- 
  



    

 | \- 40 -| 
---|---|--- 

 



    



   | (v)| provide  notice to the Corporation of any notice or other
communication from any Governmental  Authority in connection with the
Agreement (and contemporaneously provide a copy of any  such written notice
or communication to the Corporation). 
---|---|--- 
  



   | (d)| The parties understand and agree that the commercially
reasonable efforts of any party hereto shall not be deemed to include: (i)
entering into any settlement, undertaking, consent decree, consent agreement,
consent order, stipulation or agreement with the Governmental Authority in
connection with the transactions contemplated hereby; or (ii) divesting or
otherwise holding separate (including by establishing a trust or otherwise),
or taking any other action (or otherwise agreeing to do any of the foregoing)
with respect to the Acquiror or Corporation or any of their respective
subsidiaries, Affiliates, businesses, assets or properties. 
---|---|--- 
  



   | 8.2| 338 Election 
---|---|--- 
  



  

The parties understand and agree that an election will be made under Section
338(g) of the U.S. Internal Revenue Code for the Corporation and any of its
eligible subsidiaries (other than any subsidiary that is treated as a U.S.
corporation under U.S. federal Tax laws). The parties agree to cooperate as
reasonably required to effectuate said election.

  



   | 8.3| Access 
---|---|--- 
  



  

Upon reasonable notice and subject to the Confidentiality Agreement, the
Corporation agrees to continue to provide the Acquiror and its
Representatives with reasonable access (without disruption to the conduct of
the Corporation's business) during normal business hours to the books,
records, information and files in its possession and control and access to its
personnel on an as reasonably requested basis as well as reasonable access to
the properties of the Corporation in order to allow the Acquiror to continue
to conduct such investigations as the Acquiror may reasonably consider
necessary or advisable. The Corporation, the Acquiror and the Parent agree to
establish, within three (3) Business Days of the date hereof, a committee
comprised of Representatives of their respective most senior scientific,
medical and clinical officers (or in the event any such officer is not
available for a particular meeting, his or her respective designee) which
committee will discuss the status of developments of clinical trials CTH-300
and CTH-301, including relating to study cycle time line, patient and study
site recruitment and enrollment status, patient standards of care, study
objectives or strategy and protocol complexity. Such committee will meet
either in person, by telephone or other electronic means on a weekly basis.
Nothing in this Agreement shall require the Corporation to disclose to the
Acquiror (a) any material information which has not been publicly disclosed
by the Corporation in accordance with the Securities Laws or (b)
information which it is prohibited from disclosing pursuant to a written
confidentiality agreement or confidentiality provision of an agreement with
third parties, or information which, in the opinion of the Corporation is
commercially or competitively sensitive (except where it can be shared with
the other party's external counsel without risk of loss of secrecy, privilege
or confidentiality). Without limiting the foregoing, the Corporation shall,
upon the Acquiror's request, facilitate discussions between the Acquiror and
any third party from whom consent may be required.

  



    

 | \- 41 -| 
---|---|--- 

 



    



   | 8.4| Pre-Acquisition  Reorganization 
---|---|--- 
  



   | (a)| Subject  to Section 8.4(b), the Corporation agrees that, upon
the written request of the  Acquiror, the Corporation shall, and shall cause
each of its subsidiaries, to use commercially  reasonable efforts to (i)
perform such reorganizations of its corporate structure,  capital structure,
business, operations and assets or such other transactions as the  Acquiror
may request (each a "Pre-Acquisition Reorganization"), and  (ii) cooperate
with the Acquiror and its advisors to determine the nature of the  Pre-
Acquisition Reorganizations (or any transactions or other steps contemplated
by the  Acquiror following the Effective Time) that might be undertaken and
the manner in which  they would most effectively be undertaken, and (iii)
cooperate with the Acquiror  and its advisors to seek to obtain any consents
or other pre-conditions to implementing  the transactions or other steps
contemplated by the Pre-Acquisition Reorganization (or  any transactions or
other steps contemplated by the Acquiror following the Effective  Time). 
---|---|--- 
  



   | (b)| The  Corporation will not be obligated to participate in any
Pre-Acquisition Reorganization  under 8.4(a) unless the Corporation
determines that such Pre-Acquisition Reorganization: 
---|---|--- 
  



   | (i)| can  be completed prior to the Effective Date without adversely
affecting the Corporation,  any of its subsidiaries or its Securityholders; 
---|---|--- 
  



   | (ii)| is  not prejudicial to the Corporation, any of its subsidiaries
or its Securityholders; 
---|---|--- 
  



   | (iii)| does  not impair, impede, delay or prevent the receipt of any
regulatory approvals or the satisfaction  of any conditions set forth in this
Agreement or the ability of the Corporation, the  Parent or the Acquiror to
consummate, and will not materially delay the consummation  of, the
Arrangement; 
---|---|--- 
  



   | (iv)| does  not require the Corporation to obtain the approval of any
Securityholders or, after the  mailing of the Circular, to require any
amendment thereto; 
---|---|--- 
  



   | (v)| is effected  as close as reasonably practicable prior to the
Effective Time; 
---|---|--- 
  



   | (vi)| does  not require the Corporation or its subsidiaries to take
any action that could reasonably  be expected to result in Taxes being
imposed on, or any adverse Tax or other consequences  to, any Securityholders
incrementally greater than the Taxes or other consequences to  such party in
connection with the completion of the Arrangement in the absence of action 
being taken pursuant to this Section 8.4; 
---|---|--- 
  



   | (vii)| does  not require the Corporation to contravene any applicable
Laws or its organizational documents  or result in any breach by the
Corporation or any of its subsidiaries of any Contract; 
---|---|--- 
  



    

 | \- 42 -| 
---|---|--- 

 



    



   | (viii)| does  not require the directors, officers, employees or
agents of the Corporation or its subsidiaries  to take any action in any
capacity other than as a director, officer, employee or agent;  and 
---|---|--- 
  



   | (ix)| shall  not become effective unless the Parent and the Acquiror
each has irrevocably waived or  confirmed in writing the satisfaction of all
conditions in its favour under this Agreement  and shall have confirmed in
writing that each of them is prepared to promptly and without  condition
(other than compliance with this Section 8.4) proceed to effect the
Arrangement. 
---|---|--- 
  



   | (c)| The  Acquiror must provide written notice to the Corporation of
any proposed Pre- Acquisition  Reorganization at least fifteen (15) Business
Days prior to the Effective Date. Upon  receipt of such notice, the
Corporation and the Acquiror shall work cooperatively and  use their
commercially reasonable efforts to prepare prior to the Effective Time all 
documentation necessary and do such other acts and things as are necessary to
give effect  to such Pre-Acquisition Reorganization (subject to Section
8.4(b)), including any  amendment to this Agreement or the Plan of
Arrangement and shall seek to have any such  Pre-Acquisition Reorganization
made effective at the times reasonably requested by the  Acquiror. 
---|---|--- 
  



   | (d)| The  Acquiror agrees that (i) it will be responsible for all
costs and expenses associated  with any Pre-Acquisition Reorganization to be
carried out at its request and shall indemnify  and save harmless the
Corporation and its Affiliates from and against any and all liabilities, 
losses, damages, claims, costs, expenses, interest awards, judgements and
penalties (after  the Corporation has taken commercially reasonable efforts
to mitigate any such liabilities,  losses, damages, claims, costs, expenses,
interest awards, judgements and penalties)  suffered or incurred by any of
them in connection with or as a result of any such Pre-Acquisition 
Reorganization, and (ii) if the Arrangement is not completed as contemplated
herein,  it shall indemnify and save harmless the Corporation, its Affiliates
and Securityholders  from and against any and all direct and indirect
liabilities, losses, Taxes, damages,  claims, costs, expenses, interest
awards, judgements and penalties suffered or incurred  by any of them in
connection with or as a result of any Pre-Acquisition Reorganization  if
after participating in any Pre-Acquisition Reorganization the Arrangement is
not completed  other than due to a breach by the Corporation of the terms and
conditions of this Agreement,  including any reasonable costs incurred by the
Corporation in order to restore the organizational  structure of the
Corporation to a substantially identical structure of the Corporation  as at
the date hereof. 
---|---|--- 
  



   | (e)| The  Acquiror acknowledges and agrees that the planning for and
implementation of any Pre-Acquisition  Reorganization shall not be considered
a breach of any covenant under this Agreement  and shall not be considered in
determining whether a representation or warranty of the  Corporation
hereunder has been breached, and the Acquiror and the Parent waive any
breach  of a representation, warranty or covenant by the Corporation, where
such breach is a  result of an action taken by the Corporation or a
subsidiary in good faith pursuant to  a request by the Acquiror in accordance
with this Section 8.4. 
---|---|--- 
  



    

 | \- 43 -| 
---|---|--- 

 



    



   | (f)| For  the purposes of Section 8.4(d) and Section 8.4(e), above,
section 2.3  of the Plan of Arrangement shall be considered to form part of a
Pre-Acquisition Reorganization. 
---|---|--- 
  



   | 8.5| De-listing  and Deregistration 
---|---|--- 
  



  

Subject to Applicable Laws, the Acquiror and the Corporation shall use their
commercially reasonable efforts to cause the Common Shares to be de-listed
from the Exchanges and the deregistration of the Common Shares under the U.S.
Exchange Act promptly, with effect immediately following the acquisition by
the Acquiror of the Common Shares pursuant to the Arrangement.

  



   | 8.6| Shareholder  Litigation 
---|---|--- 
  



  

In the event that any shareholder litigation related to this Agreement or the
transactions contemplated by this Agreement is brought, or, to the knowledge
of the Corporation, threatened in writing, against the Corporation and/or the
members of the Board prior to the Effective Time, the Corporation shall
promptly notify the Acquiror thereof and shall keep the Acquiror reasonably
informed with respect to the status thereof (it being understood that the
Corporation shall control the defense and settlement of litigation against
any of its directors or the members of the Corporation and any of its
subsidiaries with counsel of its own choosing). Neither the Corporation, its
subsidiaries nor their respective representatives shall compromise, settle,
come to an arrangement regarding or agree to compromise, settle or come to an
arrangement regarding any such shareholder litigation or consent to the same
unless the Acquiror shall have consented in writing, acting reasonably.

  



   | 8.7| Directors  and Officers Insurance and Indemnification 
---|---|--- 
  



   | (a)| The  Acquiror shall honour all rights to indemnification
existing on the date hereof in favour  of the current and former directors
and officers of the Corporation and its subsidiaries  pursuant to the
Corporation's Constating Documents, the Act or any indemnity agreements  with
such persons to the extent that any such indemnity agreements have been
disclosed  in Section 8.7(a) of the Disclosure Letter, and acknowledges that
such rights, to the  extent that they have been so disclosed, shall survive
the completion of the Plan of  Arrangement and shall continue in full force
and effect in accordance with their terms  for a period of not less than six
years following the Effective Date. 
---|---|--- 
  



    

 | \- 44 -| 
---|---|--- 

 



    



   | (b)| The  Acquiror acknowledges and agrees that, notwithstanding any
other provision of this Agreement,  the Corporation shall, prior to the
Effective Date, purchase, as an extension to the  Corporation's current
insurance policies, pre-paid non-cancellable run-off directors'  and
officers' liability insurance providing such coverage for all present and
former  directors and officers of the Corporation and the subsidiary covering
Claims in respect  of acts or omissions in their capacity as directors or
officers of the Corporation or  the subsidiary occurring prior to the
Effective Time made prior to or within a period  of six (6) years after the
Effective Time, on terms comparable to those contained in the  Corporation's
current insurance policies, provided that the Acquiror will not be  required
to pay any amounts in respect of such coverage prior to the Effective Time
and  provided further that the cost of such policies shall not exceed 300% of
the Corporation's  current annual aggregate premium for policies currently
maintained by the Corporation;  it being understood that if the annual
premiums payable for such insurance coverage exceed  such amount, the
Acquiror shall be obligated to obtain a policy with the greatest coverage 
available for a cost equal to such amount. 
---|---|--- 
  



   | (c)| The  provisions of this Section 8.7 are: (i) intended for the
benefit of all present  and former directors and officers of the Corporation
and any of its subsidiaries, as  and to the extent applicable in accordance
with their terms, and shall be enforceable  by each of such persons and his
or her heirs, executors administrators and other legal  representatives
(collectively, the "Third Party Beneficiaries") and  the Corporation shall
hold the rights and benefits of this Section 8.7 in trust  for and on behalf
of the Third Party Beneficiaries and the Corporation hereby accepts  such
trust and agrees to hold the benefit of and enforce performance of such
covenants  on behalf of the Third Party Beneficiaries; and (ii) are in
addition to, and not  in substitution for, any other rights that the Third
Party Beneficiaries may have by  contract or otherwise. Furthermore, this
Section 8.7 shall survive the termination  of this Agreement as a result of
the occurrence of the Effective Date for a period of  six (6) years. 
---|---|--- 
  



   | 8.8| Employment  Matters 
---|---|--- 
  



  

The Corporation shall use its commercially reasonable efforts to deliver to
the Acquiror on the Effective Date resignations and releases (in a form
satisfactory to the Acquiror, acting reasonably) effective on the Effective
Date, of the directors and officers of the Corporation or any of its
subsidiaries designated in writing by the Acquiror at least 10 Business Days
prior to the Effective Date, provided that such resignations will be subject
to consummation of the Contemplated Transactions, Section 8.7 as well as any
right to receive any Consideration, Change of Control Payment as well as any
compensation not yet paid or accrued benefits not yet provided.

  



   | 8.9| Covenants  of the Parent 
---|---|--- 
  



  

The Parent hereby unconditionally and irrevocably guarantees in favour of the
Corporation the due and punctual performance by the Acquiror of the
Acquiror's obligations hereunder. The Parent hereby agrees that the
Corporation shall not have to proceed first against the Acquiror in respect
of any such matter before exercising its rights under this guarantee against
the Parent and agrees to be liable for all guaranteed obligations as if it
were the principal obligor of such obligations.

  



  

    

 | \- 45 -| 
---|---|--- 

 



    



   | 8.10| Outstanding  Rights 
---|---|--- 
  



  

In accordance with the terms of the Plan of Arrangement, at the Effective
Time, each Option which is outstanding and that has not been exercised prior
to the Effective Time, shall be cancelled and the holder thereof shall receive
the Consideration therefor, and each Warrant which is outstanding and that
has not been exercised prior to the Effective Time, shall be purchased by the
Acquiror and the holder thereof shall receive the Consideration therefor. The
parties to this Agreement acknowledge and agree that (a) none of
the Acquiror, the Corporation, and all persons not dealing at arm's length
with the Acquiror will claim any deduction under the Tax Act with respect to
any payment made to a holder of Options described herein or in the Plan of
Arrangement and (b) they will comply with the requirements described in
subsection 110(1.1) of the Tax Act (including, where applicable, the
filing of the election described therein) as regards payments to holders of
Options, it being understood that the holders of Options shall be entitled to
claim any deductions available to such persons pursuant to the Tax Act in
respect of the calculation of taxable income arising thereunder.

  



  

Article 9 
 Conditions

  



   | 9.1| Mutual Conditions 
---|---|--- 
  



  

The obligations of the Corporation and the Acquiror to complete the
transactions contemplated herein are subject to fulfillment of the
following conditions on or before the Effective Date:

  



   | (a)| the  Interim Order and the Final Order shall each have been
obtained on terms consistent with  this Agreement, and shall not have been
set aside or modified in a manner unacceptable  to the parties, acting
reasonably, on appeal or otherwise; 
---|---|--- 
  



   | (b)| the  Arrangement Resolution shall have been approved at the
Meeting in accordance with the  Interim Order; 
---|---|--- 
  



   | (c)| there  shall not be in force any Law and no Governmental
Authority shall have issued any order  or decree restraining or prohibiting
the completion of the transactions contemplated  herein; 
---|---|--- 
  



   | (d)| this  Agreement shall not have been terminated in accordance
with its terms; and 
---|---|--- 
  



   | (e)| the  HSR Approval shall have been obtained. 
---|---|--- 
  



  

The foregoing conditions are for the mutual benefit of each of the
Corporation and the Acquiror and may only be waived, in whole or in part by
mutual written consent of the parties.

  



    

 | \- 46 -| 
---|---|--- 

 



    



   | 9.2| Corporation  Conditions 
---|---|--- 
  



  

The obligation of the Corporation to complete the transactions contemplated
herein is subject to the fulfillment of the following conditions on or before
the Effective Date or such other time as specified below:

  



   | (a)| the  representations and warranties contained in Article 3
(disregarding all qualifications  set forth therein relating to "materiality"
or other qualifications based  on the word "material" or similar phrases)
shall be true and correct as of  the Effective Time with the same force and
effect as if made on and as of such date (except  to the extent such
representations and warranties are, by their terms, made as of a specified 
date, in which case such representations and warranties shall be so true and
correct  as of such specified date), except where the failure of such
representations and warranties  to be so true and correct would not have, or
would not reasonably be expected individually,  or in the aggregate, to
prevent or materially impair or delay completion of the Arrangement,  and the
Acquiror and Parent shall have provided to the Corporation the certificate
of  two (2) senior officers of the Acquiror certifying such accuracy as of
the Effective Time;  and 
---|---|--- 
  



   | (b)| the  Acquiror shall have complied in all material respects with
its covenants herein and the  Acquiror and Parent shall have provided to the
Corporation the certificate of two (2) senior  officers of the Acquiror
certifying that the Acquiror has so complied with its covenants  herein as of
the Effective Date. 
---|---|--- 
  



  

The foregoing conditions precedent are for the benefit of the Corporation and
may be waived, in whole or in part, by the Corporation in writing at any
time.

  



   | 9.3| Acquiror  Conditions 
---|---|--- 
  



  

The obligation of the Acquiror to complete the transactions contemplated
herein is subject to the fulfillment of the following conditions on or before
the Effective Date or such other time as specified below:

  



    

 | \- 47 -| 
---|---|--- 

 



    



   | (a)| (i) the  representations and warranties of the Corporation in
Section 1 of Schedule C to  this Agreement (Board Approval), Section 2 of
Schedule C to this Agreement (Corporate  Existence and Power), Section 3 of
Schedule C to this Agreement (Corporate Authorization),  Section 4 of
Schedule C to this Agreement (Authority and No Violation), Section  5 of
Schedule C to this Agreement (Consent and Approvals), Section 8 of Schedule
C  to this Agreement (Subsidiaries), Section 15 of Schedule C to this
Agreement (No  Material Adverse Effect) and Section 17 of Schedule C to this
Agreement (No Brokers)  shall, if qualified by materiality or "Material
Adverse Effect" be true and  correct in all respects or, if not so qualified,
be true and correct in all material  respects as of the Effective Time with
the same force and effect as if made on and as  of such date, (ii) the
representation and warranty of the Corporation in Section  7 of Schedule C to
this Agreement (Capitalization) shall be true and correct in  all respects as
of the date hereof and as of the Effective Time with the same force and 
effect as if made on and as of such date, unless the failure of such
representation and  warranty to be true and correct would not result in the
Acquiror paying additional aggregate  consideration of $250,000 or more to
Securityholders as a result of the failure of such  representation and
warranty to be so true and correct, provided however, that any increase  in
the aggregate Consideration payable as a result of the exercise of Options or
Warrants  listed in Section 7(a) of the Disclosure Letter for Common Shares
shall not be considered  an increase to the Consideration payable for
purposes of this condition, and (iii) each  of the other representations and
warranties contained in Article 4 (disregarding  all qualifications set forth
therein relating to "materiality", "Material  Adverse Effect" or other
qualifications based on the word "material"  or similar phrases) shall be
true and correct as of the Effective Time with the same  force and effect as
if made on and as of such date (except to the extent such representations 
and warranties are, by their terms, made as of a specified date, in which case
such representations  and warranties shall be so true and correct as of such
specified date), except where  the failure of such representations and
warranties in this clause (iii) to be so  true and correct would not have, or
would not reasonably be expected to have, individually  or in the aggregate,
a Material Adverse Effect and the Corporation shall have provided  to the
Acquiror the certificate of two (2) senior officers of the Corporation
certifying  such accuracy as of the Effective Time; 
---|---|--- 
  



   | (b)| the  Corporation shall have complied in all material respects
with its covenants herein, and  the Corporation shall have provided to the
Acquiror the certificate of two (2) senior officers  of the Corporation
certifying that the Corporation has so complied with its covenants  herein as
of the Effective Date; 
---|---|--- 
  



   | (c)| from  the date hereof and up to and including the Effective
Date, there shall not have been  or occurred a Material Adverse Effect in
respect of the Corporation; and 
---|---|--- 
  



   | (d)| there is no action or proceeding (whether, for greater
certainty, by a Governmental Authority or any other person) pending in any
jurisdiction to: 
---|---|--- 
  



   | (i)| cease  trade, enjoin, prohibit, or impose any material
limitations, damages or conditions on,  the Acquiror's ability to acquire,
hold, or exercise full rights of ownership over,  any Common Shares,
including the right to vote the Common Share; 
---|---|--- 
  



   | (ii)| prohibit,  restrict or impose terms or conditions beyond those
terms and conditions which the Acquiror  are required to accept pursuant to
Section 8.2 of the Arrangement, or the ownership  or operation by the
Acquiror of the business or assets of the Acquiror, its Affiliates  and
related entities, the Corporation or any of the Corporation's subsidiaries 
and related entities, or compel the Acquiror to dispose of or hold separate
any of the  business or assets of the Acquiror, its Affiliates and related
entities, the Corporation  or any of the Corporation's subsidiaries and
related entities as a result of the  Arrangement;  or 
---|---|--- 
  



    

 | \- 48 -| 
---|---|--- 

 



    



   | (iii)| prevent  or materially delay the consummation of the
Arrangement, or if the Arrangement were to  be consummated, have a Material
Adverse Effect. 
---|---|--- 
  



  

The foregoing conditions precedent are for the benefit of the Acquiror and
may be waived, in whole or in part, by the Acquiror in writing at any time.

  



   | 9.4| Notice and  Cure 
---|---|--- 
  



  

Each party will give prompt notice to the other party of the occurrence, or
failure to occur, at any time from the date hereof until the Effective Date,
of any event or state of facts of which it is aware which occurrence or
failure would, or would be likely to:

  



   | (a)| cause  any of the representations and warranties of such party
contained herein that are qualified  by materiality or Material Adverse
Effect to be untrue or inaccurate in any respect or  any of the
representations and warranties of such party that are not qualified by
materiality  or Material Adverse Effect to be untrue or incorrect in any
material respect, in each  case, at any time between the date hereof and the
Effective Date; 
---|---|--- 
  



   | (b)| result  in the failure to comply with or satisfy any covenant or
agreement to be complied with  or satisfied by any other party at or prior to
the Effective Date; or 
---|---|--- 
  



   | (c)| result  in the failure to satisfy any of the conditions
precedent contained in Sections 9.1,  9.2 or 9.3, as the case may be. 
---|---|--- 
  



  

Subject to the provisions of this Agreement, a party may elect not to
complete the transactions contemplated hereby pursuant to the conditions
contained in Sections 9.1, 9.2 or 9.3 or exercise any termination right
arising therefrom; provided, however, that (i) forthwith and in any event
prior to the filing of the Final Order and Articles of Arrangement
for acceptance by the Director, the party intending to rely thereon has
delivered a written notice to the other party specifying in reasonable detail
all breaches of covenants, representations and warranties or other matters
which the party delivering such notice is asserting as the basis for the non-
fulfillment of the applicable condition precedent or termination right,
as the case may be and (ii) if any such notice is delivered, and a party is
proceeding diligently to cure such matter and if such matter is capable of
being cured prior to the Outside Date, the other party may not terminate this
Agreement until the earlier of (a) the Outside Date, and (b) expiration of a
period of 15 Business Days from such notice, if such matter has not been
cured by such date. If such notice has been delivered prior to the date of the
Meeting, unless the parties agree otherwise, the Corporation shall postpone
such Meeting until to the earlier of (a) five (5) Business Days prior to the
Outside Date and (b) the expiry of the period. If such notice is delivered
prior to the making of the application for the Final Order or the filing of
the Articles of Arrangement with the Director, such application or filing, as
the case may be, shall be postponed until to the earlier of (a) five (5)
Business Days prior to the Outside Date and (b) the expiry of the period.

  



    

 | \- 49 -| 
---|---|--- 

 



    



   | 9.5| Merger of  Conditions 
---|---|--- 
  



  

The conditions in Sections 9.1, 9.2 or 9.3 shall be conclusively deemed to
have been satisfied, waived or released upon the filing of Articles of
Arrangement as contemplated herein and the issuance of a Certificate of
Arrangement under the Act in respect thereof.

  



  

Article 10 
 Termination

  



   | 10.1| Term 
---|---|--- 
  



  

This Agreement shall be effective from the date hereof until the earlier of
the Effective Time and the termination of this Agreement in accordance with
its terms.

  



   | 10.2| Termination 
---|---|--- 
  



  

This Agreement may be terminated at any time prior to the Effective Date
(except in the case of Section 10.2(e) which may only be exercised prior to
the approval by the Securityholders of the Arrangement Resolution):

  



   | (a)| by mutual  written agreement of the Acquiror and the
Corporation; 
---|---|--- 
  



   | (b)| by the  Acquiror or the Corporation, if: 
---|---|--- 
  



   | (i)| the  Meeting shall have been held and the Securityholders do not
approve the Arrangement Resolution  in the manner required by with the
Interim Order, except that the right to terminate  this Agreement under this
Section 10.2(b)(i) will not be available to any party  whose action or
failure to act has been the cause or resulted in the failure to obtain  the
approval of the Arrangement Resolution and such action or failure to act
constitutes  a breach of this Agreement or failure of such party to perform
any of its covenants or  agreements under this Agreement; 
---|---|--- 
  



   | (ii)| the  Effective Date has not occurred on or prior to the Outside
Date, other than as a result  of the breach by such party of any covenant or
obligation under this Agreement or as  a result of any representation or
warranty of such party in this Agreement being untrue  or incorrect; or 
---|---|--- 
  



    

 | \- 50 -| 
---|---|--- 

 



    



   | (iii)| any  Law is enacted, made, enforced or amended or any
Governmental Authority shall have issued  an order, decree or ruling that
makes consummation of the Arrangement illegal or otherwise  permanently
restraining or enjoining or otherwise prohibiting any of the transactions 
contemplated herein (unless such order, decree or ruling has been withdrawn,
reversed  or otherwise made inapplicable) which order, decree or ruling is
final and non-appealable; 
---|---|--- 
  



   | (c)| by the  Acquiror or the Corporation, if: 
---|---|--- 
  



   | (i)| subject  to Section 9.4, any representation or warranty of the
Corporation (in the case of  a termination by the Acquiror) or the Acquiror
or Parent (in the case of a termination  by the Corporation) under this
Agreement is untrue or incorrect or shall have become  untrue or incorrect
such that the condition contained in Section 9.2(a) or 9.3(a),  as
applicable, would be incapable of satisfaction, and such breach or failure is
incapable  of being cured on or prior to the Outside Date or is not cured in
accordance with the  terms of Section 9.4; provided that any wilful or
intentional breach by one party  shall be deemed to be incurable; or 
---|---|--- 
  



   | (ii)| subject  to Section 9.4, the other party is in default of a
covenant or obligation hereunder  such that the condition contained in
Section 9.2(b) or 9.3(b), as applicable, would  be incapable of satisfaction,
and such breach or failure is incapable of being cured  on or prior to the
Outside Date or is not cured in accordance with the terms of Section 9.4; 
provided that any wilful or intentional breach by one party shall be deemed to
be incurable; 
---|---|--- 
  



   | (d)| by the  Acquiror, if: 
---|---|--- 
  



   | (i)| the  Meeting has not occurred by the date specified in Section
2.3(a) or such later date  as the Acquiror has agreed or requested in
writing, and the failure to hold the Meeting  by such date was primarily
caused by, or was primarily the result of, the Corporation  (A) intentionally
or wilfully failing to fulfil any obligation hereunder, or (B) adjourning, 
postponing or cancelling the Meeting other than as permitted under Section
2.3(a),  and in any event the right to terminate this Agreement under this
Section 10.2(d)(i)  shall not be available to the Acquiror if the failure to
hold the Meeting by such date  was primarily caused by, or was primarily the
result of, the Acquiror failing to fulfil  any obligation hereunder; 
---|---|--- 
  



   | (ii)| (A) the  Board or any committee of the Board fails to
unanimously recommend or withdraws, amends,  modifies or qualifies, or
publicly proposes or states an intention to withdraw, amend,  modify or
qualify, the Board Recommendation, (B) the Board or any committee of the 
Board accepts, approves, endorses or recommends, or publicly proposes to
accept, approve,  endorse or recommend an Acquisition Proposal other than
this Agreement or any amendment  to this Agreement, or takes no position or
remains neutral with respect to a publicly  announced, or otherwise publicly
disclosed, Acquisition Proposal for more than five (5)  Business Days (or
beyond the third (3rd) Business Day prior to the date of  the Meeting, if
sooner)), (C) the Board or any committee of the Board accepts or  enters into
(other than a confidentiality agreement permitted by and in accordance with 
Section 6.3) or publicly proposes to accept or enter into any agreement,
understanding  or arrangement in respect of an Acquisition Proposal, (D) the
Board or any committee  of the Board fails to publicly recommend or reaffirm
the Board Recommendation in accordance  with Section 6.3(d) within five (5)
Business Days after having been requested in  writing by the Acquiror to do
so (or in the event that the Meeting is scheduled to occur  within such five
(5) Business Day period, prior to the third (3rd) Business  Day prior to the
date of the Meeting), or (E) the Corporation breaches Article 6  in any
material respect; or 
---|---|--- 
  



    

 | \- 51 -| 
---|---|--- 

 



    



   | (iii)| notwithstanding Section 9.4,  a Material Adverse Effect shall
have occurred and be continuing with respect to the Corporation. 
---|---|--- 
  



   | (e)| by the Corporation, if, prior to  the approval by the
Securityholders of the Arrangement Resolution, the Board authorizes  the
Corporation to enter into a written agreement with respect to a Superior
Proposal  (other than a confidentiality agreement as contemplated by Section
6.3), and approves  or recommends a Superior Proposal, provided that (i) the
Corporation is then in  compliance with Article 6, and (ii) no termination by
the Corporation under  this Section 10.2(e) shall be effective unless and
until the Corporation shall have  paid the Acquiror the Termination Payment
in accordance with Section 10.3; or 
---|---|--- 
  



   | (f)| by the Acquiror by the close of  business on the next Business
Day following the Meeting, if Dissent Rights or similar  rights have been
exercised with respect to more than 15% of the issued and outstanding  Common
Shares. 
---|---|--- 
  



  

Any termination pursuant to (b) - (f) shall be effected by written notice
from the terminating party to the other party.

  



   | 10.3| Termination and Payment 
---|---|--- 
  



   | (a)| The Acquiror, in consideration  for the disposition of its
rights under this Agreement, shall be entitled to a cash termination  payment
in the amount of $24,000,000 (the "Termination Payment"),  upon the
occurrence of any of the following events (each a "Termination Payment 
Event") which shall be paid by the Corporation within the time specified in 
respect of each such Termination Payment Event: 
---|---|--- 
  



   | (i)| this Agreement is terminated by the  Acquiror pursuant to
Section 10.2(d)(i) (other than where the reason for adjourning or  postponing
the Meeting is only as a result of the occurrence of a postal disruption)  or
Section 10.2(d)(ii), in which case the Termination Payment shall be paid to
the Acquiror  no later than 10:00 a.m. (Eastern Daylight Time) on the next
Business Day following  the date the Agreement is terminated; 
---|---|--- 
  



  

   

 | \- 52 -| 
---|---|--- 

 



    



   | (ii)| this Agreement is terminated by  the Corporation pursuant to
Section 10.2(e) in which case the Termination Payment  shall be paid to the
Acquiror in accordance with Section 6.3(b)(vii); and 
---|---|--- 
  



   | (iii)| this Agreement is terminated by  the Acquiror pursuant to
Section 10.2(b)(i) but only if: (A) prior to the time  of the holding of the
Meeting, an Acquisition Proposal is publicly announced or otherwise  publicly
disclosed, and not publicly withdrawn prior to the date of the Meeting, by
any  person (other than the Acquiror or any of its Affiliates) or any person
(other than the  Acquiror or any of its Affiliates) shall have publicly
announced or otherwise publicly  disclosed an intention to make an
Acquisition Proposal; and (B) within 12 months  following the date of such
termination (1) an Acquisition Proposal is consummated  or effected, or (2)
the Corporation and/or one or more of its subsidiaries enters  into a
definitive agreement in respect of an Acquisition Proposal and such
Acquisition  Proposal is consummated or effected, whether or not within such
12 month period, in which  case the Termination Payment shall be payable
concurrently with the consummation or effectiveness  of such Acquisition
Proposal. For purposes of this clause (iii), the term "Acquisition  Proposal"
shall have the meaning assigned to such term in Section 1.1, except  that
references to "20%" shall be deemed to be references to "50% or  more". 
---|---|--- 
  



   | (b)| The Termination Payment shall be  paid by the Corporation to the
Acquiror by wire transfer in immediately available funds  to an account
specified by the Acquiror, provided that in no event will the Corporation  be
required to pay more than one Termination Payment. For greater certainty, the
obligations  of the Corporation under this Section 10.3 shall survive the
termination of this  Agreement, regardless of the circumstances thereof. 
---|---|--- 
  



   | (c)| Except as set out in Section 10.4(b)  with respect to wilful
breach, the Corporation acknowledges that the amount set out in  this Section
10.3 in respect of the Termination Payment represents liquidated damages 
which are a genuine pre-estimate of the damages, including opportunity costs,
which the  Acquiror will suffer or incur as a result of the event giving rise
to such damages and  resultant termination of this Agreement, and is not a
penalty. The Corporation irrevocably  waives any right it may have to raise
as a defence that any such liquidated damages are  excessive or punitive. 
---|---|--- 
  



   | 10.4| Effect of Termination 
---|---|--- 
  



  

In the event of termination of this Agreement pursuant to Section 10.2, this
Agreement shall be of no further force and effect without liability of any
party (or any shareholder, director, officer, employee, agent, consultant or
representative of such party) to any other party to this Agreement, except
that:

  



  

   

 | \- 53 -| 
---|---|--- 

 



    



   | (a)| in the event of termination under  Section 10.1 as a result of
the Effective Time occurring, Section 8.7 shall  survive for a period of six
(6) years following such termination; 
---|---|--- 
  



   | (b)| in the event of termination under  Section 10.2, this Section
10.4 and Article 11 shall survive the termination  of this Agreement, and
provided further that no party shall be relieved of any liability  for any
wilful breach by it of this Agreement; 
---|---|--- 
  



   | (c)| nothing contained in this Agreement  shall relieve or have the
effect of relieving any party in any way from liability for  damages incurred
or suffered by a party if the Agreement is terminated in any circumstances 
other than pursuant to a Termination Payment Event; and 
---|---|--- 
  



   | (d)| upon any termination of this Agreement  under circumstances
where the Acquiror is entitled to a Termination Payment and such  Termination
Payment is paid in full, the Acquiror and the Parent shall be precluded from 
any other remedy against the Corporation at Law or in equity or otherwise
(including,  without limitation, an order for specific performance), and
shall not seek to obtain  any recovery, judgment, or damages of any kind,
including consequential, indirect, or  punitive damages, against the
Corporation or any of its subsidiaries or any of their  respective directors,
officers, employees, partners, managers, members, shareholders  or Affiliates
or their respective Representatives in connection with this Agreement or  the
transactions contemplated hereby, provided that the foregoing limitation shall
not  apply in the event of wilful breach by the Corporation of this
Agreement. 
---|---|--- 
  



   | 10.5| Remedies 
---|---|--- 
  



  

Subject to Section 10.4, the parties acknowledge and agree that an award of
money damages would be inadequate for any breach of this Agreement by any
party or its Representatives and any such breach would cause the non-
breaching party irreparable harm. Accordingly, the parties agree that, in the
event of any breach of this Agreement by one of the parties, the non-breaching
party will also be entitled, without the requirement of posting a bond or
other security, to equitable relief, including injunctive relief and specific
performance. Such remedies will not be the exclusive remedies for any breach
of this Agreement but will be in addition to all other remedies available at
law or equity to each of the parties.

  



  

Article 11 
 General Provisions

  



   | 11.1| Amendment 
---|---|--- 
  



  

Subject to the provisions of the Interim Order, the Plan of Arrangement and
applicable Laws, this Agreement and the Plan of Arrangement may, at any time
and from time to time before or after the holding of the Meeting but not
later than the Effective Date, be amended by mutual written agreement of the
parties, without further notice to or authorization on the part of the
Securityholders.

  



  

   

 | \- 54 -| 
---|---|--- 

 



    



   | 11.2| Waiver 
---|---|--- 
  



   | (a)| At any time prior to the termination  of this Agreement pursuant
to Section 10.2, either party may: 
---|---|--- 
  



   | (i)| extend the time for the performance  of any of the obligations
or other acts of the other party; or 
---|---|--- 
  



   | (ii)| waive compliance with any of the  agreements of the other party
or with any conditions to its own obligations, in each  case only to the
extent such obligations, agreements and conditions are intended for  its
benefit. 
---|---|--- 
  



   | (b)| No waiver by any party shall be  effective unless in writing and
any waiver shall affect only the matter, and the occurrence  thereof,
specifically identified and shall not extend to any other matter or
occurrence.  No failure or delay in exercising any right, power or privilege
under this Agreement  will operate as a waiver thereof, nor will any single
or partial exercise thereof preclude  any other or further exercise thereof
or the exercise of any right, power or privilege  under this Agreement. 
---|---|--- 
  



   | 11.3| Expenses and Expense Reimbursement. 
---|---|--- 
  



  

Except as expressly provided in this Agreement, all costs and expenses of the
parties relating to the transactions contemplated herein, including legal
fees, accounting fees, financial advisory fees, regulatory filing fees, stock
exchange fees, all disbursements of advisors and printing and mailing
costs, shall be paid by the party incurring such expenses, whether or not the
Arrangement is consummated.

  



   | 11.4| Notices 
---|---|--- 
  



  

Any notice, consent, waiver, direction or other communication required or
permitted to be given under this Agreement by a party shall be in writing and
may be given by delivering same or sending same by facsimile transmission or
by delivery addressed to the party to which the notice is to be given at its
address for service herein. Any notice, consent, waiver, direction or other
communication aforesaid shall, if delivered, be deemed to have been given and
received on the date on which it was delivered to the address provided herein
(if a Business Day, if not, the next succeeding Business Day) and if sent by
facsimile transmission be deemed to have been given and received at the time
of receipt (if a Business Day, if not the next succeeding Business Day) unless
actually received after 4:30 p.m. (Eastern Daylight Time) at the point of
delivery in which case it shall be deemed to have been given and received on
the next Business Day.

  



  

The address for service for each of the parties hereto shall be as follows:

  



  

   

 | \- 55 -| 
---|---|--- 

 



    



  

   | (a)| if to the Corporation: 
---|---|--- 
  



  

Cynapsus Therapeutics Inc.

  

828 Richmond Street West

  

Toronto, Ontario M6J 1C9

  



   | Attention:| Anthony Giovinazzo, President and Chief Executive 
Officer  
---|---|--- 
   | Fax:| (416) 703-8752  
---|---|--- 
  | Email: | _ajg@cynapsus.ca_ 
     

  



  

with a copy to (which shall not constitute notice):

  



  

Borden Ladner Gervais LLP 
 Scotia Plaza, 40 King Street West 
 Toronto, Ontario 
 M5H 3Y4 
  

       | Attention:  | Alfred Page 
---|---|--- 
     | Facsimile:  | (416) 367-6749 
     | Email:  | _apage@blg.com_ 
     |   | 
     | Attention:  | Jason Saltzman 
     | Fax:  | (416) 367-6749 
     | Email:  | _jsaltzman@blg.com_ 
  



  

and to:

  



  

Troutman Sanders LLP 
 401 9th Street, N.W., Suite 1000 
 Washington, D.C. 20004-2134 
  

       | Attention:  | Thomas Rose 
---|---|--- 
     | Facsimile:  | 757-687-1529 
     | Email:  | _thomas.rose@troutmansanders.com_ 
  



   | (b)| if to the Acquiror or the Parent: 
---|---|--- 
  



  

Sunovion Pharmaceuticals Inc.

  

84 Waterford Dr.

  

Marlborough, MA 01752

  



   | Attention:| Gregory M. Bokar, Senior Vice President, Legal Affairs and
Corporate Secretary 
---|---|--- 
  | Facsimile:| (508) 357-7511  
  | Email: | _gregory.bokar@sunovion.com_ 
     



  

   

 | \- 56 -| 
---|---|--- 

 



    



  

with a copy to (which shall not constitute notice):

  



  

Reed Smith LLP 
 Suite 250 
 136 Main Street 
 Princeton, New Jersey 08540 
  

       | Attention:  | Diane M. Frenier 
---|---|--- 
     | Facsimile:  | (609) 951.0824 
     | Email:  | _dfrenier@reedsmith.com_ 
     |   | 
     | Attention:  | Edward P. Bromley III 
     | Facsimile:  | (609) 951.0824 
     | Email:  | _ebromley@reedsmith.com_ 
  



  

and to:

  



  

Goodmans LLP 
 Bay Adelaide Centre 
 333 Bay Street, Suite 3400 
 Toronto, Ontario M5H 2S7 
  

       | Attention:  | Stephen H. Halperin 
---|---|--- 
     | Facsimile:  | (416) 979.1234 
     | Email:  | _shalperin@goodmans.ca_ 
     |   | 
     | Attention:  | Sheldon N. Freeman 
     | Facsimile:  | (416) 979.1234 
     | Email:  | _sfreeman@goodmans.ca_ 
  



   | 11.5| Process Agent 
---|---|--- 
  



  

The Parent hereby irrevocably designates GODA Incorporators Inc. (in such
capacity, the "Process Agent"), Attention: Ken Crofoot, with an office at
Goodmans LLP, Bay Adelaide Centre, 333 Bay Street, Suite 3400, Toronto,
Ontario M5H 2S7 as its designee, appointee and agent to receive, for and on
its behalf and on behalf of the Acquiror service of process in
such jurisdiction in any legal action or proceedings with respect to this
Agreement or the transactions contemplated hereby, and such service shall be
deemed complete upon delivery thereof to the Process Agent; provided that, in
the case of any such service upon the Process Agent, the party effecting such
service shall also deliver a copy thereof to the Parent in the manner
provided in Section 11.4. The Parent shall take all such action as may be
necessary to continue said appointment in full force and effect or to appoint
another agent so that Parent will at all times have an agent for service of
process for the above purposes in the Province of Ontario. Nothing herein
shall affect the right of any party to serve process in any manner permitted
by Law.

  



  

   

 | \- 57 -| 
---|---|--- 

 



    



   | 11.6| Severability 
---|---|--- 
  



  

If any term, provision, covenant or restriction of this Agreement is held by
a court of competent jurisdiction to be invalid, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions of this
Agreement shall remain in full force and effect and shall in no way be
affected, impaired or invalidated and the parties shall negotiate in good
faith to modify the Agreement to preserve each party's anticipated benefits
under this Agreement.

  



   | 11.7| Entire Agreement 
---|---|--- 
  



  

This Agreement and the Confidentiality Agreement (together with all other
documents and instruments referred to herein and therein) constitute the
entire agreement and supersede all other prior agreements and undertakings,
both written and oral, among the parties with respect to the subject
matter hereof.

  



   | 11.8| Assignment 
---|---|--- 
  



  

This Agreement shall enure to the benefit of and be binding upon the parties
and their respective successors and permitted assigns. This Agreement may not
otherwise be assigned by either party without the prior written consent of
the other parties (such consent not to be unreasonably withheld by the
Corporation if the Acquiror requests to be permitted to assign its rights and
obligations under this Agreement to an Affiliate), provided that if such
assignment and/or assumption is consented to, the party making such assignment
shall continue to be liable joint and severally with the assignee of the
Agreement for all of its obligations hereunder.

  



   | 11.9| Governing Law 
---|---|--- 
  



  

This Agreement shall be governed in all respects, including validity,
interpretation and effect, by the Laws of the Province of Ontario and the
federal Laws of Canada applicable therein, without giving effect to any
principles of conflict of Laws thereof which would result in the
application of the Laws of any other jurisdiction, and all actions and
proceedings arising out of or relating to this Agreement shall be heard and
determined exclusively in the courts of the Province of Ontario.

  



   | 11.10| Contra Proferentem 
---|---|--- 
  



  

The parties waive the application of any rule of Law which otherwise would be
applicable in connection with the construction of this Agreement that
ambiguous or conflicting terms or provisions should be construed against the
party who (or whose counsel) prepared the executed agreement or any
earlier draft of the same.

  



   | 11.11| No Third Party Beneficiaries 
---|---|--- 
  



  

Except as provided in Section 8.7, which without limiting its terms, is
intended as stipulations for the benefit of the third persons mentioned in
such provisions, this Agreement shall not confer any rights or remedies upon
any person other than the parties and their respective successors and
permitted assigns.

  



   | 11.12| Time of Essence 
---|---|--- 
  



  

Time shall be of the essence in this Agreement.

  



  

   

 | \- 58 -| 
---|---|--- 

 



    



   | 11.13| No Liability 
---|---|--- 
  



  

No director or officer of the Acquiror or the Parent shall have any personal
liability whatsoever to the Corporation under this Agreement or any other
document delivered in connection with the transactions contemplated hereby on
behalf of the Acquiror or the Parent. No director or officer of
the Corporation or any of its subsidiaries shall have any personal liability
whatsoever to the Acquiror or the Parent under this Agreement or any other
document delivered in connection with the transactions contemplated hereby on
behalf of the Corporation or any of its subsidiaries.

  



   | 11.14| Counterparts 
---|---|--- 
  



  

This Agreement may be executed in any number of counterparts, each of which
shall be deemed to be an original and all of which taken together shall be
deemed to constitute one and the same instrument, and it shall not be
necessary in making proof of this Agreement to produce more than one
counterpart. The parties shall be entitled to rely upon delivery of an
executed facsimile, PDF email transmission or similar executed
electronic copy of this Agreement, and such facsimile, PDF email transmission
or similar executed electronic copy shall be legally effective to create a
valid and binding agreement among the parties.

  



  

[THE REMAINDER OF THIS PAGE HAS BEEN LEFT BLANK INTENTIONALLY]

  



    

 | \- 59 -| 
---|---|--- 

 



    



  

IN WITNESS WHEREOF, this Agreement has been executed and delivered as of the
date first above written, by the duly authorized representatives of the
parties hereto.

  



  



    

       |   | CYNAPSUS  THERAPEUTICS INC. 
---|---|--- 
     |   | 
     |   | By:  | /s/ Anthony Giovinazzo 
     |   |   | Name: Anthony Giovinazzo 
     |   |   | Title: President  and Chief Executive Officer 
  



       |   | SUNOVION CNS DEVELOPMENT  CANADA ULC 
---|---|--- 
     |   | 
     |   | By:  | /s/ Gregory M. Bokar 
     |   |   | Name: Gregory M. Bokar 
     |   |   | Title: Director 
     |   |   | 
   



  



       |   | SUNOVION PHARMACEUTICALS  INC. 
---|---|--- 
     |   | 
     |   | By:  | /s/ Nobuhiko Tamura 
     |   |   | Name: Nobuhiko Tamura 
     |   |   | Title: Chairman  and Chief Executive Officer 
   



  



    

 | | 
---|---|--- 

 



    



  

Schedule A 
 Plan of Arrangement 
 Under Section 192 of the 
  _Canada Business Corporations Act_

  



  

Article 1 
  
 INTERPRETATION

  



   | 1.1| Definitions 
---|---|--- 
  



  

In this Plan of Arrangement, unless there is something in the subject matter
or context inconsistent therewith, the following terms shall have the
respective meanings set out below and grammatical variations of such terms
shall have corresponding meanings:

  



  

"Act" means the _Canada Business Corporations Act_ , as amended, including
the regulations promulgated thereunder;

  



  

"Acquiror" means Sunovion CNS Development Canada ULC;

  



  

"Arrangement Agreement" means the arrangement agreement dated August 31, 2016
between the Acquiror, the Parent and the Corporation, as the same may be
amended, supplemented or otherwise modified from time to time in accordance
with the terms thereof;

  



  

"Arrangement" means the arrangement under the provisions of section 192 of
the Act, on the terms and subject to the conditions set out in
the Arrangement Agreement and in this Plan of Arrangement, subject to any
amendments or variations thereto made in accordance with the Arrangement
Agreement or the Plan of Arrangement or made at the direction of the Court in
the Final Order with the consent of the parties, each acting reasonably;

  



  

"Arrangement Resolution" means the special resolution of Securityholders
approving the Arrangement to be considered at the Meeting, substantially in
the form attached as Schedule D to the Arrangement Agreement and any
amendments or variations thereto made in accordance with the provisions of
the Arrangement Agreement or the Plan of Arrangement;

  



  

"Articles of Arrangement" means the articles of arrangement in respect of the
Arrangement to be filed with the Director after the Final Order is made;

  



  

"Business Day" means a day, other than a Saturday or a Sunday, on which the
principal commercial banks located in Toronto, Ontario and New York, New York
are open for the conduct of non-automated business;

  



  

"Certificate of Arrangement" means the certificate of arrangement giving
effect to the Arrangement to be issued by the Director pursuant to subsection
192(7) of the Act in respect of the Articles of Arrangement;

  



  

"Circular" means the notice of the Meeting and accompanying management
information circular of the Corporation, including all schedules,
appendices and exhibits thereto, and all information incorporated by
reference therein, to be prepared and sent to the Securityholders
in connection with the Meeting, as amended, supplemented or otherwise
modified from time to time in accordance with the terms of the Arrangement
Agreement;

  



  

   

 | | 
---|---|--- 

 



    



  

"Common Share" means a common share of the Corporation;

  



  

"Consideration" means $40.50 in cash per Common Share or, in the case of a
Warrant or Option, the excess of $40.50 over the exercise price of
such Warrant or Option;

  



  

"Corporation" means Cynapsus Therapeutics Inc.;

  



  

"Corporation Sub" means an unlimited liability company to be formed pursuant
to the _Business Corporations Act_ (British Columbia) as a direct, wholly-
owned subsidiary of the Corporation for the purposes of effectuating the
Arrangement;

  



  

"Court" means the Ontario Superior Court of Justice (Commercial List) or any
appellate court, as the case may be;

  



  

"Depositary" means any trust company, bank or financial institution agreed to
in writing by the Acquiror and the Corporation to act as depository for the
Arrangement;

  



  

"Director" means the Director appointed pursuant to section 260 under the
Act;

  



  

"Dissent Rights" means the rights of dissent granted in favour of
Securityholders in respect of the Arrangement as described in Article 3
hereof and the Interim Order;

  



  

"Dissenting Shareholder" means a Shareholder who properly dissents in respect
of the Arrangement in strict compliance with the procedures for
exercising Dissent Rights and does not withdraw such dissent prior to the
Effective Time;

  



  

"Dissenting Securityholder" means a Dissenting Shareholder or a Dissenting
Warrantholder;

  



  

"Dissenting Warrantholder" means a Warrantholder who properly dissents in
respect of the Arrangement in strict compliance with the procedures for
exercising Dissent Rights and does not withdraw such dissent prior to the
Effective Time;

  



  

"Effective Date" means the date shown on the Certificate of Arrangement
giving effect to the Arrangement;

  



  

"Effective Time" means 11:59 p.m. (Eastern Daylight Time) on the Effective
Date;

  



  

"Final Order" means the final order of the Court in a form and content
satisfactory to the parties, each acting reasonably, approving the
Arrangement, as such order may be amended by the Court (with the consent of
the parties, each acting reasonably) at any time prior to the
Arrangement becoming effective or, if appealed, then, unless such appeal is
withdrawn or denied, as affirmed or as amended (provided that any such
amendment is in a form and content satisfactory to the parties, each acting
reasonably) on appeal;

  



  

"Interim Order" means the interim order of the Court, in a form and content
satisfactory to the parties, each acting reasonably, as the same may
be amended by the Court (with the consent of the parties, each acting
reasonably), containing declarations and directions with respect to the
Arrangement and providing for, among other things, the holding of the Meeting;

  



  

   

 | A-2| 
---|---|--- 

 



    



  

"Letter of Transmittal" means the letter of transmittal to be sent by the
Corporation to the Securityholders with the Circular in connection with
the Arrangement;

  



  

"Meeting" means the special meeting of Securityholders to be called and held
for the purpose of considering the Arrangement Resolution and any
adjournments or postponements thereof in accordance with the terms of the
Arrangement Agreement;

  



  

"Option Plan" means the stock option plan of the Corporation as amended and
restated on May 10, 2016;

  



  

"Optionholder" means a holder of an Option;

  



  

"Options" means the outstanding options to purchase Common Shares issued
pursuant to the Option Plan or any predecessor plan, as set out in the
Disclosure Letter (as such term is defined in the Arrangement Agreement);

  



  

"Parent" means Sunovion Pharmaceuticals Inc.;

  



  

"person" means an individual, general partnership, limited partnership,
corporation, company, limited liability company, unincorporated association,
unincorporated syndicate, unincorporated organization, trust, estate,
trustee, executor, administrator or other legal representative,
government (including Governmental Authority) or other entity, whether or not
having legal status;

  



  

"Securityholder Encumbrance" means any lien (statutory or otherwise), pledge,
hypothecation, charge, restriction or adverse right or Claim (as defined in
Arrangement Agreement), mortgage, encroachments, option, right of first
refusal or first offer, occupancy right, covenant, assignment,
security interest, adverse interest, defect of title, statutory or deemed
trust, other third party interest or encumbrance of any kind, in each case,
whether contingent or absolute;

  



  

"Securityholders" means, collectively, the Shareholders and the
Warrantholders;

  



  

"Shareholders" means holders of Common Shares;

  



  

"Tax Act" means the  _Income Tax Act_ (Canada) and the regulations
promulgated thereunder, as amended;

  



  

"Warrantholder" means a holder of Warrants; and

  



  

"Warrants" means the common share purchase warrants of the Corporation set
out in the Disclosure Letter (as such term is defined in the
Arrangement Agreement).

  



  

   

 | A-3| 
---|---|--- 

 



    



   | 1.2| Construction 
---|---|--- 
  



  

In this Plan of Arrangement, unless otherwise expressly stated or the context
otherwise requires:

  



   | (a)| references to "herein",  "hereby", "hereunder", "hereof" and
similar expressions  are references to this Plan of Arrangement and not to
any particular Section of  this Plan of Arrangement; 
---|---|--- 
  



   | (b)| references to a "Section"  are references to a Section to this
Plan of Arrangement; 
---|---|--- 
  



   | (c)| words importing the singular shall  include the plural and vice
versa, and words importing gender shall include the masculine,  feminine and
neuter genders; 
---|---|--- 
  



   | (d)| the use of headings is for convenience  of reference only and
shall not affect the construction or interpretation hereof; 
---|---|--- 
  



   | (e)| if the date on which any action  is required to be taken
hereunder by any of the parties is not a Business Day, such action  shall be
required to be taken on the next succeeding day that is a Business Day; 
---|---|--- 
  



   | (f)| a period of Business Days is to  be computed as beginning on the
day following the event that began the period and ending  at 4:30 p.m.
(Eastern Daylight Time) on the last day of the period if the period is a 
Business Day or at 4:30 p.m. on the next Business Day if the last day of the
period does  not fall on a Business Day; 
---|---|--- 
  



   | (g)| references to any legislation or  to any provision of any
legislation shall include any modification or re-enactment thereof,  any
legislation provision substituted therefor and all regulations, rules and
interpretations  issued thereunder or pursuant thereto; 
---|---|--- 
  



   | (h)| references to any agreement or  document shall be to such
agreement or document (together with the schedules and exhibits  attached
thereto), as it may have been or may hereafter be amended, modified,
supplemented,  waived or restated from time to time; and 
---|---|--- 
  



   | (i)| wherever the term "includes"  or "including" is used, it shall
be deemed to mean "includes, without  limitation" or "including, without
limitation", respectively. 
---|---|--- 
  



   | 1.3| Currency 
---|---|--- 
  



  

Unless otherwise indicated, all dollar amounts referred to in this Agreement
are expressed in United States dollars. Unless specifically provided for in
this Plan of Arrangement, all payments to be made in cash pursuant to this
Plan of Arrangement shall be made in United States dollars. The exercise
price of the Options or Warrants or any other amount that is denominated in
Canadian dollars shall be converted to United States dollars at the Bank of
Canada noon rate on the date that is two (2) Business Days prior to the
Meeting.

  



  

   

 | A-4| 
---|---|--- 

 



    



   | 1.4| Time 
---|---|--- 
  



  

Time shall be of the essence in this Plan of Arrangement.

  



  

Article 2 
  
 ARRANGEMENT

  



   | 2.1| Arrangement Agreement 
---|---|--- 
  



  

This Plan of Arrangement is made pursuant to, is subject to the provisions
of, and forms part of, the Arrangement Agreement, and constitutes an
arrangement as referred to in section 192 of the Act.

  



   | 2.2| Binding Effect 
---|---|--- 
  



  

This Plan of Arrangement and the Arrangement, upon the filing of the Articles
of Arrangement and the issuance of the Certificate of Arrangement, will become
effective at and be binding on and after the Effective Time, on: (a) the
Corporation, (b) the Acquiror, (c) the Parent, (d) all registered and
beneficial Securityholders (including Dissenting Securityholders) and
Optionholders, (e) the Depositary, and (f) any registrar and transfer agent
in respect of the Common Shares, Options or Warrants, in each case without any
further authorization, act or formality on the part of any person, except as
expressly provided herein.

  



   | 2.3| Arrangement 
---|---|--- 
  



  

The following transactions shall occur and shall be deemed to occur, without
any further authorization, act or formality, in the following order, provided
that none of the following will occur or will be deemed to occur unless all
of the following occurs:

  



   | (a)| the Corporation shall transfer,  assign and otherwise dispose of
all of its property and assets to Corporation Sub. In  consideration of this
transfer, Corporation Sub shall assume all liabilities and other  obligations
of the Corporation, and shall issue one million (1,000,000) common shares  of
Corporation Sub's capital stock to the Corporation. 
---|---|--- 
  



   | (b)| at 12:01 a.m. on the day following  the Effective Date, each
Option outstanding immediately prior to the Effective Time shall  be deemed
to be surrendered by the holder in exchange for payment of the Consideration 
by the Corporation, and: 
---|---|--- 
  



   | (i)| the holder thereof shall cease to  be the holder of such Option
and shall cease to have any rights as a holder in respect  of such Option or
under the Option Plan; 
---|---|--- 
  



   | (ii)| such holder's name shall be  removed from the register of
Options, as of such time, and all option agreements, grant  agreements and
similar instruments relating thereto shall be cancelled; and 
---|---|--- 
  



   | (iii)| each Option and the Option Plan  shall be cancelled as of such
time; 
---|---|--- 
  



  

   

 | A-5| 
---|---|--- 

 



    



  

and

  



   | (c)| at 12:03 a.m. on the day following  the Effective Date, each
Warrant outstanding immediately prior to the Effective Time  (other than
Warrants outstanding immediately prior to the Effective Time held by
Dissenting  Warrantholders, the Acquiror or Affiliates of the Acquiror) shall
be deemed to be transferred  (free and clear of any Securityholder
Encumbrances) by the holder thereof to the Acquiror  in exchange for the
Consideration, and: 
---|---|--- 
  



   | (i)| the holder thereof shall cease to  be the holder of such Warrant
and shall cease to have any rights as a holder in respect  of such Warrant;
and 
---|---|--- 
  



   | (ii)| such holder's name shall be  removed from the register of
Warrants, as of such time, and all warrant agreements, indentures,  grants
and similar instruments relating thereto shall be cancelled 
---|---|--- 
  



  

and

  



   | (d)| concurrently with Section 2.3(c),  each Warrant outstanding
immediately prior to the Effective Time held by a Dissenting  Warrantholder
shall be deemed to have been transferred to the Acquiror (free and clear  of
any Securityholder Encumbrances); and 
---|---|--- 
  



   | (i)| such Dissenting Warrantholder shall  cease to have any rights as
a holder in respect of such Warrants, other than the rights  set out in
Section 3.1; 
---|---|--- 
  



   | (ii)| such Dissenting Warrantholder shall  cease to be the holder of
such Warrant and shall cease to have any rights as a holder  in respect of
such Warrant; and 
---|---|--- 
  



   | (iii)| such holder's name shall  be removed from the register of
Warrants, as of such time, and all warrant agreements,  indentures, grants
and similar instruments relating thereto shall be cancelled 
---|---|--- 
  



  

and

  



   | (e)| at 12:05 a.m. on the day following  the Effective Date, each
Common Share outstanding immediately prior to the Effective  Time (other than
those held by Dissenting Shareholders, the Acquiror or Affiliates of  the
Acquiror) shall be transferred (free and clear of any Securityholder
Encumbrances)  to the Acquiror in exchange for the Consideration; and 
---|---|--- 
  



   | (i)| the holder thereof shall cease to  be the holder of such Common
Share and shall cease to have any rights as a holder in  respect of such
Common Share; 
---|---|--- 
  



   | (ii)| such holder's name shall be  removed from the register of
holders of Common Shares of the Corporation, as of such  time; 
---|---|--- 
  



  

   

 | A-6| 
---|---|--- 

 



    



   | (iii)| the certificate representing such  Common Share shall be
deemed to have been cancelled as of such time; and 
---|---|--- 
  



   | (iv)| the Acquiror shall be entered as  the sole holder of such
Common Share on the register of holders of Common Shares of the  Corporation
as of such time, and shall be deemed to be the sole legal and beneficial 
owner of the such Common Share as of such time (free and clear of all
Securityholder  Encumbrances); and 
---|---|--- 
  



   | (f)| concurrently with Section 2.3(e),  each Common Share outstanding
immediately prior to the Effective Time held by a Dissenting  Shareholder
shall be deemed to have been transferred to the Acquiror (free and clear  of
any Securityholder Encumbrances); and 
---|---|--- 
  



   | (i)| such Dissenting Shareholder shall  cease to have any rights as a
holder in respect of such Common Share, other than the  rights set out in
Section 3.1; 
---|---|--- 
  



   | (ii)| such Dissenting Shareholder shall  cease to be the holder of
such Common Share and shall cease to have any rights as a holder  in respect
of such Common Share; 
---|---|--- 
  



   | (iii)| such holder's name shall  be removed from the register of
holders of Common Shares of the Corporation, as of such  time; 
---|---|--- 
  



   | (iv)| the certificate representing such  Common Share shall be deemed
to have been cancelled as of such time; and 
---|---|--- 
  



   | (v)| the Acquiror shall be entered as  the sole holder of such Common
Share on the register of holders of Common Shares of the  Corporation as of
such time, and shall be deemed to be the sole legal and beneficial  owner of
such Common Share. 
---|---|--- 
  



  

Article 3 
  
 RIGHTS OF DISSENT

  



   | 3.1| Rights of Dissent 
---|---|--- 
  



  

A holder of Common Shares or Warrants immediately prior to the Effective Time
may exercise Dissent Rights in accordance with the procedures set out
in section 190 of the Act, as modified by this Article 3, the Interim Order
and the Final Order, with respect to such Common Shares or Warrants in
connection with the Arrangement, provided that notwithstanding section 190(5)
of the Act, the written objection to the Arrangement Resolution contemplated
by section 190(5) of the Act must be received by the Corporation by 5:00 pm
(Eastern Daylight Time) two (2) Business Days prior to the date of the
Meeting. Each Dissenting Securityholder who is:

  



  

   

 | A-7| 
---|---|--- 

 



    



   | (a)| ultimately entitled to be paid  fair value for such holder's
Common Shares or Warrants, as applicable, which fair  value, notwithstanding
anything to the contrary contained in Part XV of the Act, shall  be
determined as of the close of business on the day before the Arrangement
Resolution  is adopted, shall be deemed to have transferred such holder's
Common Shares or  Warrants, as applicable to Acquiror as of the time set out
in Section 2.3(d) or  2.3(f) hereof, as applicable, and will not be entitled
to any other payment or consideration,  including any payment that would be
payable under the Arrangement had such Dissenting  Securityholder not
exercised Dissent Rights in respect of such Common Shares or Warrants;  or 
---|---|--- 
  



   | (b)| ultimately not entitled, for any  reason, to be paid such fair
value for such Warrants or Common Shares, as applicable,  shall be deemed to
have participated in the Arrangement with respect to such Warrants  or Common
Shares, as applicable, as of the time set out in Section 2.3(c) or 2.3(e) 
hereof, on the same basis as a Shareholder or a Warrantholder to which Section
2.3(c)  or 2.3(e) hereof applies, as applicable. 
---|---|--- 
  



   | 3.2| Recognition of Dissenting Securityholders 
---|---|--- 
  



   | (a)| In no circumstances shall the Corporation,  the Parent, the
Acquiror or any other person be required to recognize a Dissenting
Securityholder  as the holder of any Common Shares or Warrants at and after
the Effective Time, and the  names of such Dissenting Securityholders shall
be removed from the register of Common Shares  or Warrants, as applicable,
maintained by or on behalf of Corporation. 
---|---|--- 
  



   | (b)| In addition to any other restrictions  under section 190 of the
Act, Securityholders who voted (or have instructed a proxyholder  to vote) in
favour of the Arrangement Resolution, shall not be entitled to exercise
Dissent  Rights. 
---|---|--- 
  



  

Article 4 
  
 PAYMENT AND CERTIFICATES

  



   | 4.1| Payment of the Consideration 
---|---|--- 
  



   | (a)| Prior to the filing of the Articles  of Arrangement, the
Acquiror shall deposit, for the benefit of the holders of Common  Shares
(other than Dissenting Shareholders) and Warrants (other than Dissenting 
Warrantholders), as applicable, sufficient cash to pay (i) the aggregate
Consideration  payable to holders of Common Shares (other than Dissenting
Shareholders) pursuant to  Section 2.3(e), and (ii) the aggregate
Consideration payable to holders of  Warrants (other than Dissenting
Warrantholders) pursuant to Section 2.3(c). 
---|---|--- 
  



  

   

 | A-8| 
---|---|--- 

 



    



   | (b)| Upon surrender to the Depositary  for cancellation of a
certificate which immediately prior to the Effective Time represented 
outstanding Common Shares transferred pursuant to Section 2.3(e), together
with  a duly completed and executed Letter of Transmittal and such additional
documents and  instruments as the Depositary may reasonably require, the
holder thereof shall be entitled  to receive in exchange therefor, and the
Depositary shall deliver to such holder, the  aggregate Consideration which
such holder has the right to receive under Section 2.3(e),  less any amounts
withheld pursuant to Section 4.3, and any share certificate so  surrendered
shall forthwith be cancelled. Upon surrender to the Depositary for
cancellation  of a certificate which immediately prior to the Effective Time
represented outstanding  Warrants transferred pursuant to Section 2.3(c),
together with a duly completed  and executed Letter of Transmittal and such
additional documents and instruments as the  Depositary may reasonably
require, the holder thereof shall be entitled to receive in  exchange
therefor, and the Depositary shall deliver to such holder, the aggregate
Consideration  which such holder has the right to receive under Section
2.3(c), less any amounts  withheld pursuant to Section 4.3, and any warrant
certificate so surrendered shall  forthwith be cancelled. 
---|---|--- 
  



   | (c)| On the day following the Effective  Date, the Corporation shall
pay the amounts to be paid to holders of Options either (i)  pursuant to the
normal payroll practices and procedures of the Corporation, or (ii) in  the
event that payment pursuant to the normal payroll practices and procedures of
the  Corporation is not practicable for any such holder, by cheque (delivered
to such holder  of Options as reflected on the register maintained by or on
behalf of the Corporation  in respect of the Options), less any amounts
withheld pursuant to Section 4.3. The  Acquiror shall advance by way of a
demand, non-interest bearing loan to the Corporation  on the Effective Date
by wire transfer in immediately available funds an amount, not  exceeding the
aggregate of the amounts to be so paid to the holders of Options and the 
amounts to be so withheld, as requested by the Corporation to the Acquiror by
notice  in writing given not less than three (3) Business Days prior to the
Effective Date. 
---|---|--- 
  



   | (d)| Pursuant to Section 2.3(e), each  certificate that immediately
prior to the Effective Time represented Common Shares shall  be deemed as of
and from the time specified in Section 2.3(e) to represent only the right  to
receive upon surrender of such certificate the Consideration, without
interest, in  lieu of such certificate as contemplated in this Section 4.1,
less any amounts withheld  pursuant to Section 4.3. Pursuant to Section
2.3(c), each certificate that immediately  prior to the Effective Time
represented Warrants shall be deemed as of and from the time  specified in
Section 2.3(c) to represent only the right to receive upon surrender of  such
certificate the Consideration under Section 2.3(c), without interest, in
lieu  of such certificate as contemplated in this Section 4.1, less any
amounts withheld  pursuant to Section 4.3. Any such certificate formerly
representing Common Shares  or Warrants, as applicable, not duly surrendered
on or before the sixth anniversary of  the Effective Date shall cease to
represent a claim by or interest of any former holder  of Common Shares or
Warrants, as applicable, of any kind or nature against the Corporation,  the
Acquiror or the Parent. On such date, all Consideration to which such former
holder  was entitled shall be deemed to have been surrendered to the Acquiror
and all Consideration  to which such former holder was entitled shall be
returned to the Acquiror. 
---|---|--- 
  



  

   

 | A-9| 
---|---|--- 

 



    



   | (e)| Any payment made by way of cheque  by the Depositary or the
Corporation pursuant to this Plan of Arrangement that has not  been deposited
or has been returned to the Depositary or the Corporation, as the case  may
be, or that otherwise remains unclaimed, in each case, on or before the sixth
anniversary  of the Effective Time, and any right or claim to payment
hereunder that remains outstanding  on the sixth anniversary of the Effective
Time shall cease to represent a right or claim  of any kind or nature and the
right of the holder to receive the Consideration for Common  Shares, Options
or Warrants pursuant to this Plan of Arrangement shall terminate and  be
deemed to be surrendered and forfeited for no consideration, and all cash to
which  such holder was entitled shall be returned to the Acquiror or the
Corporation, as applicable. 
---|---|--- 
  



   | (f)| No holder of Common Shares, Options  or Warrants shall be
entitled to receive any consideration with respect to Common Shares,  Options
or Warrants other than as described in and in accordance with Section 2.3 
and this Section 4.1, and, for greater certainty, no such holder will be
entitled  to receive any interest (by reason of any delay in paying for such
securities or otherwise),  dividends, premium or other payment in connection
therewith. 
---|---|--- 
  



   | 4.2| Lost Certificates 
---|---|--- 
  



  

In the event any certificate which immediately prior to the Effective Time
represented one or more outstanding Common Shares or Warrants exchanged
pursuant to Section 2.3 shall have been lost, stolen or destroyed, upon the
making of an affidavit of that fact by the person claiming such
certificate to be lost, stolen or destroyed, the Depositary will pay and
deliver in exchange for such lost, stolen or destroyed certificate, the
consideration which such holder is entitled to receive pursuant to Section 2.3
(net of amounts required to be withheld pursuant to Section 4.3). When
authorizing such payment and delivery in exchange for any lost, stolen or
destroyed certificate, the person to whom the payment is made shall, as a
condition precedent to the delivery of such payment thereof, give a bond
satisfactory to the Corporation, the Parent, the Acquiror and the Depositary
in such sum as the Parent, or the Acquiror may direct or otherwise indemnify
the Corporation, the Parent, the Acquiror and the Depositary in a manner
satisfactory to the Corporation, the Parent and the Acquiror against any
claim that may be made against the Corporation, the Parent, the Acquiror or
the Depositary with respect to the certificate alleged to have been lost,
stolen or destroyed.

  



   | 4.3| Withholding Rights 
---|---|--- 
  



  

The Corporation, the Acquiror and the Depositary shall be entitled to deduct
and withhold from any amount payable to any Optionholder or Securityholders
(including any payments to Dissenting Securityholders), such amounts as the
Corporation, the Acquiror, or the Depositary may be entitled or required to
deduct and withhold with respect to such payment under the _Tax Act_ or any
provision of provincial, state, local or foreign tax law, in each case, as
amended or succeeded, and to remit such deducted and withheld amounts to
the appropriate taxing authority. To the extent that amounts are so properly
deducted and withheld, such deducted and withheld amounts shall be treated
for all purposes as having been paid to the Optionholder or Securityholder in
respect of which such deduction and withholding was made, provided that such
deducted and withheld amounts are actually remitted in accordance with
applicable law to the appropriate taxing authority.

  



  

   

 | A-10| 
---|---|--- 

 



    



  

Article 5 
  
 AMENDMENTS

  



   | 5.1| Amendments to Plan of Arrangement 
---|---|--- 
  



   | (a)| The Corporation, the Parent and  the Acquiror reserves the right
to amend, modify and/or supplement this Plan of Arrangement  at any time and
from time to time prior to the Effective Time, provided that each such 
amendment, modification or supplement must be (i) set out in writing, (ii)
approved  by the parties, acting reasonably, (iii) filed with the Court and,
if made following  the Meeting, approved by the Court, and (iv) communicated
to Securityholders if  and as required by the Court. 
---|---|--- 
  



   | (b)| Any amendment, modification or  supplement to this Plan of
Arrangement, if agreed to by the parties, made at any time  prior to the
Meeting with or without any other prior notice or communication, and if  so
proposed and approved by the persons voting at the Meeting (as may be required
under  the Interim Order), shall become part of this Plan of Arrangement for
all purposes. 
---|---|--- 
  



   | (c)| Any amendment, modification or  supplement to this Plan of
Arrangement that is approved or directed by the Court following  the Meeting
shall be effective only if (i) it is consented to by each of the
Corporation,  the Parent and the Acquiror (in each case, acting reasonably),
and (ii) if  required by the Court, it is approved by the Securityholders
voting in the manner directed  by the Court. 
---|---|--- 
  



   | (d)| Any amendment, modification or  supplement to this Plan of
Arrangement may be made unilaterally by the Acquiror, provided  that it
concerns a matter which, in the reasonable opinion of the Acquiror, is of an 
administrative nature required to better give effect to the implementation of
this Plan  of Arrangement, is not materially adverse to the financial or
economic interests of any  Securityholders or Optionholders, and is agreed to
by the Corporation, acting reasonably. 
---|---|--- 
  



   | (e)| This Plan of Arrangement may be  withdrawn prior to the
Effective Time in accordance with the terms of the Arrangement  Agreement. 
---|---|--- 
  



  

Article 6 
  
 FURTHER ASSURANCES

  



  

Notwithstanding that the transactions and events set out herein shall occur
and be deemed to occur in the order set out in this Plan of Arrangement and
shall become effective without any further act or formality, each of the
Acquiror, the Parent and the Corporation shall make, do and execute, or cause
to be made, done and executed, all such further acts, deeds, agreements,
transfers, assurances, instruments or documents as may reasonably be required
by any of them in order further to document or evidence any of the
transactions or events set out herein.

  



  

   

 | A-11| 
---|---|--- 

 



    



  

Article 7 
  
 PARAMOUNTCY

  



  

From and after the Effective Time (a) this Plan of Arrangement shall take
precedence and priority over any and all Common Shares, Options and Warrants
issued and outstanding prior to the Effective Time, (b) the rights and
obligations of registered and beneficial Optionholders or
Securityholders, and the Corporation, the Acquiror, the Parent, the
Depositary and any registrar and transfer agent for the Common Shares,
Options or Warrants in relation thereto, shall be solely as provided for in
this Plan of Arrangement, and (c) all actions, causes of action, claims or
proceedings (actual or contingent and whether or not previously asserted)
based on or in any way relating to any Common Shares, Options or Warrants
shall be deemed to have been settled, compromised, released and determined
without liability except as set forth herein.

  



    

 | A-12| 
---|---|--- 

 



    



  

Schedule B 
 Representations and Warranties of the Parent and Acquiror

  



   | 1.| Organization and Qualification. 
---|---|--- 
  



   | (a)| The Parent is a corporation duly  incorporated under the Laws of
Delaware, is validly existing and has all necessary  corporate power,
authority and capacity to own, lease and operate its property and assets  and
to carry on its business as currently owned and conducted. 
---|---|--- 
  



   | (b)| The Acquiror is an unlimited liability  company duly
incorporated under the Laws of British Columbia, is validly existing and  has
all necessary corporate power, authority and capacity to own, lease and
operate its  property and assets and to carry on its business as currently
owned and conducted. The  Parent owns, directly or indirectly, all of the
issued and outstanding shares of the  Acquiror. 
---|---|--- 
  



   | 2.| Authority Relative to this Agreement. 
---|---|--- 
  



  

Each of the Parent and the Acquiror has the requisite power, authority and
capacity to execute this Agreement and to perform its respective obligations
hereunder. The execution and delivery of this Agreement by the Acquiror and
the Parent and the consummation by the Parent and the Acquiror of the
transactions contemplated by this Agreement (the "Contemplated Transactions")
have been duly authorized by their respective boards of directors and no
other corporate proceedings on the part of the Parent or the Acquiror
(including the approval of their shareholders), as the case may be, are
necessary to authorize this Agreement or the Contemplated Transactions. This
Agreement has been duly executed and delivered by each of the Parent and the
Acquiror and constitutes the legal, valid and binding obligation of the
Parent and the Acquiror, enforceable against each of them in accordance with
its provisions, subject to bankruptcy, insolvency, reorganization, fraudulent
transfer, moratorium and other Laws relating to limitations of actions
or affecting the availability of equitable remedies and the enforcement of
creditors' rights generally and general principles of equity and public
policy and to the qualification that equitable remedies such as specific
performance and injunction may be granted only in the discretion of a court
of competent jurisdiction.

  



   | 3.| Consents and Approvals. 
---|---|--- 
  



  

No consent, approval, order or Authorization of, or declaration or filing
with, any Governmental Authority is required to be obtained by the Acquiror or
the Parent in connection with the consummation of the transactions
contemplated by this Agreement, except for:

  



   | (a)| the Interim Order and any approvals  required by the Interim
Order; 
---|---|--- 
  



   | (b)| the Final Order; 
---|---|--- 
  



   | (c)| the HSR Approval; 
---|---|--- 
  



   | (d)| notification pursuant to the Investment  Canada Act; 
---|---|--- 
  



   | (e)| filings with the Director under  the Act; and 
---|---|--- 
  



  

   

 | | 
---|---|--- 

 



    



   | (f)| the Authorizations contemplated  by this Agreement. 
---|---|--- 
  



   | 4.| Non Contravention. 
---|---|--- 
  



  

The authorization of this Agreement, the execution, delivery and performance
by each of the Parent and the Acquiror of its obligations under this Agreement
and the consummation of the Contemplated Transactions (for greater certainty,
if applicable, in compliance with the Interim Order and the Final Order), do
not and will not (i) contravene, conflict with, or result in any violation or
breach of any provision of the constating documents of the Parent or the
Acquiror or any agreement with any shareholder of the Parent or the Acquiror,
(ii) subject to obtaining applicable regulatory approvals contemplated by
this Agreement, contravene, conflict with or result in a violation or breach
of any provision of any applicable Laws, except to the extent that the
violation or breach of, or default under, any applicable Laws, would
not, individually or in the aggregate, reasonably be expected to impede or
delay the consummation of the Arrangement or materially adversely affect the
ability of the Parent or the Acquiror to perform its respective obligations
under this Agreement, (iii) contravene, conflict with, or result in any
violation or breach of any note, bond, mortgage, indenture, contract, licence,
permit or government grant to which the Parent or the Acquiror is party or by
which it is bound, except as would not, individually or in the
aggregate, reasonably be expected to impede or delay the consummation of the
Arrangement or materially adversely affect the ability of the Parent or the
Acquiror to perform its respective obligations under this Agreement or any
judgment, decree, order or award of any Governmental Authority or arbitrator.

  



   | 5.| Share Ownership. 
---|---|--- 
  



  

Neither the Parent nor the Acquiror beneficially owns, or has control or
direction over, directly or indirectly, any Common Shares.

  



   | 6.| Sufficiency of Funds. 
---|---|--- 
  



  

The Acquiror will make, or the Parent will cause the Acquiror to make, prior
to the Effective Time, adequate arrangements to ensure that the required funds
are available to effect payment in full of the Consideration in accordance
with this Agreement.

  



   | 7.| Brokers. 
---|---|--- 
  



  

Except for any fee required to be paid to Nomura Securities International,
Inc., no agent, broker, person or firm acting on behalf of the Acquiror or any
of its Affiliates is, or will be, entitled to any commission or brokers' or
finders' fees in connection with any of the Contemplated Transactions.

  



   | 8.| _Investment Canada Act_. 
---|---|--- 
  



  

The Acquiror is a WTO Investor within the meaning of the _Investment Canada
Act_.

  



   | 9.| _Competition Act_. 
---|---|--- 
  



  

The Acquiror and its affiliates do not have assets in Canada that exceed, on
a combined basis, C$200,000,000, or gross revenues from sales in, from or
into Canada that exceed, on a combined basis, C$390,000,000.00, all as
determined in accordance with Part IX of the _Competition Act_.

  



    

 | B-2| 
---|---|--- 

 



    



  

Schedule C 
 Representations and Warranties of the Corporation

  



   | 1.| Board Approval. 
---|---|--- 
  



  

The Board has unanimously determined, after receiving financial and legal
advice, that the Arrangement is fair, from a financial point of view, to
Shareholders and the Arrangement is in the best interest of the Corporation.
The Board has unanimously approved the entering into of the Agreement and the
making of a recommendation that the Securityholders vote for the Arrangement
Resolution.

  



   | 2.| Corporate Existence and Power. 
---|---|--- 
  



   | (a)| The Corporation and each of its  subsidiaries is a corporation
validly existing and in good standing under the laws of  the jurisdiction of
its formation and has all requisite corporate power, authority, and  capacity
to own, lease and operate its property and assets as now owned, and to carry 
on its business as currently owned and conducted and is in good standing with
respect  to the filing of all annual corporate reports. 
---|---|--- 
  



   | (b)| The Corporation and each of its  subsidiaries is duly qualified,
licensed or registered to carry on business and is in  good standing in each
jurisdiction in which the character of its assets and properties,  owned,
leased, licensed or otherwise held, or the nature of its activities make
such  qualification, licensing or registration necessary, except where the
failure to be so  qualified, registered or licensed has not had or would not
reasonably be expected to  have, individually or in the aggregate, a Material
Adverse Effect on the Corporation  and its subsidiaries, taken as a whole. 
---|---|--- 
  



   | 3.| Corporate Authorization. 
---|---|--- 
  



  

The Corporation and its subsidiaries have the necessary corporate power,
authority and capacity to enter into this Agreement and to perform its
obligations hereunder. The execution, delivery and performance of this
Agreement by the Corporation and its subsidiaries and the consummation by the
Corporation and its subsidiaries of the Contemplated Transactions have been
authorized by the Board and, except for the approval of the Arrangement by
Securityholders, no other corporate proceedings on the part of the Corporation
(excluding the Interim Order and the Final Order) or its subsidiaries are
necessary to authorize the Corporation and its subsidiaries to enter into and
to perform its obligations under this Agreement or the Contemplated
Transactions. This Agreement has been duly executed and delivered by the
Corporation and constitutes a valid and binding agreement of the Corporation,
enforceable against the Corporation in accordance with its
provisions, subject to the qualification that such enforceability may be
limited by bankruptcy, insolvency, reorganization, fraudulent
transfer, moratorium or other Laws relating to limitations of actions or
affecting the availability of equitable remedies and the enforcement of
creditors' rights generally and general principles of equity and public policy
and to the qualification that equitable remedies such as specific performance
and injunction may be granted only in the discretion of a court of competent
jurisdiction.

  



  

   

 | | 
---|---|--- 

 



    



   | 4.| Authority and No Violation. 
---|---|--- 
  



   | (a)| The authorization of this Agreement,  the execution and delivery
by the Corporation of this Agreement and the performance by  the Corporation
and its subsidiaries of their obligations under this Agreement, and the 
consummation of the Contemplated Transactions (for greater certainty, if
applicable,  in compliance with the Interim Order and the Final Order), will
not result (with or without  notice or the passage of time) in a violation or
breach of or constitute a default under  any provision of: 
---|---|--- 
  



   | (i)| the constating documents of the Corporation  or its
subsidiaries; 
---|---|--- 
  



   | (ii)| subject to obtaining the applicable  Authorizations
contemplated by this Agreement, any applicable Laws; 
---|---|--- 
  



   | (iii)| any note, bond, mortgage, indenture,  contract, licence or
permit to which the Corporation or any of its subsidiaries is party  or by
which it is bound; or 
---|---|--- 
  



   | (iv)| any judgment, decree, order or award  of any Governmental
Authority against the Corporation or its subsidiaries; 
---|---|--- 
  



  

except in the case of (ii), (iii) or (iv) above, such violations, breaches or
defaults as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on the Corporation or its
subsidiaries, taken as a whole.

  



   | (b)| Other than as set out in Section 4(b)  the Disclosure Letter or
as would not reasonably be expected to have a Material Adverse  Effect on the
Corporation or its subsidiaries, taken as a whole, the authorization of  this
Agreement, the execution and delivery by the Corporation of this Agreement and
the  performance by the Corporation of its obligations under this Agreement,
and the consummation  of the Contemplated Transactions will not: 
---|---|--- 
  



   | (i)| allow any person to exercise any  rights, require any consent or
notice under or other action by any person, or constitute  a default under,
or cause or permit the termination, cancellation, acceleration or other 
change of any right or obligation or the loss of any benefit to which the
Corporation  or its subsidiaries are entitled (including by triggering any
rights of first refusal  or first offer, change in control provision or other
restriction or limitation) under  any Contract or any Authorization to which
the Corporation or its subsidiaries are a  party or by which the Corporation
or its subsidiaries are bound; or 
---|---|--- 
  



  

   

 | C-2| 
---|---|--- 

 



    



   | (ii)| result in the imposition of any  Encumbrance upon any assets of
the Corporation or any of its subsidiaries, except for  Encumbrances that are
not material to the Corporation or any of its subsidiaries, taken  as a
whole. 
---|---|--- 
  



   | 5.| Consents and Approvals. 
---|---|--- 
  



  

Other than as set out in Section 5 of the Disclosure Letter, no consent,
approval, order or other Authorization of, or declaration or filing with, any
Governmental Authority or any other third party is required to be obtained by
the Corporation or its subsidiaries in connection with the consummation of
the Contemplated Transactions, except for:

  



   | (a)| the Interim Order and any approvals  required by the Interim
Order; 
---|---|--- 
  



   | (b)| the Final Order; 
---|---|--- 
  



   | (c)| the filings required under the  Act; 
---|---|--- 
  



   | (d)| compliance with the HSR Act, including the HSR Approval; 
---|---|--- 
  



   | (e)| the filings required by applicable  Securities Laws or the
Exchanges; 
---|---|--- 
  



   | (f)| the filings required by the Act  and any other applicable
corporate statutes; and 
---|---|--- 
  



   | (g)| the approval of the Arrangement  Resolution by Securityholders;
and 
---|---|--- 
  



   | (h)| those that if not obtained would  not, individually or in the
aggregate, reasonably be expected to have a Material Adverse  Effect on the
Corporation and its subsidiaries, taken as a whole. 
---|---|--- 
  



   | 6.| Shareholders' and Similar Agreements. 
---|---|--- 
  



  

Except as disclosed in Section 6 of the Disclosure Letter, neither the
Corporation nor its subsidiaries are subject to, or affected by, any unanimous
shareholders agreement and is not a party to any shareholder, pooling,
voting, or other similar arrangement or agreement relating to the
ownership or voting of any of the securities of the Corporation or its
subsidiaries or pursuant to which any person other than the Corporation or
its subsidiaries may have any right or claim in connection with any existing
or past equity interest in the Corporation or its subsidiaries.

  



   | 7.| Capitalization. 
---|---|--- 
  



   | (a)| The authorized share capital of the Corporation consists of an
unlimited number of Common  Shares. As of the close of business on the date
of this Agreement, there were 12,448,108 issued and outstanding Common 
Shares. Section 7(a) of the Disclosure Letter sets forth the number of
Warrants and Options outstanding as of the close  of business on the date of
this Agreement and the number of Common Shares issuable upon exercise thereof. 
---|---|--- 
  



  

   

 | C-3| 
---|---|--- 

 



    



   | (b)| Section 7(b) of the Disclosure  Letter contains a list of the
Warrants, with the following details, in respect of each  Warrant outstanding
as of the close of business on the date of this Agreement: (i) the  weighted
average strike price, (ii) the date of grant; (iii) the date of expiry; (iv) 
the number of participants to whom such Warrants have been granted; and (v)
the name  of the registered holder. The issuance of Common Shares upon the
exercise of all Warrants  have been duly authorized by the Board in
compliance with Laws, and have been recorded  on the Corporation's financial
statements in accordance with IFRS, and no such  grants involved any "back
dating," "forward dating," "spring  loading" or similar practices. 
---|---|--- 
  



   | (c)| Section 7(c) of the Disclosure  Letter contains a list of the
Options, with the following details, in respect of each  Option outstanding
as of the close of business on the date of this Agreement: (i) the  strike
price, (ii) the date of grant; (iii) the date of expiry; (iv) the name of
the  participants to whom such Options have been granted; and (v) the name of
the registered  holder, identifying whether such holder is not an employee of
the Corporation or its  subsidiaries (and where not an employee, the basis
for the grant). The Option Plan and  the issuance of Common Shares under such
plan (including all outstanding Options) have  been duly authorized by the
Board and/or any compensation committee or similar committee  of the Board,
as applicable, in compliance with Laws and the terms of the Option Plan,  and
have been recorded on the Corporation's financial statements in accordance 
with IFRS, and no such grants involved any "back dating," "forward  dating,"
"spring loading" or similar practices. 
---|---|--- 
  



   | (d)| Except with respect to the Warrants  and the Options or as
disclosed in Section 7(d) of the Disclosure Letter, there  are no outstanding
options, warrants, conversion privileges or other Rights, agreements  or
commitments of any character whatsoever that would require the issuance, sale
or transfer  by the Corporation of any shares or other securities of the
Corporation or of its subsidiaries  or the issuance, sale or transfer of any
securities convertible into, or exchangeable  or exercisable for, or
otherwise evidencing a right to acquire, any shares or other securities  of
the Corporation or of its subsidiaries. All outstanding Common Shares have
been duly  authorized and validly issued, are fully paid and non-assessable,
and no such shares  have been issued in violation of any pre-emptive rights.
No Shareholder is entitled to  any pre-emptive right granted by the
Corporation or its subsidiaries. Other than as disclosed  in Section 7(d) of
the Disclosure Letter, there are no outstanding contractual or  other
obligations of the Corporation or its subsidiaries to repurchase, redeem or
otherwise  acquire any of its securities. 
---|---|--- 
  



   | (e)| There are no notes, bonds, debentures  or other evidences of
indebtedness or any other agreements, arrangements, instruments  or
commitments of any kind that give any person, directly or indirectly, the
right to  vote with holders of Common Shares on any matter. 
---|---|--- 
  



   | (f)| The Corporation has never declared or paid any dividends or,
except as provided in the  Adagio Purchase Agreement and Section 8.11 of the
Agreement, made or obligated itself to make any other distributions  or
payments to the holders of any securities of the  Corporation. 
---|---|--- 
  



  

   

 | C-4| 
---|---|--- 

 



    



   | 8.| Subsidiaries. 
---|---|--- 
  



  

The Corporation is the registered and beneficial owner of all of the
outstanding shares of capital stock or other equity interests of its
subsidiaries, free and clear of any Encumbrances. All of such shares and
other equity interests so owned by the Corporation are validly issued, fully
paid and non-assessable, and no such shares have been issued in violation of
any pre-emptive or similar rights. Except for the equity interests owned by
the Corporation in its subsidiaries, neither the Corporation nor any of its
subsidiaries own, beneficially or of record, any equity interest of any kind
in any other person. Except as set forth on Section 8 of the Disclosure
Letter, Cynapsus Therapeutics (USA) Inc. does not conduct any business
operations and has no material assets or liabilities.

  



   | 9.| Securities Laws Matters. 
---|---|--- 
  



  

The Corporation is a "reporting issuer" under the Securities Laws of the
provinces of British Columbia, Alberta and Ontario and no other provinces or
territories and is not on the list of defaulting issuers (or the equivalent)
under the Securities Laws of any province or territory. The Common Shares are
listed and posted for trading on each of the Exchanges. None of the
Corporation's subsidiaries is subject to any continuous or periodic, or other
disclosure requirements under any Securities Laws in any jurisdiction. The
Corporation is not in default of any material requirements of any Securities
Laws or the rules and regulations of the Exchanges. The Corporation has not
taken any action to cease to be a reporting issuer in any of the provinces or
territories of Canada nor has the Corporation received notification from any
Securities Authority seeking to revoke the reporting issuer status of the
Corporation. No delisting, suspension of trading or cease trade or other
order or restriction with respect to any securities of the Corporation is
pending, in effect, has been threatened, or is expected to be implemented or
undertaken, and to the knowledge of the Corporation, the Corporation is not
subject to any formal or informal review, enquiry, investigation or other
proceeding relating to any such order or restriction. The Corporation has
timely filed or furnished with any Governmental Authority all forms, reports,
schedules, statements and other documents required to be filed or furnished
under Securities Laws or furnished by the Corporation with the appropriate
Governmental Authority since January 1, 2014. The documents comprising the
Public Disclosure Record complied as filed or furnished in all
material respects with Securities Laws and did not, as of the date filed or
furnished (or, if amended or superseded by a subsequent filing or submission
prior to the date of this Agreement, on the date of such filing or
submission), contain any Misrepresentation. The Corporation has not filed any
confidential material change report (which at the date of this Agreement
remains confidential) or any other confidential filings (other than portions
of filings which have been redacted) filed to or furnished with, as
applicable, any Securities Authority. There are no outstanding or unresolved
comments from any Securities Authority with respect to any of the Public
Disclosure Record and to knowledge of the Corporation, neither the Corporation
nor any of the Public Disclosure Record is subject of an ongoing audit,
review, comment or investigation by any Securities Authority or either of the
Exchanges.

  



  

   

 | C-5| 
---|---|--- 

 



    



   | 10.| U.S. Securities Law Matters 
---|---|--- 
  



   | (a)| The Common Shares are registered  pursuant to Section 12(b) of
the U.S. Exchange Act. 
---|---|--- 
  



   | (b)| Other than the Common Shares, the  Corporation does not have,
nor is it required to have, any class of securities registered  under the
U.S. Exchange Act. 
---|---|--- 
  



   | (c)| Other than with respect to the  Common Shares, the Corporation
is not subject to any reporting obligation (whether active  or suspended),
pursuant to section 15(d) of the U.S. Exchange Act. 
---|---|--- 
  



   | (d)| The Corporation is not an investment  company registered or
required to be registered under the _United States Investment  Company Act_
of 1940, as amended. 
---|---|--- 
  



   | (e)| The Corporation is a "foreign  private issuer" within the
meaning of Rule 405 under the U.S. Securities Act and  Rule 3b-4 under the
U.S. Exchange Act. 
---|---|--- 
  



   | 11.| Financial Statements. 
---|---|--- 
  



  

The audited consolidated financial statements of the Corporation for the
fiscal year ended December 31, 2015, and the unaudited consolidated interim
financial statements for the three and six months ended June 30, 2016
(including, in each case, any notes and schedules thereto) that are part of
the Corporation's publicly filed documents complied as of their respective
dates in all material respects with all applicable accounting
requirements and rules and regulations and presented fairly, in all material
respects, in conformity with IFRS, the consolidated financial position of the
Corporation and the consolidated results of operations and cash flows as of
the dates thereof and for the respective periods then ended (subject to year-
end adjustments and the absence of notes in the case of any unaudited interim
financial statements). The Corporation does not intend to correct or restate,
nor, to the knowledge of the Corporation is there any basis for any
correction or restatement of, any aspect of any of the financial statements
referred to in this Paragraph 11\. There are no, nor are there any
commitments to become a party to, any off-balance sheet transaction,
arrangement, obligation (including contingent obligations) or other
relationships of the Corporation or its subsidiaries with unconsolidated
entities or other persons.

  



   | 12.| Disclosure Controls and Internal Control  over Financial
Reporting 
---|---|--- 
  



   | (a)| The Corporation and its subsidiaries  have established and
maintain a system of disclosure controls and procedures that are  designed to
provide reasonable assurance that information required to be disclosed by 
the Corporation in its annual filings, interim filings or other reports filed
or submitted  by it under Securities Laws is recorded, processed, summarized
and reported within the  time periods specified in Securities Laws. Such
disclosure controls and procedures include  controls and procedures designed
to ensure that information required to be disclosed  by the Corporation in
its annual filings, interim filings or other reports filed or submitted 
under Securities Laws are accumulated and communicated to the Corporation's
management,  including its chief executive officer and chief financial
officer, as appropriate, to  allow timely decisions regarding required
disclosure. 
---|---|--- 
  



  

   

 | C-6| 
---|---|--- 

 



    



   | (b)| The Corporation has established  and maintains a system of
internal control over financial reporting that is designed  to provide
reasonable assurance regarding the reliability of financial reporting and 
the preparation of financial statements for external purposes in accordance
with IFRS. 
---|---|--- 
  



   | (c)| There is no material weakness (as  such term is defined in
National Instrument 52-109 - _Certification of Disclosure  in Issuers '
annual and Interim Filings_) relating to the design, implementation  or
maintenance of its internal control over financial reporting, or fraud,
whether or  not material, that involves management or other employees who
have a significant role  in the internal control over financial reporting of
the Corporation. None of the Corporation,  the Corporation's subsidiaries or,
to the knowledge of the Corporation, any director,  officer, employee,
auditor, accountant or representative of the Corporation or its subsidiaries 
have received or otherwise obtained knowledge of any complaint, allegation,
assertion,  or claim, whether written or oral, regarding accounting, internal
accounting controls  or auditing matters, including any complaint,
allegation, assertion, or claim that the  Corporation or its subsidiaries
have engaged in questionable accounting or auditing practices,  or any
expression of concern from its employees regarding questionable accounting
or  auditing matters. 
---|---|--- 
  



   | 13.| Auditors 
---|---|--- 
  



  

The auditors of the Corporation are independent public accountants as
required by applicable Laws and there is not now, and there has never been,
any reportable event (as defined in National Instrument 51-102 - _Continuous
Disclosure Obligations_ ) with the present or any former auditors of
the Corporation.

  



   | 14.| No Undisclosed Liabilities. 
---|---|--- 
  



  

There are no liabilities or obligations of the Corporation or its
subsidiaries required by IFRS to be reflected on a balance sheet or in the
notes thereto, other than: (i) liabilities or obligations to the extent
reflected in the financial statements of the Corporation that are included in
the publicly filed documents of the Corporation, (ii) liabilities or
obligations incurred by the Corporation since June 30, 2016 in the ordinary
course consistent with past practices or that are otherwise described
in Section 14 of the Disclosure Letter, (iii) immaterial liabilities and
obligations, and (iv) liabilities or obligations incurred in connection with
the transactions contemplated hereby as set out in Section 14 of the
Disclosure Letter and pursuant to the amendment on the date hereof of the
Adagio Purchase Agreement.

  



   | 15.| No Material Adverse Effect. 
---|---|--- 
  



  

Since December 31, 2015, other than the transactions contemplated in this
Agreement and the amendment on the date hereof of the Adagio Purchase
Agreement, the business of the Corporation and its subsidiaries has been
conducted in the Ordinary Course and there has not occurred a Material
Adverse Effect.

  



  

   

 | C-7| 
---|---|--- 

 



    



   | 16.| Ordinary Course. 
---|---|--- 
  



  

Except as disclosed in Section 16 of the Disclosure Letter and except for the
amendment on the date hereof of the Adagio Purchase Agreement since December
31, 2015:

  



   | (a)| the Corporation and each of its  subsidiaries has conducted
their respective business only in the Ordinary Course; 
---|---|--- 
  



   | (b)| no liability or obligation of any  nature (whether absolute,
accrued, contingent or otherwise) which has had, or is reasonably  likely to
have, a Material Adverse Effect has been incurred; 
---|---|--- 
  



   | (c)| there has not been any material  change in the accounting
practices used by the Corporation and its subsidiaries; 
---|---|--- 
  



   | (d)| except for Ordinary Course adjustments  to employees (other than
directors or officers), there has not been any increase in the  salary,
bonus, or other remuneration payable to any non-executive employees of any
of  Corporation or its subsidiaries; 
---|---|--- 
  



   | (e)| there has not been a material change  in the level of accounts
receivable or payable, inventories or employees, other than  those changes in
the Ordinary Course; 
---|---|--- 
  



   | (f)| there has not been any increase  in the salary, bonus, retainer
or other remuneration payable to any director or officer  of any of
Corporation or its subsidiaries; 
---|---|--- 
  



   | (g)| there has not been any redemption,  repurchase or other
acquisition of Common Shares by the Corporation, or any declaration,  setting
aside or payment of any dividend or other distribution (whether in cash or
otherwise)  with respect to the Common Shares; 
---|---|--- 
  



   | (h)| there has not been any entering  into, or an amendment of, any
Material Contract other than in the Ordinary Course; 
---|---|--- 
  



   | (i)| there has not been any satisfaction  or settlement of any
material claims or material liabilities that were not reflected  in the
Corporation's audited financial statements, other than the settlement of 
claims or liabilities incurred in the Ordinary Course; and 
---|---|--- 
  



   | (j)| except for Ordinary Course adjustments,  there has not been any
increase in the salary, bonus, or other remuneration payable to  any officers
of the Corporation or its subsidiaries or any amendment or modification  to
the vesting or exercisability schedule or criteria, including any
acceleration, right  to accelerate or acceleration event or other entitlement
under any stock option, restricted  stock, deferred compensation or other
compensation award of any officer of the Corporation  or any of its
subsidiaries. 
---|---|--- 
  



  

   

 | C-8| 
---|---|--- 

 



    



   | 17.| No Brokers. 
---|---|--- 
  



  

Except for the fees to be paid to Merrill Lynch, Pierce, Fenner and Smith
Incorporated and Stifel, Nicolaus and Company, Incorporated and as set out in
Section 17 of the Disclosure Letter, no Securityholder of the Corporation,
director, officer, employee, consultant, broker, "finder", investment banker
or other person is entitled to any brokerage, "finder's" or other fee or
commission or similar form of compensation, or to the reimbursement of any of
its expenses, in connection with this Agreement or the Contemplated
Transactions. True and complete copies (subject only to redaction of
confidential information identifying potential alternative acquirors) of the
engagement letters between the Corporation and its financial advisors and
between the Corporation and the financial advisors to the Special Committee
have been provided to the Acquiror and the Corporation has made true and
complete disclosure to the Acquiror of all fees, commissions or other
payments that may be incurred pursuant to such engagements or that may
otherwise be payable to the Corporation's financial advisors.

  



   | 18.| Long Term and Derivative Transactions 
---|---|--- 
  



  

Neither the Corporation nor its subsidiaries have any material obligations or
liabilities, direct or indirect, vested or contingent in respect of any rate
swap transactions, basis swaps, forward rate transactions, commodity swaps,
commodity options, equity or equity index swaps, equity or equity
index options, bond options, interest rate options, foreign exchange
transactions, cap transactions, floor transactions, collar
transactions, currency swap transactions, cross currency rate swap
transactions or currency options having terms greater than 90 days
(including any option with respect to any of such transactions) or any
combination of such transactions, except in the Ordinary Course.

  



   | 19.| Compliance with Laws. 
---|---|--- 
  



  

The Corporation and its subsidiaries are, and have been since January 1,
2014, in compliance in all material respects with, and to the knowledge of the
Corporation are not under investigation with respect to and have not been
threatened in writing to be charged with or given written notice of any
material violation of, any material applicable Laws.

  



   | 20.| Regulatory Compliance. 
---|---|--- 
  



   | (a)| Section 20(a) of the Disclosure  Letter sets forth a true and
complete list, (i) identifying all material Authorizations  granted by any
Governmental Authority, and (ii) outlining the status of all pending
Authorizations  by any Governmental Authority, in each case relating to the
Product. The Corporation  has made available to the Acquiror all such
Authorizations. 
---|---|--- 
  



   | (b)| The Corporation and its subsidiaries  own, possess or have
obtained all Authorizations that are required by Law in connection  with the
operation of the business of the Corporation and its subsidiaries as
presently  or previously conducted. The Corporation has made available to the
Acquiror all such  Authorizations. The Corporation or its subsidiaries, as
applicable, lawfully hold, own  or use, and have complied with, all such
Authorizations, except as would not, individually  or in the aggregate, have
a Material Adverse Effect on the Corporation and its subsidiaries,  taken as
a whole. Each Authorization is valid and in full force and effect, and is
renewable  by its terms or in the Ordinary Course, except as would not,
individually or in the aggregate,  have a Material Adverse Effect on the
Corporation and its subsidiaries, taken as a whole. 
---|---|--- 
  



  

   

 | C-9| 
---|---|--- 

 



    



   | (c)| The Corporation or its subsidiaries  have filed with the
applicable Governmental Authority (including the FDA, Health Canada  or any
other Governmental Authority performing functions similar to those performed
by  the FDA) all required filings, approvals, authorizations, clearances,
Claims, declarations,  listings, notices, registrations, reports or
submissions, including but not limited to  the investigational new drug
application ("IND") relating to the Product,  the protocols relating to each
clinical trial of the Corporation, and all Serious Adverse  Events deemed
reportable to the applicable Governmental Authority. The Corporation has 
made available to the Acquiror true and complete copies of all such documents,
where  available, or provided current true and complete current information
with respect to  such matters where no documentation is available. All such
documents were when filed  or submitted, and continue to be, in material
compliance with applicable Laws, including  guidance documents, good
laboratory practices, and good clinical practices requirements  (all such
Laws in this Section being "Approval Requirements"), of  the applicable
Governmental Authority and no material deficiencies have been asserted  by
any applicable Governmental Authority with respect to any such filings,
approvals,  authorizations, clearances, Claims, declarations, listings,
notices, registrations, reports  or submissions. 
---|---|--- 
  



   | (d)| Except as set forth on Section 20(d)  of the Disclosure Letter,
the Corporation has not amended the protocol relating to clinical  trials
CTH-300 and CTH-301, modified or taken any action that deviated from the
current  clinical trial study designs, timelines for clinical trials CTH-300
and CTH-301, including  without limitation, taken any action that has or
would reasonably be expected to impact  the study cycle time line, patient
and study site recruitment and enrollment status,  patient standards of care,
study objectives or strategy, protocol complexity, or the  statistical
analyses. 
---|---|--- 
  



   | (e)| Neither the Corporation nor its  subsidiaries have initiated,
conducted, or issued any recall, withdrawal, safety alert,  warning,
investigator notice, or other notice relating to an alleged lack of safety
or  efficacy of the Product. Neither the Corporation nor its subsidiaries are
currently contemplating  such actions. 
---|---|--- 
  



  

   

 | C-10| 
---|---|--- 

 



    



   | (f)| Except as described in Section 20(f)  of the Disclosure Letter,
all business operations, including preclinical and clinical  investigations
sponsored by the Corporation or its subsidiaries, and those in which any  or
all obligations under the FDCA or Approval Requirements administered by any
other  Governmental Authority have been transferred to a third party, have
been in compliance  in all material respects with, and have not been
threatened in writing to be charged  with or given written notice of and, to
the knowledge of the Corporation, are not under  investigation with respect
to any violation of, any applicable Laws, including (i) the  FDCA, as
amended, 21 U.S.C.  301 et seq., (ii) the federal False Claims Act, 31 
U.S.C.  3729 3733, as amended, (iii) the Physician Payments Sunshine Act, 42
U.S.C.   1320a 7h, (iv) the Patient Protection and Affordable Care Act, P.L.
111 148, (v)  the United States federal Medicare and Medicaid statutes and
related state or local statutes  or regulations, (vi) the federal Anti-
Kickback Statute, 42 U.S.C.  1320a 7b, the  federal Physician Self-Referral
(Stark) Law, 42 U.S.C.  1395nn, and the Federal  Civil Monetary Penalties
Law, 42 U.S.C.  1320a 7a, (vii) 42 U.S.C.   1320d through 1320d 8 and 42
C.F.R.  160, 162 and 164, which are commonly  referred to as the "Health
Insurance Portability and Accountability Act of 1996"  or "HIPAA", (viii) the
following binding rules and regulations: Good Clinical  Practices, Good
Laboratory Practices, and Good Manufacturing Practices as promulgated  by the
FDA under and in accordance with the U.S. Federal Food, Drug and Cosmetic
Act,  Title 21, Parts 50, 54, 56, 58, 210, 211, and 312 of the C.F.R, (ix)
the applicable European  regulation and UK regulation, including the European
Directive 2001/83/EC on the Community  code relating to medicinal products
for human use, the European Clinical Trial Directive  2001/20/EC, the
European Clinical Trial Guidelines, the applicable transparency and anti-
gift  Laws, and the European Data Protection Directive 95/46/EC, in each case
except as would  not, individually or in the aggregate, have a Material
Adverse Effect on the Corporation  and its subsidiaries, taken as a whole.
The Corporation has made available to Acquiror  all such written threats or
written notices of non-compliance with applicable Laws. 
---|---|--- 
  



   | (g)| Except as described in Section 20(g)  of the Disclosure Letter,
neither the Corporation nor its subsidiaries have received  any warning
letters, untitled letters, regulatory letters, notices of inspectional
observations  (Form FDA 483s), correspondence regarding the termination or
suspension or delay or modification  of any ongoing clinical or pre-clinical
studies or tests, establishment inspection reports  or other correspondence
or notices from the FDA, Health Canada or any other applicable  Governmental
Authority relating to deficiencies in the Development, investigation, and 
manufacture of the Product, in each case except as would not, individually or
in the  aggregate, have a Material Adverse Effect on the Corporation and its
subsidiaries, taken  as a whole. All such documents described in Section
20(g) of the Disclosure Letter  have been made available to the Acquiror. 
---|---|--- 
  



   | (h)| Except as described in Section 20(h)  of the Disclosure Letter,
neither the Corporation nor its subsidiaries have received  written notice of
any threatened or pending investigation, hearing, finding of deficiency  or
noncompliance, adverse inspection report, penalty, fine, sanction, request for
recall,  relabeling or other remedial action, audit or other regulatory
action (other than non-material  routine or periodic inspections or reviews)
by any Governmental Authority against (i)  the Corporation or its
subsidiaries or, (ii) any person that manufactures, packages,  labels,
imports/exports, stores, distributes or sells pursuant to a manufacturing,
supply  or other arrangement with the Corporation or its subsidiaries, in
each case except as  would not, individually or in the aggregate, have a
Material Adverse Effect on the Corporation  and its subsidiaries, taken as a
whole. All such documents described in Section 20(h)  of the Disclosure
Letter have been made available to the Acquiror. 
---|---|--- 
  



  

   

 | C-11| 
---|---|--- 

 



    



   | (i)| Neither the Corporation nor its  subsidiaries, nor, to the
knowledge of the Corporation, any officer or employee, of the  Corporation or
its subsidiaries, have made an untrue statement of fact or a fraudulent 
statement, including, but not limited to certification to the FDA, Health
Canada or any  other Governmental Authority or agent thereof, failed to
disclose a fact required to  be disclosed to the FDA, Health Canada or any
other Governmental Authority or agent thereof,  or committed an act, made a
statement or failed to make a statement that, at the time  such disclosure
was made, would reasonably be expected to provide a basis for the FDA, 
Health Canada or any other Governmental Authority or agent thereof to invoke
its policy  respecting "Fraud, Untrue Statements of Material Facts, Bribery,
and Illegal Gratuities,"  set forth in 56 Fed. Reg. 46191 (September 10,
1991) or for the FDA. Neither the Corporation  nor its subsidiaries, nor any
officer or employee of the Corporation or its subsidiaries,  have been
debarred or convicted of any crime or engaged in any conduct that would
reasonably  be expected to result in debarment under 21 U.S.C. Section 335a
or any similar Laws or  exclusion under 42 U.S.C. Section 1320a 7 or any
similar Laws. Neither the Corporation  nor its subsidiaries nor any officer
or employee of the Corporation or its subsidiaries  are subject to an
investigation or proceeding by any Governmental Authority that would 
reasonably be expected to result in such suspension, exclusion or debarment
and to the  knowledge of the Corporation, there are no facts that would
reasonably be expected to  give rise to such suspension, exclusion or
debarment. 
---|---|--- 
  



   | (j)| Neither the Corporation nor its  subsidiaries are currently
developing, nor has it developed or sought approval for, any  product other
than the Product. 
---|---|--- 
  



   | 21.| Clinical Studies. 
---|---|--- 
  



  

All clinical studies undertaken by the Corporation or its subsidiaries have
been conducted in all material respects in accordance with all applicable Law,
including good clinical practices.

  



   | 22.| Litigation. 
---|---|--- 
  



  

Except as disclosed in Section 22 of the Disclosure Letter and any inquiry,
investigation or proceeding solely related to satisfying or obtaining the
Authorizations, there are no claims, actions, suits, arbitrations, inquiries,
investigations or proceedings pending, or, to the knowledge of
the Corporation threatened, against the Corporation or its subsidiaries by or
affecting any of their respective current or former properties or assets by
or before any Governmental Authority that, if determined adverse to the
interests of the Corporation or its subsidiaries, could potentially result in
criminal sanctions, or would have, individually or in the aggregate, a
Material Adverse Effect or would or would be reasonably expected to prevent
or delay the consummation of the Arrangement or the transactions contemplated
hereby or would or would be reasonably expected to materially affect the
Acquiror's ability to own or operate the business of the Corporation or its
subsidiaries,, nor, to the knowledge of the Corporation, are there any events
or circumstances which could reasonably be expected to give rise to any such
claim, action, suit, arbitration, inquiry, investigation or proceeding. There
is no bankruptcy, liquidation, winding up or other similar proceeding pending
or in progress, or, to the knowledge of the Corporation, threatened against
or relating to the Corporation or its subsidiaries before any Governmental
Authority. Neither the Corporation nor its subsidiaries nor any of their
respective properties or assets are subject to any outstanding
judgment, order, writ, injunction or decree that would have or would be
reasonably expected to have, individually or in the aggregate, a Material
Adverse Effect or that would or would be reasonably expected to prevent or
delay the consummation of the Arrangement or the transactions contemplated
hereby.

  



  

   

 | C-12| 
---|---|--- 

 



    



   | 23.| Taxes. 
---|---|--- 
  



  

Except as disclosed in Section 23 of the Disclosure Letter:

  



   | (a)| Each of the Corporation and its  subsidiaries have duly and
timely filed all material Tax Returns required to be filed  by them prior to
the date hereof (taking into account any extended due dates therefor)  and
all such material Tax Returns are complete and correct in all material
respects and  no such material Tax Return has been amended. 
---|---|--- 
  



   | (b)| Each of the Corporation and its  subsidiaries have paid all
assessments and reassessments of Taxes, and all other material  Taxes
required to be paid on or before the date hereof, other than those which are
being  or have been contested in good faith and in respect of which reserves
have been provided  in the most recently published consolidated financial
statements of the Corporation.  The Corporation has provided adequate
accruals in accordance with IFRS in the most recently  published consolidated
financial statements of the Corporation for any Taxes of the Corporation  and
its subsidiaries for the period covered by such financial statements that have
not  been paid whether or not shown as being due on any Tax Returns. Since
such publication  date, no material liability in respect of Taxes not
reflected in such statements or otherwise  provided for has been assessed,
proposed to be assessed, incurred or accrued, other than  in the Ordinary
Course. Neither the Corporation nor its subsidiaries have received a  refund
to which it was not entitled. 
---|---|--- 
  



   | (c)| No material deficiencies, litigation,  proposed adjustments or
matters in controversy exist or have been asserted with respect  to Taxes of
the Corporation or its subsidiaries, and neither the Corporation nor its 
subsidiaries are a party to any action or proceeding for assessment or
collection of  Taxes and no such event has been asserted or, to the knowledge
of the Corporation, threatened  against the Corporation or any of its
subsidiaries or any of their respective assets. 
---|---|--- 
  



   | (d)| Each of the Corporation and its  subsidiaries have withheld or
collected all material amounts required to be withheld  or collected by it on
account of Taxes and has remitted all Taxes required to be remitted  to the
appropriate Governmental Authority when required by Law to do so. 
---|---|--- 
  



   | (e)| No claim has been made by any Governmental  Authority in a
jurisdiction where the Corporation or its subsidiaries do not file Tax 
Returns that the Corporation or its subsidiaries are subject to material Tax
by that  jurisdiction. 
---|---|--- 
  



  

   

 | C-13| 
---|---|--- 

 



    



   | (f)| There are no Encumbrances with  respect to Taxes upon any of the
assets of the Corporation or its subsidiaries. 
---|---|--- 
  



   | (g)| There are no outstanding agreements  extending or waiving the
statutory period of limitations applicable to any claim for,  or the period
for the collection or assessment or reassessment of Taxes due from the 
Corporation or its subsidiaries for any taxable period and no request for any
such waiver  or extension are currently pending. 
---|---|--- 
  



   | (h)| The Corporation and its subsidiaries  have made available to the
Acquiror true, correct and complete copies of all material  Tax Returns,
examination reports and statements of deficiencies for taxable periods,  or
transactions consummated, for which the applicable statutory periods of
limitations  have not expired. 
---|---|--- 
  



   | (i)| Neither the Corporation nor its  subsidiaries have ever directly
or indirectly transferred any property to or supplied  any services to or
acquired any property or services from a person with whom it was not  dealing
at arm's length (for the purposes of the _Tax Act_ ) for consideration  other
than consideration equal to the fair market value of the property or services
at  the time of the transfer, supply or acquisition of the property or
services. 
---|---|--- 
  



   | (j)| There are no circumstances existing  which could result in the
application of Section 78 or Sections 80 to 80.04 of the  _Tax Act_ , or any
equivalent provision under provincial Law, to the Corporation  or its
subsidiaries. Other than in the Ordinary Course, the Corporation and its
subsidiaries  have not claimed nor will they claim any reserve under any
provision of the _Tax Act _ or any equivalent provincial provision, if any
amount could be included in the income  of the Corporation or its
subsidiaries for any period ending after the Effective Time. 
---|---|--- 
  



   | (k)| The Corporation is a taxable Canadian  corporation within the
meaning of the _Tax Act_. 
---|---|--- 
  



   | 24.| Employee Matters. 
---|---|--- 
  



   | (a)| For the purposes hereof, "Employee  Plans" means all health,
medical, dental, welfare, supplemental unemployment  benefit, bonus, profit
sharing, stock option, insurance, incentive, incentive compensation, 
deferred compensation, share purchase, share based compensation, disability,
pension,  retirement or supplemental retirement plans and all other material
compensation or benefit  plans or agreements for the benefit of employees or
former employees or directors or  former directors of the Corporation and/or
its subsidiaries, or their dependents or beneficiaries,  which are maintained
by, contributed to, or binding upon the Corporation or its subsidiaries  or
in respect of which the Corporation or its subsidiaries have any material
liability  (contingent or otherwise), with the exception of (i) any statutory
plans or agreements  which the Corporation or its subsidiaries are required
to participate in or comply with  under applicable Laws, including the Canada
Pension Plan, and (ii) any other plans or  agreements established or
administered under applicable health, workplace safety and  insurance and
employment insurance legislation. True and complete copies of each written 
Employee Plan, as amended to the date hereof, and summaries of any unwritten
Employee  Plans, have been delivered or made available to the Acquiror. 
---|---|--- 
  



  

   

 | C-14| 
---|---|--- 

 



    



   | (b)| All of the Employee Plans have  been, as applicable,
established, registered (including registration with the relevant 
authorities where such registration is required to qualify for Tax exemption
or other  beneficial Tax status), and administered, in accordance with all
applicable Laws, and  in accordance in all material respects with their
terms, except in either such case where  any such failure would not
reasonably be expected to have, individually or in the aggregate,  a Material
Adverse Effect on the Corporation and its subsidiaries, taken as a whole. 
All contributions and premiums required to be made or remitted by the
Corporation or  its subsidiaries, as applicable, under the terms of each
Employee Plan or by applicable  Laws in respect of the Employee Plans have
been made or remitted in accordance with applicable  Laws and the terms of
the applicable Employee Plan when due, except where any such failure  would
not reasonably be expected to have, individually or in the aggregate, a
Material  Adverse Effect on the Corporation and its subsidiaries, taken as a
whole. Except as disclosed  in Section 24(b) of the Disclosure Letter, no
currently outstanding notice of underfunding,  noncompliance, or failure to
be in good standing has been received by the Corporation  or its subsidiaries
thereof from any applicable Governmental Authority in respect of  any
Employee Plan. The Corporation and its subsidiaries have made no legally
binding  promise or commitment to create any additional Employee Plan or to
improve or change  the benefits provided under any Employee Plan. Except as
disclosed in Section 24(b)  of the Disclosure Letter, none of the Employee
Plans provide benefits beyond retirement  or other termination of service to
employees or former employees or to the dependents  or beneficiaries of such
employees. 
---|---|--- 
  



   | (c)| Section 24(c) of the Disclosure  Letter contains a complete and
correct list of all employees, dependent contractors and  independent
contractors who are employed by or work in connection with the business of 
the Corporation which sets forth the following information with respect to
each: (i)  name; (ii) title or position; (iii) in the case of employees, age;
(iv) date of hire;  (v) entity or entities by which such individual is
employed or engaged; (vi) current  wage or salary rate and last bonus; (vii)
in the case of employees, accrued but unused  vacation or paid time off;
(viii) in the case of employees, active or inactive status  and, if
applicable, the reason for the inactive status and anticipated return to
work  date; (ix) in the case of employees, full time or part time status; and
(x) employment  location. 
---|---|--- 
  



  

   

 | C-15| 
---|---|--- 

 



    



   | (d)| Except as disclosed in Section 24(d)  of the Disclosure Letter,
the amount of salaries, bonuses, commissions and other material  remuneration
of any nature, including vacation pay and overtime pay as well as any
termination  pay, severance pay and compensation in lieu of notice of
termination to employees, consultants,  officers and/or directors of the
Corporation or its subsidiaries that are earned and  due have been paid in
full or accrued (except for amounts due as normal salaries and  bonuses and
in reimbursement of ordinary expenses) in all material respects in
accordance  with all applicable accounting requirements and rules and
regulations, and neither the  Corporation or its subsidiaries have received
any notice of any outstanding overdue assessment,  order, lien or judgment
under applicable Laws relating to such matters. All other liabilities  to or
arising in connection with all employees of the Corporation or its
subsidiaries  (including Taxes and all payments, contributions or premiums
required to be remitted  or paid in respect of each of the Employee Plans,
employment insurance, Canada Pension  Plan, employer health tax, workers'
compensation any other employment related legislation)  have been paid in a
timely fashion when due. 
---|---|--- 
  



   | (e)| Neither the Corporation nor its  subsidiaries are a party to or
negotiating, and none of their employees are covered by,  any collective
bargaining agreement or union agreement or employee association agreement. 
Neither the Corporation nor its subsidiaries are aware of any current attempts
to organize  or establish any trade union, employee association or other
similar entity affecting  its employees and no collective bargaining
agreement is currently being negotiated. There  is no labour strike, dispute,
slowdown, stoppage or other labour difficulty pending,  involving, affecting
or, to the knowledge of the Corporation, threatened against the  Corporation
or any of its subsidiaries, and there have been none of the foregoing during 
the three (3) years preceding the date of this Agreement. 
---|---|--- 
  



   | (f)| The Corporation and each of its  subsidiaries has complied in
all material respects with all applicable Laws pertaining  to the employment
or termination of employment of their respective employees, including  all
Laws relating to employment standards and practices (including wages and hours
or  work and overtime), labour relations, employment equity, pay equity,
human rights, privacy,  occupational health and safety, workers\'
compensation, employment insurance and employer  health tax. Neither the
Corporation nor any of its subsidiaries are aware of any pending  or
threatened proceedings before any Governmental Authority with respect to any
of the  foregoing. 
---|---|--- 
  



   | (g)| Each of the Corporation and its  subsidiaries has properly
characterized retained individuals as either employees or independent 
contractors for the purposes of Tax Laws and none of the Corporation or any of
its subsidiaries  has received any written notice from any Governmental
Authority disputing such classification. 
---|---|--- 
  



   | (h)| There are no outstanding assessments,  penalties, fines, liens,
charges, surcharges or other amounts due or owing pursuant to  any workplace
safety and insurance legislation or pay equity legislation and the
Corporation  has not been reassessed in any material respect under such
legislation during the past  three (3) years and no audit of the Corporation
is currently being performed pursuant to  any applicable workplace safety and
insurance legislation or pay equity legislation and  neither the Corporation
nor any of its subsidiaries are aware of any potential inspection  orders,
violations, investigations or prosecutions against the Corporation under any 
applicable workplace safety and insurance legislation or pay equity
legislation. There  are no claims or potential claims which may materially
adversely affect the Corporation's  accident cost experience. 
---|---|--- 
  



  

   

 | C-16| 
---|---|--- 

 



    



   | 25.| Change of Control Payments. 
---|---|--- 
  



  

Except for the amendment on the date hereof of the Adagio Purchase Agreement,
Section 25 of the Disclosure Letter discloses all material payments
the Corporation or its subsidiaries are required to make to employees,
officers and/or directors as a result of the Contemplated Transactions,
including any change of control, severance, retention, bonus, termination or
other amounts (collectively, the "Change of Control Payments"), including
Change of Control Payments that are conditional on consummation of the
Contemplated Transactions and an additional event such as the termination of
any employee's employment.

  



   | 26.| Related Party Transactions. 
---|---|--- 
  



  

Other than as disclosed in Section 26 of the Disclosure Letter, the
Corporation and its subsidiaries are not indebted to any director, officer,
employee or Securityholder of the Corporation (except for amounts due as
normal salaries and bonuses and in reimbursement of ordinary expenses). Other
than as disclosed in Section 26 of the Disclosure Letter, no director,
officer, employee or Securityholder of the Corporation or its subsidiaries
are a party to any loan, contract, arrangement or understanding or other
transactions with the Corporation or its subsidiaries.

  



   | 27.| No "Collateral Benefit". 
---|---|--- 
  



  

Except as disclosed in Section 27 of the Disclosure Letter, to the knowledge
of the Corporation, no related party of the Corporation or its subsidiaries,
together with its associated entities, beneficially owns or exercises control
or direction over 1% or more of the outstanding Common Shares, except for
related parties who will not receive a "collateral benefit" (within the
meaning of MI 61-101) as a consequence of the transactions contemplated by
this Agreement.

  



   | 28.| Shareholder Rights Plan. 
---|---|--- 
  



  

The Corporation and its subsidiaries do not have a shareholder rights plan
and is not a party to any pooling, voting trust or other similar agreement
relating to the voting of the securities of the Corporation or its
subsidiaries, or pursuant to which any person other than the Corporation
or its subsidiaries may have any right or claim in connection with any
existing or past equity interest in the Corporation or its subsidiaries,
other than in respect of Options disclosed in Section 7(c) of the Disclosure
Letter, Warrants disclosed in Section 7(b) of the Disclosure Letter and the
rights of the parties under the Adagio Purchase Agreement.

  



   | 29.| Investment Canada Act. 
---|---|--- 
  



  

The enterprise value of the assets of the Corporation, calculated in the
manner prescribed under the _Investment Canada Act_ , is less than
C$600,000,000. The Corporation is not engaged in a "cultural business" as
defined in section 14.1 of the _Investment Canada Act_.

  



   | 30.| Competition Act 
---|---|--- 
  



  

The Corporation and its affiliates do not have assets in Canada that exceed,
on a combined basis, C$200,000,000 or gross revenue from sales in, from or
into Canada that exceed, on a combined basis, C$10,000,000, all as determined
in accordance with Part IX of the Competition Act.

  



  

   

 | C-17| 
---|---|--- 

 



    



   | 31.| Personal Property. 
---|---|--- 
  



  

The Corporation and its subsidiaries have good title to all material personal
property of any kind or nature which the Corporation and its subsidiaries
purport to own free and clear of all Encumbrances, except (i) such as set out
in Section 31 of the Disclosure Letter or (ii) where the failure to hold any
such title free and clear of any Encumbrances, singly or in the aggregate,
would not reasonably be expected to result in a Material Adverse Effect on
the Corporation. The Corporation and its subsidiaries, as lessee, have the
right under valid and subsisting leases to use, possess and control all
personal property leased by and material to the Corporation as now used,
possessed and controlled by the Corporation.

  



   | 32.| Environmental Matters. 
---|---|--- 
  



  

Except as would not, individually or in the aggregate, result in a Material
Adverse Effect on the Corporation:

  



   | (a)| no written notice, Claim, order,  complaint or penalty has been
received by the Corporation alleging that the Corporation  or its
subsidiaries are in violation of, or have any liability or any potential
material  Environmental Liability which either has been received in the past
twelve (12) months  or is outstanding or unresolved, and, there are no
judicial, administrative or other  actions, suits, proceedings, orders,
decrees or judgments unresolved, pending or threatened  which allege a
violation by the Corporation of any Environmental Laws or relating to  the
environment or the presence of contaminant, pollutant, waste or other material
or  substance in the environment that could reasonably give rise to material
Environmental  Liability; and 
---|---|--- 
  



   | (b)| the Corporation has all permits  necessary for its operations to
comply in all material respects with all Environmental  Laws and the
operations of the Corporation and its subsidiaries are and have been in 
compliance in all material respects with such permits. 
---|---|--- 
  



   | 33.| Immoveable Property. 
---|---|--- 
  



  

Neither the Corporation nor its subsidiaries own any real or immoveable
property. Section 33 of the Disclosure Letter sets out a list of all real
property (the "Corporation Leased Property") leased by the Corporation. The
Corporation is the tenant of the Corporation Leased Property subject to the
terms and conditions of leases appertaining thereto. The Corporation has, to
its knowledge, the right to possess, use and occupy the Corporation Leased
Property for the purposes of conducting its business as currently conducted.
Except as disclosed in Section 33 of the Disclosure Letter or where the
failure to hold any such title free and clear of any Encumbrances,
individually or in the aggregate, would not reasonably be expected to result
in a Material Adverse Effect on the Corporation, all interests of the
Corporation in the Corporation Leased Property as lessee under the leases are
free and clear of all Encumbrances.

  



  

   

 | C-18| 
---|---|--- 

 



    



   | 34.| Intellectual Property. 
---|---|--- 
  



   | (a)| Section 34(a)(ai) of the Disclosure Letter sets forth a true and
complete list of all Company Owned Registered IP. Section 34(a)(aii) of the
Disclosure Letter sets forth a true and complete list of all Company Licensed
Registered IP. Section 34(a)(ai) of the Disclosure Letter identifies the
following for each patent of the Company Owned Registered IP therein: (i) the
name of applicant/registrant, (ii) the current title owner, (iii) the
jurisdiction of application/registration, and (iv) the application number and
registration number, if applicable. Section 34(a)(ai) of the Disclosure
Letter identifies the following for each trademark of Company Owned Registered
IP therein: (i) the brand, (ii) the status, (iii) the origin, (iv) the
holder, (v) the number, (vi) the application date, and (vii) Nice cl. Section
34(a)(ai) of the Disclosure Letter identifies the following for each domain
name of Company Owned Registered IP therein: (i) the domain name, (ii) the
creation date, (iii) the expiration date, and (iv) the registrar. Section
34(a)(aii) of the Disclosure Letter identifies the following for each Company
Licensed Registered IP therein: (i) the jurisdiction of the
application/registration, (ii) the application number, and (iii) the
registration number, if applicable. The Company Owned Registered IP listed in
Section 34(a)(ai) of the Disclosure Letter (A) is subsisting, and, to the
knowledge of the Corporation, enforceable and valid, (B) to the knowledge of
the Corporation, has not been misused, withdrawn, cancelled or abandoned, and
(C) to the knowledge of the Corporation, all applications, registrations,
issuances, renewals and maintenance fees due for such Company Owned Registered
IP listed in Section 34(a)(ai) of the Disclosure Letter having a final due
date on or before the date hereof have been paid in full and are current.
Except as disclosed in the Disclosure Letter, to the knowledge of the
Corporation, there is no pending or threatened litigation,
interference, opposition, cancellation, reissue, re-examination, post-grant
proceeding or other Legal Proceeding of any nature (other than
communications arising from the prosecution of Registered Company IP with
Governmental Authorities) in which the scope, validity,
registrability, enforceability, use or ownership of any Company Owned
Registered IP in Section 34(a)(ai) of the Disclosure Letter is being or has
been contested or challenged. Neither the Corporation nor its subsidiaries
have failed to: diligently prosecute or cause to be prosecuted, maintained or
cause to be maintained, any application or registration, or to comply with any
agreement or order of any court, board or other Governmental Authority which
would prevent the Corporation from owning, using, commercializing,
exploiting or enforcing any Company Owned Registered IP with claims of the
same scope as listed in Section 34(a)(ai) of the Disclosure Letter. The
Company Licensed Registered IP listed in Section 34(a)(aii) of the Disclosure
Letter (I) to the knowledge of the Corporation is subsisting, (II) to the
knowledge of the Corporation, none of such Company Licensed Registered IP has
been misused, withdrawn, cancelled or abandoned, and (III) to the knowledge
of the Corporation, all applications, registrations, issuances, renewals
and maintenance fees due for such Company Licensed Registered IP listed in
Section 34(a)(aii) of the Disclosure Letter having a final due date on or
before the date hereof have been paid in full and are current. Neither the
Corporation nor its subsidiaries have failed to comply with any agreement or
order of any court which would prevent the Corporation from owning, using,
commercializing, exploiting or enforcing any Company Licensed Registered IP
with claims of the same scope as listed in Section 34(a)(aii) of the
Disclosure Letter. 
---|---|--- 
  



  

   

 | C-19| 
---|---|--- 

 



    



   | (b)| Section 34(b) of the Disclosure  Letter sets forth (i) all known
previous owners or assignees of the Company Owned Registered  IP listed in
Section 34(a)(ai) of the Disclosure Letter, (ii) all assignments with  any
other Governmental Authority of the Company Owned Registered IP listed in
Section 34(a)(ai)  of the Disclosure Letter from all previous owners, whether
or not a Corporation Associate,  (iii) all recordals of Company Owned
Registered IP in writing, listed in Section 34(a)(ai)  of the Disclosure
Letter, and (iv) all receipts for recordals of such assignments, to  the
extent available. 
---|---|--- 
  



   | (c)| Section 34(c) of the Disclosure  Letter sets forth a true and
complete list, identifying each license agreement or other  contract pursuant
to which the Corporation and/or its subsidiaries have acquired or has  the
right to acquire rights, title and/or interest in present or future Company
Licensed  Registered IP or any other Intellectual Property Rights as a
licensee. 
---|---|--- 
  



   | (d)| Except as described in Section 34(d)  the Disclosure Letter and
without giving effect to 35 U.S.C. 271(e)(i) or any other  Law of similar
effect in any jurisdiction, to the knowledge of the Corporation, (i) the 
Corporation or its subsidiaries own exclusively and possesses all right, title
and interest  in and to, or has the exclusive right to exploit fully, enforce
and use, including by  sublicensing, pursuant to a valid and enforceable
agreement, all Company Owned Registered  IP listed in Section 34(a)(ai) of
the Disclosure Letter, free and clear of all Encumbrances  and neither the
Corporation nor its subsidiaries have granted any rights into, and to  the
knowledge of the Corporation, no third parties have rights to, such Company
Owned  Registered IP listed in Section 34(a)(ai) of the Disclosure Letter;
and (ii) the  Corporation or its subsidiaries has the exclusive right to use
in the Licensed Field,  including by sublicensing, pursuant to a valid and
enforceable agreement, all Company  Licensed Registered IP listed in Section
34(a)(aii) of the Disclosure Letter, free  and clear of all Encumbrances and
neither the Corporation nor its subsidiaries have granted  any rights into,
and to the knowledge of the Corporation, no third parties have rights  in the
Licensed Field to, such Company Licensed Registered IP listed in Section
34(a)(aii)  of the Disclosure Letter. 
---|---|--- 
  



   | (e)| Except as provided in Section 34(e)  of the Disclosure Letter,
neither the Corporation nor its subsidiaries owe or will owe  any royalties
or other payments to any third party as a result of the use or exploitation 
of any of the Registered Company IP. 
---|---|--- 
  



  

   

 | C-20| 
---|---|--- 

 



    



   | (f)| Other than as set out in Section 34(f)  of the Disclosure
Letter, no Corporation Associate owns or has any Claim, right (whether  or
not currently exercisable), interest to, or interest in any Company IP,
including  without limitation any Company Owned Registered IP in Section
34(a)(ai) of the Disclosure  Letter and each Corporation Associate who is or,
to the knowledge of the Corporation,  was or is involved in the conception
and reduction to practice of any Intellectual Property  Rights for the
Corporation or its subsidiaries have signed a valid, enforceable agreement 
containing an assignment to the Corporation of a grant of exclusive ownership
of all  such Intellectual Property Rights (without further payment being owed
to any such Corporation  Associate and without any restrictions or
obligations on the Corporation's ownership  and use thereof), or where such
an assignment is not permitted under applicable Laws,  a waiver of moral
rights, and contains confidentiality provisions, non-disclosure provisions 
or the like protecting such Company Owned Registered IP listed in Section
34(a)(ai) of the  Disclosure Letter, which has not been materially breached
by such Corporation Associate. 
---|---|--- 
  



   | (g)| To the knowledge of the Corporation  and without giving effect
to 35 U.S.C. 271(e)(1) or any other Law of similar effect  in any
jurisdiction no person is infringing, misappropriating or otherwise
violating  any Company Owned Registered IP. The Corporation has not
threatened, asserted, initiated  or served any Legal Proceeding claiming
actual, alleged, or suspected, infringement,  misappropriation, or other
violation of any Company IP. 
---|---|--- 
  



   | (h)| To the knowledge of the Corporation  the operation of the
business of the Corporation and its subsidiaries as currently conducted  does
not infringe, misappropriate or otherwise violate any Intellectual Property
Rights  owned, in whole or in part, by any other person. 
---|---|--- 
  



   | (i)| Neither the Corporation nor its  subsidiaries have received any
written notice or other written communication of any claim,  demand, threat,
assertion or complaint relating to any actual, alleged or suspected
infringement,  misappropriation or other violation of any Intellectual
Property Right of another person  by the Corporation or its subsidiaries. 
---|---|--- 
  



   | (j)| Excluding communications arising  from the prosecution of
Registered Company IP with Governmental Authorities and except  as provided
in Section 22 of the Disclosure Letter, none of the Corporation or its 
subsidiaries have received any written notice or other written communication
of any claim,  notice, threat or assertion challenging the validity or scope
of any Registered Company  IP listed in Section 34(a)(ai) or Section
34(a)(aii) of the Disclosure Letter. 
---|---|--- 
  



   | (k)| None of the Company Owned Registered  IP in Section 34(a)(ai) of
the Disclosure Letter is subject to any pending or outstanding  injunction,
directive, order, decree, award, settlement, judgment encumbrance or other 
disposition of dispute that would adversely restrict the use, enforcement,
transfer,  registration or licensing of any such Registered Company IP listed
in Section 34(a)(ai)  of the Disclosure Letter by the Corporation or its
subsidiaries, or would adversely restrict  the Company from enforcing the
Registered Company IP to exclude others from making, using,  offering for
sale, selling, manufacturing or importing the Product, or would adversely 
affect the validity, scope, use, registrability, or enforceability of any
Registered  Company IP. To the knowledge of the Corporation without
reasonable inquiry, there has  been no breach of the representations,
warranties and covenants made by the licensor  in the license agreement
conveying rights to the Company Licensed Registered IP in Section 34(a)(aii) 
of the Disclosure Letter. 
---|---|--- 
  



  

   

 | C-21| 
---|---|--- 

 



    



   | (l)| To the knowledge of the Corporation, there is no prior art that
may render any patent or patent application included in the Company Owned
Registered IP unpatentable or unenforceable that has not been disclosed to,
or was required to be disclosed to, the applicable patent office. 
---|---|--- 
  



   | (m)| No registered trademark, registered  trade name, trademark
application or trade name application included in the Company Owned  IP has
been licensed to a party other than the Corporation or its subsidiaries.
Section 34(m)  of the Disclosure Letter sets forth a true and complete list,
identifying the trademarks,  service marks and trade names in which the
Corporation and/or its subsidiaries claim  common law rights, as well as a
true and complete list, identifying all renewal and other  fee due dates and
deadlines for all trademark applications or registrations included  in the
Registered Company IP. 
---|---|--- 
  



   | 35.| Material Contracts. 
---|---|--- 
  



  

Section 35 of the Disclosure Letter lists every Material Contract that is
currently in force. Except as made available via SEDAR or EDGAR since January
1, 2015, true and complete copies of the Material Contracts which are in
writing have been made available to the Acquiror and where such
Material Contracts are oral, they are with employees and are accurately
summarized in Section 35 of the Disclosure Letter or as cross-
referenced therein. Except as disclosed in Section 35 of the Disclosure
Letter:

  



   | (a)| each Material Contract is legal,  valid, binding and in full
force and effect and is enforceable by the Corporation and  its subsidiaries,
as applicable, in accordance with its terms (subject to bankruptcy, 
insolvency and other Laws affecting creditors' rights generally, and to
general  principles of equity); 
---|---|--- 
  



   | (b)| the Corporation and its subsidiaries  have performed in all
material respects all respective obligations required to be performed  by
them to date under the Corporation and neither the Corporation nor any of its
subsidiary  is in material breach or default under any Material Contract, nor
does the Corporation  have knowledge of any condition that with the passage
of time or the giving of notice  or both would result in such a material
breach or default; 
---|---|--- 
  



   | (c)| the Corporation and its subsidiaries  do not know of, and have
not received any notice (whether written or oral) of, any material  breach or
default under, nor to the knowledge of the Corporation, does there exist any 
condition which with the passage of time or the giving of notice or both would
result  in such a material breach or default under, any such Material
Contract by any other party  to a Material Contract; and 
---|---|--- 
  



  

   

 | C-22| 
---|---|--- 

 



    



   | (d)| neither the Corporation nor any  of its subsidiaries has
received any notice (whether written or oral), that any party  to a Material
Contract intends to cancel, terminate or otherwise modify or not renew  its
relationship with the Corporation or its subsidiaries, and no such action has
been  threatened. 
---|---|--- 
  



   | 36.| Indebtedness. 
---|---|--- 
  



  

Other than as disclosed in Section 36 of the Disclosure Letter, the
Corporation and its subsidiaries have no outstanding material indebtedness for
borrowed money, capital leases, obligations under hedging arrangements,
letters of credit and similar obligations of, or outstanding guarantees of
indebtedness for borrowed money, capital leases, letters of credit and
similar obligations of any person, except as reflected in the
financial statements of the Corporation that are included in the Public
Disclosure Record.

  



   | 37.| Insurance. 
---|---|--- 
  



  

Each of the Corporation and its subsidiaries are insured by insurers that the
Corporation believes to be reputable. There are no outstanding or pending
material Claims under insurance policies of the Corporation. The insurance
policies of the Corporation and its subsidiaries are in full force and
effect in accordance with their terms and the Corporation and its
subsidiaries are not in material default under the terms of any such policy.
Section 37 of the Disclosure Letter sets forth a list of all current policies
of insurance of the Corporation.

  



    

 | C-23| 
---|---|--- 

 



    



  

Schedule D 
 Arrangement Resolution

  



  

BE IT RESOLVED THAT:

  



  

   | 1.| The arrangement (the "Arrangement") under section 192 of the
Canada Business Corporations Act (the "CBCA") involving, among others,
Cynapsus Therapeutics Inc. ("Cynapsus"), its securityholders, and Sunovion CNS
Development Canada ULC ("AcquireCo"), as more particularly described and set
forth in the management information circular (the "Circular") of  dated ,
2016, as the Arrangement may be modified or amended, and all transactions
contemplated thereby are hereby authorized and approved. 
---|---|--- 
  



   | 2.| The plan of arrangement, as it may be or have been amended (the
"Plan of Arrangement") involving, Cynapsus , its securityholders and
AcquireCo, the full text of which is set out in Schedule A to the Circular, is
hereby authorized and approved. 
---|---|--- 
  



   | 3.| The Arrangement Agreement dated August 31, 2016, between
AcquireCo, Sunovion Pharmaceuticals Inc. and Cynapsus (the
"Arrangement Agreement"), the actions of the directors of Cynapsus in
approving the Arrangement and the actions of the officers of Cynapsus in
executing and delivering the Arrangement Agreement and any amendments thereto
are hereby ratified and approved. 
---|---|--- 
  



   | 4.| Notwithstanding that this resolution has been passed (and the
Arrangement adopted) by the securityholders of Cynapsus or that the
Arrangement has been approved by the Superior Court of Justice of Ontario
(Commercial List), the directors of Cynapsus are hereby authorized and
empowered (i) to amend the Arrangement Agreement or the Plan of Arrangement to
the extent permitted by the Arrangement Agreement, and (ii) subject to the
terms of the Arrangement Agreement, not to proceed with the Arrangement. 
---|---|--- 
  



   | 5.| Any officer or director of Cynapsus is hereby authorized and
directed for and on behalf of Cynapsus to execute, under the corporate seal
of the Corporation or otherwise, and deliver articles of arrangement and such
other documents as are necessary or desirable to the Director under the CBCA
in accordance with the Arrangement Agreement. 
---|---|--- 
  



   | 6.| Any officer or director of Cynapsus is hereby authorized and
directed for and on behalf of Cynapsus to execute or cause to be executed and
to deliver or cause to be delivered, all such other documents, agreements and
instruments and to perform or cause to be performed all such other acts and
things as in such person's opinion may be necessary or desirable to give full
effect to the foregoing resolution and the matters authorized thereby, such
determination to be conclusively evidenced by the execution and delivery of
such document, agreement or instrument or the doing of any such act or thing. 
---|---|--- 
    



  

   

 | | 
---|---|--- 

    

       '

